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Abstract 
 
The aim of this work was to characterise the checkpoint 1 kinase (CHK1) 
inhibitor V158411; its effect on DNA damage-induced checkpoint function in 
parallel with chemo/radio-potentiation in a panel of cell lines characterised for 
their CHK1 expression and activity. Furthermore, to determine the single agent 
cytotoxicity in a panel of cell lines; to identify potential pharmacodynamic 
biomarkers of CHK1 activity suitable for measuring the activity of inhibitors in 
the clinic; and to explore the role of p53 and identify other potential 
determinants of sensitivity to CHK1 inhibitors. 
V158411 on its own reliably reduces CHK1serine296 phosphorylation and 
gemcitabine-mediated induction of CHK1serine296 phosphorylation. Single agent 
V158411 reduces the fraction of cancer cells in G2 of the cell cycle and 
abrogates cisplatin and IR-mediated increases in the proportion of cells in G2. 
V158411 shows significant single agent activity in a number of cell lines. There 
was significant potentiation of ionising radiation with V158411. There was no 
significant chemopotentiation of either gemcitabine or cisplatin with co-
administration with V158411. 
p53 status was not associated with significant  differences in sensitivity to single 
agent V158411, chemo or radiosensitisation. However, loss of DNA-PKcs or the 
presence of a DNA-PKcs inhibitor conferred resistance to V158411. CHK1 and 
DNA-PKcs mRNA levels were found to be elevated in tumour samples 
compared to normal tissue levels. The LC50 of V158411 was shown to correlate 
with the inducible (2 Gy IR) phosphorylation of DNA-PKcsserine2096 in a panel of 
cancer cells. 
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Chapter 1 Introduction 
1.1 Background 
DNA can be damaged by a range of exogenous and endogenous agents. In 
response to DNA damage the cell cycle has checkpoints under the control of 
regulatory proteins that allow the cell cycle to be halted and to provide time for 
DNA repair. This prevents the accumulation of mutations that are harmful to the 
cell. Unfortunately, it can also reverse the intended effects of cytotoxic and 
radiation therapy. Chemotherapy and radiotherapy aim to deliver lethal damage 
to the DNA of tumour cells. Most malignant cells appear to have a defective G1 
checkpoint and rely on their S and G2 checkpoints for DNA repair and cell 
survival (Massague, 2004). The aim of targeting the S and G2 checkpoints is to 
improve tumour cell kill with relative sparing of normal tissues with a functional 
G1 checkpoint. Figure 1.1 describes the cell cycle and its checkpoints. 
 
Figure 1-1 Cell cycle and checkpoints. 
Progression of cell cycle and the position of G1, S and G2/M cell cycle 
checkpoints and exit point to G0. 
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1.2 DNA damage and response (DDR) 
Maintaining a stable genome is required for the correct function of cells and the 
prevention of acquisition and transmission of mutations. 
There are three naturally occurring threats that lead to damage to DNA and the 
integrity of the genome (Hoeijmakers, 2001, Hoeijmakers, 2009). 
• Environmental agents. These include ultraviolet radiation, solar ionising 
radiation and chemicals (e.g. aflatoxin) that are toxic to the genome.  
• Endogenous products of cellular metabolism. Examples include reactive 
oxygen species from oxidative respiration and lipid peroxidation 
• Endogenous spontaneous DNA damage due to replication errors, and 
nucleotides may undergo hydrolysis, methylation and demethylation.  
In addition chemotherapy and therapeutic ionising radiation cause damage to 
DNA in a wide variety of ways. 
The cell attempts to repair any damage that occurs to DNA by mounting a DNA 
damage response (DDR). Any attempt at DNA repair requires detection of DNA 
damage, transient cell cycle arrest and subsequent repair. The outcome of 
attempted DNA repair may be: 
a) Success and the restoration of an intact genome. 
 
 
3 
b) Failure of DNA repair and the acquisition of mutations and 
chromosomal abnormalities that may lead to ageing or cancer 
c) Failure of DNA repair and subsequent cell death. 
Failure to repair DNA can result in genomic instability that is an enabling 
characteristic of cancer (see Figure 1-2) (Hanahan and Weinberg, 2011). 
 
 
Figure 1-2 Characteristics of cancer  
Characteristics of cancer demonstrating the role of DNA damage and 
faulty repair in carcinogenesis. Adapted from (Hanahan and Weinberg, 
2011) 
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1.3 DNA repair 
There are a variety of types of damage that can be induced in DNA and a 
corresponding range of different DNA repair mechanisms that deal with specific 
types of DNA lesion (Sehl et al., 2009, Curtin, 2012, Bouwman and Jonkers, 
2012). See table 1.1 for a summary of the main DNA repair pathways. 
 
Single strand repair 
1.3.1 Direct repair 
O6-methylguanine lesions are sometimes formed naturally by incorrect 
methylation by s-adenosyl methionine (Tricker et al., 1991). If unrepaired these 
lesions are mutagenic. O6-methylguanine DNA methyltransferase (MGMT – 
previously known as AGT) can repair these lesions by demethylation. Guanine 
can be alkylated in the O6-position by other sources including dietary 
nitrosamines, nitrosated amines and bile acids (Tubbs et al., 2007). O6-alkyl 
lesions are also caused by therapeutic intervention with alkylating agents (eg: 
the pro drugs dacarbazine and the oral agent temozolomide) and nitrosureas 
(BCNU/carmustine) (Saffhill et al., 1985). These lesions can be repaired by 
MGMT.  High expression of MGMT is associated with resistance to 
temozolomide and carmustine (Tsuzuki et al., 1996). A schematic detailing this 
repair pathway is shown in Figure 1-6. 
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Table 1-1 DNA Repair Mechanisms 
 
IR: ionising radiation; BER: base excision repair; SSBR: single strand 
break repair; NER: nucleoside excision repair; UV: ultraviolet; HRR: 
homologous recombination repair; NHEJ: non-homologous end joining; 
MMR: mismatch repair. 
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1.3.2 Base-excision repair (BER) and single strand break repair (SSBR) 
BER is the pathway by which non-bulky damaged DNA bases are repaired 
(Kinsella, 2009). The process of BER leads to transient single-strand breaks 
(SSB), that are repaired by the downstream aspects of BER and SSBR. The 
bulk of DNA damage is repaired by BER because between 10000 and 100000 
base lesions occur in every cell every day (Lindahl, 1993). These lesions are 
largely mediated by reactive oxygen species (ROS) and reactive nitrogens 
(Valko et al., 2006). Oxidation by ROS forms 8-oxoguanine and 5-
hydroxycytosine, these ‘false bases’ can incorrectly pair with adenine and 
thymine, respectively. ROS are produced as a natural product of respiration and 
the inflammatory response. Other endogenous base damage may occur e.g. 
tRough spontaneous deamination of cytosine, aberrant methylation of the N7 
position of guanine and N3 of adenine and miss-incorporation of faulty 
nucleotides during replication. Tumours have a high level of inflammation and 
hence ROS leading to more oxidative damage to DNA leading and subsequent 
SSBs that require repair (Halliwell, 2007). 
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Figure 1-3 Base excision repair (BER) 
Adapted from (Curtin, 2012). Two versions of BER – short patch BER 
predominates over long patch BER. In short patch BER a single 
nucleotide is replaced by DNA polymerase-β and in long patch up to 13 
nucleotides can be replaced by DNA polymerase δ  or ε .  
 
The damaged bases are removed by DNA glycosylases, creating an A-P site 
that is the target for A-P endonuclease (O'Connor and Laval, 1991). This 
generates a ‘nick’ or SSB that is repaired by DNA polymerases and DNA 
ligases supported by PARP-1 (poly(ADP-ribose) polymerase 1) and PARP-2 
(De Vos et al., 2012). Two forms of BER exist; short patch BER where a single 
nucleotide is replaced, or long patch BER where 2 to 13 nucleotides require 
replacing. 
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gemcitabine)69. The fairly high frequency of HRR defects 
in tumours may underlie the efficacy of cytotoxic therapy 
and provide a rationale for the use of inhibitors of HRR 
to sensitize tumours with functional HRR to conventional 
chemotherapy. Moreover, HRR-defective cells are selec-
tively killed by PARPis (discussed below). There are few 
HRR inhibitors, but mirin is an inhibitor of MRE11 endo-
nuclease activity and thus of HRR function70. However, 
MRE11 is also upstream of NHEJ, and so mirin inhibits 
NHEJ71 and its effects are not specific to HRR. This makes 
it difficult to determine whether inhibition of HRR or 
inhibition of NHEJ by mirin contributes most to sensiti-
zation and hence which pathway should be inhibited for 
the greatest clinical benefit. Activating phosphorylation of 
RAD51 and RAD51 focus formation — important steps in 
HRR — are dependent on the proto-oncogene ABL1; and 
the BCR-ABL1 inhibitor imatinib sensitized cells to DNA 
crosslinking agents and IR72,73. Other prototype RAD51 
inhibitors have been identified (TABLE 2) but the most 
common way to target HRR is by inhibition of the 
ATM–CHK2 or ATR–CHK1 pathways (discussed below).
Targeting cell cycle checkpoints
The DDR requires the integration of cell cycle control via 
checkpoint signalling to allow time for repair to prevent 
DNA damage being made permanent by replication and 
mitosis. The PIKKs ATM and ATR have crucial roles by 
signalling DNA damage to cell cycle checkpoints and 
DNA repair pathways (reviewed in REFS 74,75) (FIG. 6). 
The ATM–CHK2 pathway primarily responds to DSBs to 
induce G1 arrest, and the ATR–CHK1 pathway triggers 
S and G2 phase arrest. ATM promotes HRR by recruit-
ing BRCA1 to DSBs but can also antagonize BRCA1 
and promote NHEJ by recruiting p53 binding protein 1 
(53BP1), and these antagonistic functions may be cell 
cycle regulated76. ATR is activated by DNA single-strand– 
double- trand junctions that arise as intermediates in 
NER, at stalled replication forks and at resected DSBs, it 
phosphorylates CHK1 to activate S and G2 arrest, inter-
acts with the MMR machinery and stabilizes and re-starts 
stalled replication forks via HRR77. ATR and CHK1 
phosphorylate a number of proteins involved in HRR 
and ICL repair, including BRCA2, RAD51, Fanconi 
anaemia group D2 (FANCD2) and FANCE78. ATM 
mutations, epigenetic silencing and polymorphisms 
are associated with various types of cancer, and a high 
frequency of frameshift mutations of the A(10) repeat 
microsatellite of ATR, which results in a truncation, is 
associated with various tumours with MSI79 (TABLE 1). 
As checkpoint activation is a common feature of the 
DDR to a variety of DNA-damaging agents, and as ATM 
and ATR have multiple downstream targets, check-
point inhibitors are likely to sensitize a broad range of 
DNA-damaging agents75,80.
The first selective ATM inhibitor, KU55933, inhib-
ited IR-induced ATM-dependent phosphorylation 
events and sensitized cancer cells to IR and topoisomer-
ase inhibitors81. This, and other inhibitors (TABLE 2), are 
at an early stage of development, possibly because the 
role of ATM in promoting oncogene-induced senes-
cence and inhibiting tumorigenesis82 may have been a 
(KIWTG^Base excision repair. In the first st p of base 
GZEKUKQPTGRCKT
$'4VJGQZKFK\GFFGCOKPCVGFCPF
alkylated bases are removed by specific glycosylases; 
QZQIWCPKPG&0#IN[EQU[NCUG
1))QTOGODGTUQH
the Nei-like protein (NEIL) family are examples. The 
TGUWNVKPICRWTKPKEQTCR[TKOKFKPKE
#2UKVGKUVJGP
J[FTQN[UGFD[CP#2GPFQPWENGCUGUWEJCU#2'6JG
PKEMKPVJG&0#KUVJGPTGRCKTGFD[UJQTVRCVEJ$'4
VJG
RTGFQOKPCPVOQFGQTNQPIRCVEJ$'4FGRGPFKPIQPVJG
nature of the 5ʹCPFʹGPFUCPFRQUUKDN[#62CXCKNCDKNKV[
2QN[PWENGQVKFGMKPCUGRJQURJCVCUG
20-2Cʹ DNA 
phosphatase and 5ʹ DNA kinase) may be necessary to 
OQFKH[VJGDTQMGPGPFUHQTTGRNCEGOGPVCPFQT
TGLQKPKPI2TQNKHGTCVKPIEGNNPWENGCTCPVKIGP
2%0#VJG
9-1-1 complex and flap endonuclease 1 (FEN1) are 
required for the processing of long patches. In short 
patch repair the single nucleotide is replaced by DNA 
polymerase-β
2QNβCPFVJGICRKUTGLQKPGFD[NKICUG

.+)CPFKPNQPIRCVEJTGRCKTWRVQPWENGQVKFGUCTG
TGRNCEGFD[2QNδQT2QNεCPFTGLQKPKPIKUEQORNGVGFD[
.+)(REF. 143)2QN[
#&2TKDQUGRQN[OGTCUG
2#42CPF
XRCC1 facilitate repair by recruiting repair enzymes  
and providing the scaffold for short patch and long patch 
$'46JGJKIJPGICVKXGEJCTIGQHVJG#&2TKDQUG
polymers in the vicinity of the break is necessary for the 
recruitment of XRCC1 (REF. 20), which in turn recruits 
202-CPF&0#RQN[OGTCUGCPFCNUQHCEKNKVCVGUVJG
loosening of chromatin to facilitate repair. Single-strand 
breaks associated with trapped topoisomerase I involve 
the removal of topoisomerase I by tyrosyl-DNA 
RJQURJQFKGUVGTCUG
6&2HQNNQYGFD[202-CEVKXKV[
DQVJQHYJKEJTGN[QP2#42CPF:4%%HQTVJGKT
recruitment.
Focus
The accumulation of a 
substance (usually protein) 
that may be identified and 
visualized (usually by a 
fluorescently tagged antibody) 
in one spot.
REVIEWS
808 | DECEMBER 2012 | VOLUME 12  www.nature.com/reviews/cancer
© 2012 Macmillan Publishers Limited. All rights reserved
 
 
8 
Exogenous damage can lead directly to SSBs. Sources of exogenous damage 
that can cause SSBs include ionising radiation (both natural and therapeutic 
mediated by ROS), alkylating chemotherapy, topoisomerase inhibitors, and anti-
metabolites (thiopurines, flouropyrimidines and halogenated thymidine 
analogues). IR can also induce DNA strand breaks directly. Dysfunctional BER 
can lead to sensitivity to chemotherapy (temozolomide and alkylators) and IR. 
 
1.3.3 Nucleotide-excision repair (NER) 
NER (see Figure 1-4) involves the removal of bulky adducts that are too large to 
be removed by BER. Bulky adducts will distort the DNA helix so must be 
removed. There are 3 stages to NER; recognition of the abnormality, removal of 
25-30 nucleotides in the damaged segment of DNA followed by repair of the 
gap in the DNA (Buschta-Hedayat et al., 1999, Naegeli and Sugasawa, 2011). 
Environmental stressors including UV light, tobacco smoke, aflatoxin and 
polycyclic aromatic hydrocarbons lead to the formation of a bulky adduct that 
prevents DNA transcription (Hoeijmakers, 2001). Some chemotherapy also 
causes DNA damage that cause interstrand and intrastrand crosslinks (ICLs) 
are treated in the same way as bulky adducts. Nitrosureas, and the diamine-
platinum compounds cisplatin and carboplatin cause such ICLs. The bulky 
adducts are removed by NER. Two forms of NER occur – global genome NER 
and transcription coupled repair. Xeroderma pigmentosa (XP) proteins and 
ERCC1 are important for effective NER and ICL repair. Cells that are defective 
in components of the NER pathway are more sensitive to platinum-based 
therapy (Koberle et al., 1997). 
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Figure 1-4 Nucleotide excision repair (NER) 
Adapted from (Curtin, 2012). Two forms of exist with a final common 
pathway. TC-NER and GG-NER. 
 
 
Double strand break (DSB) repair 
DSB are relatively rare (10-50 per cell per day), but highly cytotoxic and difficult 
to repair (Vilenchik and Knudson, 2003). The difficulty in repairing DSBs means 
they are dangerous for cell viability and if unrepaired can lead to cell death; if 
they are incorrectly repaired they can lead to chromosomal translocations which 
can be a significant step in carcinogenesis (Jeggo and Lobrich, 2007).  
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deterrent from developing inhibitors. However, DDR 
pathways are generally tumour suppressive and ATM is 
still a potentially viable therapeutic target.
Targeting the S and G2 checkpoints is particularly 
attractive for cancer therapy because loss of G1 check-
point control is a common feature of cancer cells83, 
making them more reliant on the S and G2 check-
points to prevent DNA damage triggering cell death. 
Proof-of-principle genetic studies showed that inhibit-
ing the S and G2 checkpoints by inactivation of ATR or 
CHK1 abrogated DNA damage-induced G2 checkpoint 
arrest and sensitized cancer cells to a variety of DNA-
damaging chemotherapeutic agents84–86. Furthermore, 
oncogenic replicative stress may render cancer cells sen-
sitive to inhibitors that prevent the S and G2 checkpoints 
as single agents (discussed below). WEE1 and cell divi-
sion cycle 25 (CDC25) inhibitors have been developed, 
and some have entered into clinical trials (TABLE 2) but 
clinical data are limited. Most research has focused on 
the development of CHK1 inhibitors, which have entered 
clinical studies (TABLE 2). These include the nonspecific 
staurosporin analogue, UCN-01, and its derivatives, 
and highly potent selective CHK1 inhibitors (reviewed 
in REF. 87). In preclinical studies most of these inhibi-
tors had little or no impact on cell cycle distribution or 
viability per se but they did prevent cell cycle arrest and 
increased cytotoxicity induced by DNA-damaging agents. 
Xenograft studies, mostly in combination with gemcit-
abine, confirmed sensitization88–90. UCN-01 was the first 
of this type of inhibitor to enter clinical trials, but after 
Phase II trials it was discontinued owing to dose-limiting 
toxicities and a lack of convincing efficacy that was prob-
ably due to poor specificity and pharmacokinetics. The 
newer, more specific inhibitors of CHK1 have generally 
been combined with gemcitabine in Phase I studies, in 
which myelosuppression was the major toxicity that led 
to the termination of the trials, and no efficacy data have 
yet been presented (reviewed in REFS 87,91).
For a long time, the only available ATR inhibitor was 
caffeine, which lacks potency and specificity but that has 
nevertheless provided useful preclinical radiosensitization 
data92. Recently, a high-throughput cell-based screen has 
identified potent ATR inhibitors that were cytotoxic to 
cells with replicative stress93, and other groups have iden-
tified the novel ATR inhibitors, VE-821 and NU6027 
(REFS 94,95). Both drugs sensitized cells to a variety of 
DNA-damaging agents, which reflects the role of ATR in 
the response to multiple DNA lesions, but differed in their 
dependence on p53 status. As these reports are the first 
to use novel ATR inhibitors, and different cell lines were 
investigated, no conclusions can be drawn regarding the 
role of p53 in determining response. NU6027 also inhib-
ited RAD51 focus formation (indicative of HRR suppres-
sion), leading to synthetic lethality with BER inactivation95 
(discussed below).
Synthetic lethality
Perhaps the most promising prospect for the future of 
cancer treatment is the exploitation of dysregulated DDR 
by the synthetic lethality approach. This term describes 
the process by which defects in two different genes or 
pathways together result in cell death but independently 
do not affect viability (FIG. 7). The term was first applied 
to explain the selective killing of cancer cells with par-
ticular molecular defects by some agents96. For exam-
ple, hyperproliferation in tumour cells that is caused by 
defects in the RB pathway may elevate topoisomerase II 
activity, making these cells particularly sensitive to topoi-
somerase II poisons, such as doxorubicin97. However, 
doxorubicin has marked side effects on normal tissues 
and the aim of synthetic lethal approaches is to combine 
tumour-associated molecular defects with corresponding 
selectively lethal drugs or to combine drugs that confer 
selective lethality to tumour cells and not to normal tissue.
Therefore, it was exciting to discover that cells and 
xenograft tumours defective in HRR (for example, 
through BRCA1 or BRCA2 mutation) could be killed by 
concentrations of PARPis that were non-toxic to HRR-
functional cells and normal tissues98,99. One proposed 
mechanism of this synthetic lethality is that the high 
levels of endogenous SSBs (FIG. 1) remain unrepaired 
when PARP is inhibited and cause stalled replication 
(KIWTG^Nucleotide excision repair. 2TGHGTGPVKCNTGRCKTQHNGUKQPUVJCVUVCNN
transcription on the coding strand is by transcription-coupled nucleotide excision repair 

6%0'4VJGGPVKTGIGPQOGKUTGRCKTGFD[INQDCN0'4
))0'4. These pathways differ 
in their initial steps, TC-NER involves Cockayne syndrome WD repeat protein A (CSA) 
CPF%5$YJGTGCUKP))0'4TGEQIPKVKQPKUFGRGPFGPVQP:GTQFGTOCRKIOGPVQUWO
ITQWR%EQORNGOGPVKPIRTQVGKP
:2%s4#&$CPF&0#FCOCIGDKPFKPIRTQVGKP 

&&$:2#TGRNKECVKQPRTQVGKP#
42#CPF6(++*CTGKPXQNXGFKPDQVJRCVJYC[U
6JGTGCHVGTVJGUVGRUCTGEQOOQPYKVJGZEKUKQPQHVJGFCOCIGFQNKIQPWENGQVKFGD[:2)
CPF'4%%s:2(VJGPTGU[PVJGUKUQHVJGKPVCEVQNKIQPWENGQVKFGCPFNKICVKQPCTG
accomplished by DNA polymerase-δ
2QNδQT2QNεCPF&0#NKICUG
.+)2%0#
proliferating cell nuclear antigen; RFC, replication factor C.
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There are two methods of DSB repair: homologous recombination repair (HRR) 
and non-homologous end joining (NHEJ). The choice of which pathway is used 
is dependent on a number of factors (Shibata et al., 2011). 
 
Figure 1-5 DNA double strand and interstrand crosslink repair 
Adapted from (Curtin, 2012). NHEJ (non-homologous end joining) occurs 
during G0 or G1 of the cell cycle; HRR (homologous recombination repair) 
and ICL (interstrand cross-link) repair occur during S phase or G2. 
 
1.3.4 Homologous recombination repair (HRR). 
HRR requires the sister chromatid to act as a template so can only repair DSBs 
during G2 and S phase (Aylon et al., 2004). HRR is the preferred method of 
DSB repair as, if successful, it has a lower error rate than other methods. The 
broken ends adjacent to the DSB are resected so that overlapping single 
strands of DNA can invade the sister chromatid that is used as a template to 
repair broken DNA. 
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Excitement about the synthetic lethal approach 
involving PARPis must be tempered, as resistance to 
PARPis can develop owing to secondary mutations in 
BRCA1 or BRCA2 that restore their function107,197. In 
addition, even in BRCA-mutant cells, HRR function and 
PARPi resistance can be restored if 53BP1 or DNA-PKcs 
are also inactivated76,108, a phenomenon that is known 
as synthetic viability. These observations suggesting that 
NHEJ and HRR compete to repair DSBs, but that sur-
vival is dependent on DSB repair by HRR, are analogous 
to studies in Fanconi anaemia pathway-defective human 
cells in which the sensitivity to ICL-induced DSBs can 
be rescued by the inhibition of NHEJ109. 53BP1 is com-
monly lost in BRCA1-mutant and triple-negative breast 
cancer and in lung cancer110, which could compromise 
the activity of PARPis against these types of tumours in 
clinical trials.
Other examples of synthetic lethality of HRR defects 
and PARPis are emerging. For example, HRR dysfunction 
owing to ATM loss in haematological malignancies or to 
mutation of MRE11 (secondary to MMR defects) confers 
sensitivity to PARPis111–113. It is possible that such second-
ary defects in MRE11 may also contribute to the sensitiv-
ity of MSH2-defective cells to Pol β (a component of BER) 
inhibition114. The principle of tumour-selective synthetic 
lethality is to exploit defects found only in the tumour, and 
the use of two agents targeted at two compensatory path-
ways would be predicted to be generally toxic rather than 
tumour-specific. However, the cyclin-dependent kinase 
CDK1 activates BRCA1, and CDK1 inhibition in combi-
nation with PARP inhibition was cytotoxic in lung cancer 
models but spared normal tissues115. Although these data 
were only published recently, clinical trials using this com-
bination have already been initiated.
Figure 5 | DNA double-strand break and interstrand crosslink repair. #PGCTN[UVGRQH&0#FQWDNGUVTCPFDTGCM
&5$
TGRCKTKUVJGTGETWKVOGPVQHVJG/40PWENGCUGEQORNGZ
EQORTKUGFQH/4'4#&CPF0KLOGIGPDTGCMCIGU[PFTQOG

0$5 +PPQPJQOQNQIQWUGPFLQKPKPI
0*',DKPFKPIQHVJG-7s-7JGVGTQFKOGTCPFVJG&0#FGRGPFGPVRTQVGKP
MKPCUGECVCN[VKEUWDWPKV
&0#2-EUtVQHQTO&0#2-tGPUWTGUU[PCRUKUQHVJG&0#GPFU144&0#2-EURJQURJQT[NCVGU
JKUVQPG*#:CPFETWEKCNN[CNUQKVUGNHYJKEJCNNQYUFKUUQEKCVKQP#TVGOKURTQEGUUGUVJG&0#GPFUYJKEJCTGVJGPNKICVGF
D[&0#NKICUG
.+)CPFUVCDKNK\GFD[VJG:4%%s:4%%NKMGHCEVQT
:.(EQORNGZ56. In homologous recombination 
TGRCKT
*44$4%#tCPFRQUUKDN[RQN[
#&2TKDQUGRQN[OGTCUG
2#42tHCEKNKVCVGUTGETWKVOGPVQHVJG/40EQORNGZ
YJKEJVQIGVJGTYKVJ%V$2KPVGTCEVKPIRTQVGKP
%V+2CPFGZQPWENGCUG
':1TGUGEVVJG&0#GPFU145,1466JG/40
EQORNGZTGETWKVUCPFCEVKXCVGUCVCZKCVGNCPIKGEVCUKCOWVCVGF
#6/YJKEJUVKOWNCVGU/4'0$5%V+2CPF':1D[
RJQURJQT[NCVKQP#6/CNUQRJQURJQT[NCVGUJKUVQPG*#:YJKEJCKFUTGETWKVOGPVQHRDKPFKPIRTQVGKP
$2CPF
$4%#(REF. 147)6JGUKPINGUVTCPFGF&0#QXGTJCPIKUTCRKFN[EQCVGFYKVJTGRNKECVKQPRTQVGKP#
42#YJKEJRTGXGPVUKV
HTQODGKPIFGITCFGF6JKUTGETWKVUVJGCVCZKCVGNCPIKGEVCUKCCPF4CFTGNCVGF
#64s#64KPVGTCEVKPIRTQVGKP
#64+2
EQORNGZYJKEJUKIPCNUXKCRJQURJQT[NCVKQPQH%*-VQKPFWEG5CPF)CTTGUV
PQVUJQYP#6/CPF#64RJQURJQT[NCVG
$4%#YJKEJUVKOWNCVGUKVU'WDKSWKVKPNKICUGCEVKXKV[#64CNUQRJQURJQT[NCVGU42#CPFVJGMKPCUG%*-YJKEJKPVWTP
RJQURJQT[NCVGU4#&4#&KUVJGPFGNKXGTGFD[$4%#VQFKURNCEG42#VQHQTOVJGPWENGQRTQVGKPHKNCOGPVVJCVECP
KPXCFGVJGEQORNGOGPVCT[FWRNGZ&0#HQTOKPIC*QNNKFC[LWPEVKQP,149. The invading strand is extended by DNA 
RQN[OGTCUGCPFTGLQKPUVJGGPFQHVJG&5$VQHQTOCETQUUQXGTQTPQPETQUUQXGTTGRCKTRTQFWEV5VCNNGFTGRNKECVKQPHQTMU
RTKOCTKN[CEVKXCVG#64TCVJGTVJCP#6/6JG(CPEQPKCPCGOKC
(#0%RTQVGKPUCNUQRTQOQVG*44CVUVCNNGFTGRNKECVKQP
HQTMUTGUWNVKPIHTQOKPVGTUVTCPFETQUUNKPMU
+%.U4GETWKVOGPVQHVJG$NQQOUU[PFTQOGJGNKECUGEQORNGZNGCFUVQUKIPCNNKPI
VQEGNNE[ENGEJGEMRQKPVUXKC#64s%*-CPFTGRCKTRTQVGKPUKPENWFKPI42#$4%#(#0%0CPF$4%#YJKEJCTGKORQTVCPV
EQORQPGPVUQH*44
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Unrepaired single strand breaks will lead to stalled replication forks. Though 
less common than SSBs, this scenario is very serious for a cell so requires a 
dedicated efficient repair mechanism. Any type of chemotherapy that can cause 
a single strand break can also cause stalled replication forks. Single strand 
breaks are converted into DSBs as the replication fork collides with the SSB. 
Ionising radiation and some types of chemotherapy (eg: etoposide) cause 
DSBs. However, platinum compounds cause intrastrand cross-links between 
guanine residues (5’-GG-3’ and 5’-GNG-3’) and adenine and guanine residues 
(5’-AG-3’), but no frank DSBs (Noll et al., 2006). The collision of a platinum-
mediated cross-link with the replication fork will cause replication fork collapse 
(Annunziata and O'Shaughnessy, 2010). Failure of DSB repair leads to loss of 
chromosome fragments and if the wrong ends are ligated together chromosome 
translocations (Sehl et al., 2009). 
Cells that lack functional BRCA1 or BRCA2, or other components of HRR can 
not perform HRR and DSB DNA repair has to be by NHEJ which is more prone 
to errors (see Figure 1-5). Tumours that have HRR defects are sensitive to most 
types of cytotoxic therapy, but are exquisitely sensitive to cross-linking agents 
such as platinum, IR and to topoisomerase I inhibitors. HRR is dependent on 
the Chk1-mediated phosphorylation of BRCA2 and RAD51 (Bahassi et al., 
2008). 
 
1.3.5 Non-homologous end-joining (NHEJ) 
DNA DSBs can also be repaired by NHEJ. Such breaks can be caused directly 
by reactive oxygen species, IR (both natural and therapeutic) and 
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topoisomerase II inhibitors. IR causes approximately 1 DSB for every 25 SSBs 
(Nikjoo et al., 2001). NHEJ and single-strand annealing (SSA) are less accurate 
than HRR, but can repair DSBs that occur during G0 and G1 when only one 
copy of the DNA is available. NHEJ accounts for the repair of more than 85% of 
IR-mediated DSBs (Mahaney et al., 2009). NHEJ is more error prone than HRR 
and there is the potential for the loss or gain of nucleotides (up to 20 
nucleotides can be lost or gained). NHEJ is dependent on DNA-PK, Ku70, 
Ku80, XRCC4 and DNA ligase IV and artemis (Takata et al., 1998, Kysela et al., 
2005). 
 
1.3.6 Mismatch repair (MMR) 
Errors in replication may lead to the mismatch of bases (ie: A:C or T:G, insertion 
of additional nucleotides or the removal of bases (Kinsella, 2009). Insertions 
and deletions can lead to frame-shift mutations. Mismatches normally occur 
during S phase of the cell cycle. The commonest cause of base mismatches is 
faulty replication, but therapy with nucleoside analogues and temozolomide can 
also cause mismatches. 
Mismatches are repaired by MMR, the mechanism of MMR is outlined in Figure 
1-6. MMR recognition of lesions relies on MSH2 and MSH6 where an incorrect 
nucleotide has been inserted and a MSH2 and MSH3 heterodimer recognises 
deletions and insertions of additional nucleotides (Acharya et al., 1996). This 
particularly occurs in repetitive sequences (microsatellites) leading to 
microsatellite instability (MSI) in cells, which have defective MMR. Defects in 
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MMR cause tolerance to temozolomide and platinum induced DNA lesions and 
hence drug resistance (Irving and Hall, 2001).  
 
Figure 1-6 Mismatch repair (MMR) and Direct repair 
Adapted from (Curtin, 2012). MMR repairs defects where incorrect base 
pairing has occurred and where there have been insertions or deletions. 
Direct repair is involved in the repair of O6-methylguanine lesions. 
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forks that require HRR for their resolution. The trap-
ping of PARP1 at these breaks (PARPis prevent cata-
lytic activity but not DNA binding) may further impede 
repair and require HRR for resolution. Alternatively, 
PARP1 — similar to HRR — may have a role in restart-
ing stalled replication forks100. In HRR-defective cells 
these stalled forks persist or are erroneously repaired, 
which leads to cell death (FIG. 4b). HRR defects are not 
limited to the classic examples of BRCA1 and BRCA2 
defects and their association with inherited breast 
and ovarian cancer syndrome. Epigenetic silencing of 
BRCA1 also rendered cells and xenografts sensitive 
to PARP inhibition, demonstrating the potential of 
PARPis in sporadic cancer38. Moreover, hypoxia causes 
the downregulation of several HRR genes, resulting 
in ‘contextual synthetic lethality’ with PARPis, and it 
has recently been suggested that hyperthermia induces 
BRCA2 degradation101,102.
The prospect of non-toxic therapy has real clini-
cal potential, with multiple clinical trials of PARPis as 
single agents underway (TABLE 2). Data with the PARPi 
olaparib are very encouraging. Good responses were 
seen in patients with BRCA-associated breast and 
ovarian cancer, and even in unselected patients with 
high-grade serous ovarian cancer103,104, which is a can-
cer type that is now known to have a high frequency 
of HRR defects. Furthermore, knockdown of various 
other genes involved in HRR also confers sensitivity to 
PARPis105, expanding the range of potential targets for 
PARPi therapy. Reliable biomarkers to identify tumours 
carrying these defects that would render them sensitive 
to PARPis are needed (discussed below). Similarly, inhi-
bition of BER with APE1 inhibitors is also synthetically 
lethal in cells with HRR dysfunction106. One would pre-
dict that inhibitors of Pol β (another BER component) 
would have similar activity.
Figure 4 | Mismatch repair. a | DNA mismatches resulting from the insertion of a mispaired or fraudulent nucleotide 
CTG|TGEQIPK\GFD[/5*s/5*JGVGTQFKOGTUYJGTGCUFGNGVKQPUCPFKPUGTVKQPUCTGTGEQIPK\GFD[/5*s/5*
JGVGTQFKOGTU &QYPUVTGCORTQEGUUKPITGSWKTGU2/5CPF/.*s/.*JGVGTQFKOGTU%QORQPGPVUQHQVJGT&0#TGRCKT
RCVJYC[UUWEJCUGPFQPWENGCUGTGRNKECVKQPRTQVGKP#
42#RTQNKHGTCVKPIEGNNPWENGCTCPVKIGP
2%0#TGRNKECVKQPHCEVQT
C (RFC), DNA polymerase-δ
2QNδQT2QNε and flap endonuclease 1 (FEN1) have also been implicated in excision and 
TGU[PVJGUKURCUVVJGNGUKQP+ORQTVCPVN[OKUOCVEJTGRCKT
//4KUUVTCPFURGEKHKEEQTTGEVKPIVJGFCWIJVGTUVTCPF
Therefore, this pathway is crucial for the repair of replication errors inserted opposite the correct template strand under 
normal circumstances. b^ *QYGXGTYJGPFCOCIGQPVJGVGORNCVGUVTCPFUWEJCUO6-methylguanine (O6OG)QT
VJKQIWCPKPG
6)ECWUGUOKURCKTKPICVTGRNKECVKQPVJG//4OCEJKPGT[CVVGORVUVQTGRCKTVJGPGYN[U[PVJGUK\GF
strand, rather than the damaged one, which results in a DNA double-strand break during the subsequent S phase or 
ECWUGUCRQRVQUKUQYKPIVQUKIPCNNKPID[VJG//4OCEJKPGT[VQCVCZKCVGNCPIKGEVCUKCCPF4CFTGNCVGF
#64s%*-
(REF. 51).+)&0#NKICUG/)/6O6-methylguanine DNA alkyltransferase.
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1.4 Anticancer agents used in combination with CHK1 inhibitors  
The subject of this thesis is the evaluation of a novel CHK1 inhibitor. Previously 
described CHK1 inhibitors, in pre-clinical in vitro and in vivo work and clinical 
trials with CHK1 inhibitors have been investigated in combination with certain 
types of chemotherapy, mainly antimetabolites, topoisomerase poisons and 
DNA cross-linking agents, and radiotherapy as described below.  
 
1.4.1 Antimetabolites, 
Antimetabolites interfere with DNA synthesis, either as inhibitors of the 
anabolism of deoxynucleotides or fraudulent nucleoside analogues, that may 
inhibit enzymes necessary to synthesise natural nucleotides or be incorporated 
into the DNA.  
Cytarabine (also known as ARA-C) is an analogue of the nucleoside, cytosine. 
It competitively inhibits DNA polymerase (Kufe et al., 1984). It acts as a false 
nucleoside leading to partial chain termination. Ara-CTP is formed from 
cytarabine and then incorporated into DNA. The rate of incorporation of 
cytarabine into DNA correlates with the loss of clonogenic survival in pre-clinical 
studies in acute myelogenous leukaemia (AML). It only has an effect on 
proliferating cells in S phase. Cytarabine is used in acute and chronic 
leukaemias. 
Gemcitabine is another antimetabolite deoxycytidine analogue. It is 
phosphorylated intracellularly by deoxycytidine kinase and phosphorylated 
gemcitabine depletes the cellular pools of dNTPs via the inhibition of 
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ribonucleotide reductase (Plunkett et al., 1995). Incorporation of gemcitabine 
triphosphate into DNA causes the stalling of the DNA polymerase one base 
beyond the incorporation site (Huang et al., 1991). This leads to partial chain 
termination (where DNA polymerase ε cannot extend the 3’ terminus) and the 
stalling of replication forks.  Gemcitabine is highly toxic to cells in S phase and 
prevents their progression into G2. Gemcitabine is used in the treatment of 
pancreatic cancer, lung cancer and breast cancer. It is commonly used in 
combination with platinum compounds 
5FU (5-fluorouracil) is an antimetabolite nucleobase that acts as a pyrimidine 
antagonist (Pinedo and Peters, 1988). 5FU itself is an inactive pro-drug. It 
enters the cell by the uracil transporter and is converted to FUdR by thymidine 
phosphorylase and then to FdUMP by thymidine kinase. FdUMP is converted 
into FdUTP; αdUMP is converted into dUTP. FdUTP and dUTP are 
incorporated into DNA and then excised by uracil glycosylases leading to single 
strand breaks in the DNA. There is an accumulation of dUMP. 5FU is also 
available as the oral pro-drug capecitabine. Capecitabine is not active itself but 
converted by carboxylesterase, cytidine deaminase and thymidine 
phosphorylase to form 5FU (Shewach and Lawrence, 2007). The manufacturers 
claim that as thymidine phosphorylase is more abundant in tumours compared 
to normal tissues higher final concentrations of 5FU are found in tumours 
following the oral administration of capecitabine. 5FU and capecitabine are the 
mainstays of treatment for colorectal cancer; they are also used in the treatment 
of upper gastrointestinal malignancy and breast cancer. 
Hydroxyurea (also known as hydroxycarbamide) has been in clinical use for the 
treatment of leukaemias since the 1960’s. It was shown to block the 
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incorporation of thymidine into DNA (Young and Hodas, 1964). Though this 
mechanism partly contributes to the cytotoxicity of hydroxyurea, its principle 
mechanism is inhibition of ribonucleotide reductase (RNR). RNR converts 
nucleoside diphosphates into deoxynucleoside diphosphates thus depleting 
cellular deoxynucleoside triphosphates for DNA synthesis (Xie and Plunkett, 
1996). Hydroxyurea is currently used in the treatment of chronic myeloid 
leukaemia (CML). 
 
1.4.2 Topoisomerase poisons 
Topoisomerases modify the tertiary structure of DNA, they are essential to DNA 
replication as they cleave, unwind and re-ligate DNA to relieve torsional 
stresses in supercoiled DNA (Pommier et al., 1998a, van Maanen et al., 1988). 
This initiates the uncoiling of DNA to allow for transcription. Topoisomerase I 
and II poisons mediate their cytotoxicity in late S phase and G2 respectively. 
Topoisomerase I cleaves a single strand of DNA and topoisomerase II cleaves 
both. Topoisomerase poisons stabilise the cleavable complex to prevent 
completion of the cycle, resulting in topoisomerase-associated DNA breaks. 
Topoisomerase I poisons cause SSB and topoisomerase II poisons DSBs. 
Etoposide is a semi-synthetic member of the family of epipodophyllotoxins. 
Etoposide’s primary mode of action is as a topoisomerase II poison (van 
Maanen et al., 1988, Hande, 1998). It may also inhibit mitosis by blocking 
microtubule assembly. Cells treated with etoposide accumulate in late S and 
G2. It is used in the treatment of germ cell tumours, small cell lung cancer, 
sarcomas and acute leukaemias 
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Irinotecan, and its active metabolite SN-38, are topoisomerase I poisons 
(Pommier et al., 1998b).  Irinotecan is a semi-synthetic derivative of 
camptothecin. Camptothecin is an alkaloid drug derived from the tree 
Camptotheca acuminata.  Irinotecan is metabolized to the active drug SN-38 by 
a carboxylesterase. Cell-based pre-clinical studies often use the topoisomerase 
I poison camptothecin or the pro-drug SN-38 neither of which are used in 
clinical practice with irinotecan being used for in vivo studies. Irinotecan is used 
either alone or in combination with 5FU in the treatment of colorectal cancer. It 
is also used in combination with other chemotherapy in the treatment of 
sarcoma. 
 
1.4.3 DNA cross-linking agents 
Platinum chemotherapy (cisplatin, carboplatin and oxaliplatin) causes platinum-
DNA adducts that result in intrastrand and interstrand cross-links; these prevent 
DNA replication and ultimately leads to apoptosis. (Raymond et al., 1998) 
(Siddik, 2003). Other platinum-based compounds have been used in pre-clinical 
research. Platinum compounds also cause mild impairment of RNA and protein 
synthesis. The cross-links caused by platinum chemotherapy seem to be most 
damaging in S phase. 
Cisplatin and carboplatin are diamine-platinum compounds (Rixe et al., 1996). 
Both platinum based drugs act in a similar way but have differing profiles of 
which tumour types are sensitive or resistant. They also differ in toxicity profile; 
carboplatin is the most myelosuppressive, and cisplatin is associated with 
greater renal toxicity and ototoxicity. 
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Platinum chemotherapy is very widely used in upper gastrointestinal 
malignancy, colorectal cancer, lung cancer and germ cell malignancies. 
Cisplatin is also used as a radio-sensitising agent in head and neck and cervical 
cancer. 
 
1.4.4 Anti-tubulin agents 
The growth and contraction of tubulin fibres connecting the spindle poles with 
the centromeres of chromosomes is an obligatory step in the segregation of 
chromosomes at mitosis and thus anti-tubulin agents disrupt this process. There 
are two types, the vinca alkaloids, which prevent tubulin assembly, and the 
taxanes, which promote microtubule assembly, but then prevent the 
disassembly by preventing tubulin depolymerisation. Paclitaxel (Taxol™) is a 
taxane used in breast, ovarian and other cancers. It was originally synthesised 
from the bark of the yew tree. Its synthetic analogue Docetaxel (Taxotere™) is 
also used as a cytotoxic in breast cancer, upper gastrointestinal cancer and 
some types of sarcoma.  There is a spindle checkpoint which delays anaphase 
onset if spindle defects have occurred. 
 
1.4.5 Ionising radiation 
Ionising radiation (IR) leads to DNA damage in a number of ways (Teoule, 
1987). Radiation can cause a wide range of DNA damage including SSBs, 
DSBs, base modifications and an entity unique to radiation-induced damage 
known as ‘clustered damage sites’ (Harper et al., 2010). The authors 
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demonstrated that radiation-induced SSBs and other radiation-induced DNA 
damage lead to the formation of DSBs during replication and these can be 
quantified by RAD51 foci formation in vitro assays. The response to IR differs 
between cells that are directly targeted and ‘bystander’ cells (Burdak-Rothkamm 
and Prise, 2009). Directly targeted cells have energy-dependent IR-mediated 
DNA damage. Bystander cells have a different profile of response to IR, but are 
key recruiters of the DNA damage response via ATM and ATR. 
A number of the cytotoxic therapies discussed in this section can be used as 
radiosensitisers. Gemcitabine, cisplatin and 5FU have been used effectively as 
radiosensitisers in in vitro and in vivo studies and have been used in the 
treatment of some tumour types (Shewach and Lawrence, 2007). Cisplatin is 
used widely as a radiosensitiser in the treatment of head and neck cancers, 
cervical cancer and in conjunction with 5FU in the treatment of oesophageal 
cancers. Gemcitabine is used in conjunction with radiotherapy in the treatment 
of pancreatic cancers. Temozolomide is used with radiation in the management 
of glioblastoma multiforme. 
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1.5 Cell cycle arrest 
The cell cycle is under the control of checkpoints that trigger cell cycle arrest in 
response to DNA damage.  The pathway depends on sensors, transducers and 
effectors (Zhou and Elledge, 2000). The downstream kinase and signalling 
cascade has been explored in the literature in great detail; however, the 
mechanism by which DNA damage is detected at the molecular level remains 
unclear (Tse et al., 2007a). 
It has been shown that part of the DNA repair apparatus, Mre-11-Rad50-Nbs1 
(MRN), is not only involved in the repair of broken DNA ends, but also acts as a 
sensor of DNA damage (Moreno-Herrero et al., 2005). This is important in the 
ATM pathway where MRN acts to recruit ATM to DSBs and the Nbs1 
component activates ATM (Yoshiyama et al., 2013). The MRN recruits other 
factors including BRCA1, the mediator of DNA-damage checkpoint 1 (MDC1) 
and p53-binding protein (53BP1) (Shiloh, 2006). The downstream kinase 
cascades are explored in more detail in Chapters 1.6.4 – 1.6.7 
The level of DNA damage that is required to trigger cell cycle arrest had been 
shown to be a single DSB based on data from yeast (Bennett et al., 1997). 
However, work with mammalian fibroblasts has suggested that there is a 
threshold below which cells are released from G2/M arrest even if some DSBs 
persist (Lobrich and Jeggo, 2007). Persistent DSBs in mammalian fibroblasts 
have been quantified by measuring γ-H2AX foci. The threshold for cell cycle 
arrest is between 10-20 DSBs. 
The sensitivity of the G1 checkpoint to DNA damage is less well understood. It 
appears that the G1 checkpoint has a higher sensitivity than the G2/M 
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checkpoint and may even be able to respond to a single site of DNA damage 
(d'Adda di Fagagna et al., 2003). 
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Figure 1-7 The role of ATM, ATR, CHK1 and CHK2 in the DDR 
The interactions (arrows denote activation and T-bars denote inhibition) of 
CHK1 with p53, CDC25A, CDC25B, CDC25C and Wee1: adapted from 
(Bouwman and Jonkers, 2012). 
 
1.5.1 Loss of G1 checkpoint in cancer 
Loss of G1 cell cycle checkpoint control is common in cancers (Massague, 
2004). The most well documented defects affect p53, but other defects are also 
important. DNA replication in G1 is triggered by some of the CDK family. 
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in cellular response is thought to be because ATM 
inhibition reduces p53-dependent apoptosis in p53- 
proficient cells, whereas it promotes mitotic catastrophe 
in p53-deficient cells with a dysfunctional G1/S check-
point. Many cancers lack a functional G1/S checkpoint 
because of defects in the p53 pathway. This feature makes 
them in principle sensitive to G2/M checkpoint inactiva-
tion via inhibition of ATM or other DNA damage check-
point proteins such as WEE1, which was recently shown 
to be required for G2/M checkpoint induction and DNA 
repair in mouse glioblastoma cells after treatment with 
temozolomide or ionizing radiation46.
Sensitization by inhibition of DNA repair. Synthetic lethal 
strategies that target specific DNA repair deficiencies can 
also be exploited to sensitize tumours to chemotherapy. 
Clear examples are combinations of PARP inhibitors and 
DNA alkylators, which show additive or synergistic activ-
ity in preclinical models of BRCA-deficient cancer47–50. 
Besides PARP, other BER proteins such as DNA polymer-
ase β (Pol β), O-6-methylguanine-DNA methyltransferase 
(MGMT), N-methylpurine-DNA glycosylase (MPG), 
apurinic-apyrimidinic endonuclease 1 (APE1; also known 
as APEX1) or flap endonuclease 1 (FEN1) may be targeted 
to enhance the sensitivity of tumour cells to alkylating 
chemotherapeutics51. Also, other DNA repair pathways 
may be targeted to sensitize tumours to chemotherapy 
drugs. For example, the inhibition of error-prone DNA 
translesion synthesis (TLS) via suppression of REV3L, the 
catalytic subunit of Pol ζ, sensitizes drug-resistant lung 
adenocarcinomas in mice to cisplatin52,53.
Histone deacetylases (HDACs) may also represent 
druggable targets for the inhibition of DNA repair, as 
several class I and class II HDACs (HDAC1–4) have been 
shown to promote DNA repair54–57. Hence, HDAC inhibi-
tors such as vorinostat might be used as chemosensitizers. 
The same principle might also apply to class III HDACs 
or the sirtuin family of deacetylases, of which SIRT1 
(REFS 58–62) and SIRT6 (REFS 63,64) have been implicated 
in DNA repair. However, SIRT6 has recently been shown 
to facilitate HR by deacetylating CtBP-interacting protein 
(CtIP; also known as RBBP8), and consequently deple-
tion of SIRT6 sensitizes cells to DNA damaging agents63. 
Furthermore, activation of SIRT1 seems to be especially 
detrimental for BRCA1-deficient tumour cells, possibly 
because it downregulates the apoptosis inhibitor survivin 
(also known as BIRC5)65. These observations call for a 
careful selection of patients to be treated with HDAC 
inhibitors. In general, most current inhibitors of epige-
netic modifiers lack target specificity, and genome-wide 
alterations may result in adverse effects on the tumours 
or increase side effects when combined with chemother-
apy. A better insight into the mechanisms through which 
these compounds sensitize to chemotherapy may lead to 
the identification of relevant target genes and ultimately 
yield more selective therapeutic strategies.
Sensitization of HR-proficient tumours to PARP inhi-
bition. Inherently HR-proficient tumours may be sen-
sitized to PARP inhibition by suppression of HR via 
blocking the recruitment of repair proteins to DSBs21,66. 
In some cases it may even be possible to specifically tar-
get tumour cells, thereby creating a therapeutic window. 
Inactivation of cyclin-dependent kinase 1 (CDK1), for 
instance, reduces BRCA1 focus formation at sites of DNA 
damage67 and renders BRCA1-proficient tumour cells 
sensitive to PARP inhibition66. By contrast, loss of CDK1 
activity in non-transformed cells results in cell cycle 
arrest at the G2/M boundary and protection against 
PARP inhibitor-induced DNA damage in S phase67.
Systemic inhibition of HR may also sensitize normal 
cells to PARP inhibition and thereby increase the toxic-
ity of PARP inhibitors. This problem may be avoided 
by using non-systemic approaches to decrease HR. An 
elegant example of such a local approach is mild hyper-
thermia via localized heat treatment, which sensitizes 
tumour cells to the PARP inhibitor olaparib, possibly via 
degradation of BRCA2 (REF. 68).
DDR-associated resistance to chemotherapy
The major problems encountered when treating cancer 
patients with chemotherapy are toxic side effects owing to 
Figure 1 | DNA damage-induced cell cycle 
checkpoints. DNA double-strand breaks and DNA 
damage induce replication fork stalling. This results in the 
respective activation of the PI3K-like kinases ataxia- 
telangiectasia mutated (ATM) and ataxia-telangiectasia 
and Rad3-related (ATR). ATM phosphorylates the 
checkpoint effector kinase CHK2, which can prevent 
replication of damaged DNA by activating p53 and p21, 
which results in G1/S che kpoint arrest. Alternatively, 
CHK2 as well as CHK1 (which is phosphorylated by ATR) 
can arrest the cell cycle at the intra-S phase or G2/M 
checkpoints by inhibiting cell division cycle 25A (CDC25A), 
CDC25B and CDC25C to allow DNA repair. In addition, 
CHK1 can activate the G2/M inhibiting kinase WEE1 to 
maintain genomic integrity. Possible therapeutic 
intervention points for inhibitors (red) or activators (green) 
of cell cycle control are indicated. CDK, cyclin-dependent 
kinase; MK2, MAPK-activated protein kinase 2.
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Important elements of this pathway at G1 include cdk2, cyclins E1 and E2 and 
cyclin A (Murray, 2004). Figure 1-8 demonstrates the role of cdk2 at the G1 
checkpoint, but also shows many other elements of the pathway including 
ATM/p53/p21 and Rb/E2/F1-3. Aberrations in any of these elements can lead to 
loss of G1 cell cycle checkpoint control. 
 
Figure 1-8 The control of G1 cell cycle checkpoint 
The control of the G1 cell cycle checkpoint and the role of 
cdk2/cyclinE/cyclin A, ATM/p53/p21 and Rb/E2/F1-3. Arrows denote 
activation and T-bars denote inhibition. Adapted from (Massague, 2004) 
 
mice lacking Cdk2 are viable6. It has been argued that the subcellular
location and timing of activation of a CDK may be as important as its
catalytic specificity2. So, compensatory effects by other CDKs might
explain these results. 
Orchestrating G1 with CDK inhibitors
Cyclin E levels are constantly high in the cells of early embryos,
allowing Cdk2 to initiate S phase as soon as M phase is over2. In most
other cells, however, various mechanisms enforce the existence of G1
phase by keeping Cdk2 inactive until mitogenic signals intervene.
One of these mechanisms is based on limiting the supply of cyclin E.
Cyclin E expression is dependent on E2F transcription factors7,8 (Fig.
2). In mitotically resting cells, and in cells that have just emerged from
M phase, E2F factors are bound to the retinoblastoma protein (Rb) or
its family members, p107 and p130 (ref. 9). Rb binding turns E2Fs
into repressors (in the case of E2F4 and E2F5) or inactive transactivators
(in the case of E2F1, -2 and -3)8.
Mitogenic stimuli change this state of affairs by increasing the
amount of D-type cyclins, which combine with Cdk4 and Cdk6 to
phosphorylate and inactivate Rb(refs 1, 2, 10; Fig. 2). Phosphorylation
dissociates Rb from E2F, allowing E2F-dependent transcription.
Along with cyclin E, the E2Fs activate transcription of a large set of
components that support DNA replication (ORCs, MCMs, DNA
polymerase !) and subsequent events (cyclin B, Cdk1 and various
DNA quality-control components)7,8. Rb seems to be the only essential
substrate of cyclin D–Cdk4/6, as cells lacking Rb no longer require
cyclin D for proliferation11. Rb can also be phosphorylated by cyclin-
E–Cdk2, creating a positive feedback loop that helps precipitate S-
phase entry once enough Cdk2 has been activated. However, it would
be a gross oversimplification to imply that Cdk4/6, Rb, E2F1–3 and
Cdk2 function in a strictly linear pathway. Indeed, when ‘knocked-in’
into the cyclin D1 locus, and so placed under the direct control of
insight review articles
Figure 1 Simple and complex cell cycles a, The essential cell cycle such as that
which occurs in early embryos comprises nuclear (and cell) division (M phase)
under the command of Cdk1, after Cdk2-directed replication of the DNA (S phase).
b, Later in development and in adult tissues, the cell cycle includes a gap period
(G1 phase) during which the activity of various CDKs and other required
components is controlled by diverse positive (growth, survival and mitogenic) and
negative (apoptotic and cytostatic; genotoxic, metabolic, oncogenic and oxidative
stress) signals. Some of these signals come from neighbouring cells or the
circulation. Others reflect the metabolic status of the cell, DNA damage caused by
genotoxic agents, physical and chemical stresses, or potentially oncogenic stimuli.
Another gap period (G2 phase) is devoted to mending replication errors and
ensuring that all is in order to proceed with mitosis. Oncogenic transformation is
largely the result of malfunctions in these G1 and G2 mechanisms.
Replication
errors
Cdk1
Cdk2
Cdk4
Cdk6
Pause
Differentiation
Death
M
S
G2
G1
+
–a b
S
M
Cdk1
Cdk2
Figure 2 A CDK engine for G1 to S transition and its built-in regulators. At the end of
mitosis, PRC bound to DNA (ORC) is ready to initiate replication on the command of
Cdk2. A limited supply of cyclins E and A, and the presence of Cdk2 inhibitor
p27Kip1, postpone Cdk2 activation. Mitogenic signals acting by means of Cdk4/6
neutralize p27Kip1 and induce E2F-dependent transcription of cyclins and other
components, resulting in Cdk2 activation and entry into S phase. Several built-in
processes enforce orderly progression of the cell cycle. APC(Cdc20) complexes
destroy mitotic cyclins, trigger sister chromatid separation and promote exit from
mitosis (M phase). Until the concentration of Cdk1 drops at the end of mitosis, Cdk1
activity prevents ORC reactivation. An APC(Cdh1) complex formed during M phase
prevents premature Skp2-dependent destruction of p27Kip1. Damaged DNA
activates the ATM–p53 pathway, which prevents CDK activation by means of the
inhibitor p21Cip1/WAF1. Unreplicated DNA activates the ATR–CHK1 pathway,
which prevents CDK1 activation and premature mitosis.
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mitogenic signals, cyclin E rescues many of the phenotypes observed
in cyclin D1 deficient mice12. Mice that are defective in all three cyclin
D genes die at mid/late gestation of severe anaemia, but not without
having normally developed many organs and tissues13. Thus,
haematopoietic cells may be cyclin-D-dependent but many other
cell types are ‘cyclin-D-independent’, perhaps indicating that Cdk2
may be sufficient for sensing mitogenic stimuli and mediating pro-
liferation in these cells13. A similar phenotype is observed in mice
lacking Cdk4 and Cdk6, in which Cdk2 with its usual partner cyclins
or with D-type cyclins may be partially compensating for the
absence of Cdk4/6 (ref. 14). These observations add to the growing
suspicion that, if necessary, different mammalian CDKs may take
each other's place in a cell-type-specific manner, or under abnormal
circumstances.
Another mechanism that prevents premature entry into S phase,
and ties the G1/S transition to regulatory inputs, relies on inhibitory
proteins that latch onto cyclin–CDK complexes and disrupt their
catalytic centre15. One of these inhibitors in particular, p27Kip1,
functions as an integral brake of the cell cycle (Fig. 2). Others, such as
p15Ink4b, p16Ink4a, p21Cip1/WAF1 and p57Kip2 are mediators of
cytostatic signals (s e section ‘Cyt static signalling by means of the
SMAD node’ below). p27 silences cyclin–Cdk2, which may be present
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Loss of one cell cycle checkpoint leads to a greater dependence on other 
checkpoints within the cell cycle (Paulovich et al., 1997). This phenomenon has 
been demonstrated in a number of studies that have sought to abrogate the 
G2/M checkpoint in cells with a constitutive defect in the G1/S phase checkpoint 
(Powell et al., 1995, Russell et al., 1995). Therefore, cancer cells are exquisitely 
dependent on S and G2 checkpoint. 
p53 is a classical tumour suppressor gene; its relationship with other important 
components of the DNA damage response pathway is shown in Figure 1-8. 
DNA damage signalling and repair in G1 is mediated by the phosphorylation and 
subsequent activation of repair and cell cycle proteins by ATM and the p53 
tumour suppressor gene (Levine, 1997). p53 is also activated by ATM via CHK2 
and directly by CHK1 (Bouwman and Jonkers, 2012). Activated p53 stimulates 
the expression of p21 (inhibits CDK2, CDK4 and CDK6) leading to cyclin-
dependent kinase (Cdk)-mediated cell cycle arrest at both the G1 and G2/M 
checkpoints (Vogelstein et al., 2000). 
 
1.5.2 The role of ATR and CHK1 inhibition in anti-cancer therapy 
The rationale for using ATR or CHK1 inhibitors in combination with conventional 
cytotoxic therapy (either chemotherapy or ionising radiation) in clinical trials is 
as follows (see Figure 1-9). Many types of cytotoxic therapy seek to kill tumour 
cells by causing DNA damage leading to subsequent cell death. This affects 
both tumour cells and normal tissues, particularly those that are undergoing 
active replacement or turnover.  
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However, cell cycle checkpoint activation allows a window of time for DNA 
repair to take place. Many cancer cells lack a functional G1 cell cycle checkpoint 
and so are dependent on the S and G2 cell cycle checkpoints, which are under 
the control of the ATR-CHK1 pathway (Sherr, 1996, Massague, 2004). 
Therefore, inhibiting this pathway, in combination with conventional cytotoxic 
therapy, in cells lacking functional G1 checkpoint, results in failure to arrest in 
response to DNA damage, accumulation of DNA damage leading to cell death. 
Since normal cells retain the G1 checkpoint inhibition of the S/G2 checkpoint 
with ATR or CHK1 inhibitors in combination with conventional cytotoxics should 
lead to preferential cytotoxicity in tumour cells. 
This principle is known as synthetic lethality (Kaelin, 2005). Sometimes 
mutations in two individual genes may lead to a viable cell if only one mutation 
is present, but if mutations in both genes occur in the same cell they are lethal. 
This is has been extrapolated into drug development where a drug is non-toxic 
in normal cells, but in cancer cells with a functional mutation the presence of the 
drug is lethal. An example of this is PARP inhibitors which are non-toxic to 
normal tissues but in cancer cells with a BRCA1 or BRCA2 mutation inhibition 
of PARP leads to cumulative DNA damage and cell death. 
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Figure 1-9 The effect of CHK1 or ATR inhibition on cancer cells with loss 
of the G1 checkpoint. 
Normal cells with a functional G1 cell cycle checkpoint can pause their cell 
cycle following DNA damage even with exposure to a CHK1 or ATR 
inhibitor. Tumour cells, with a loss of a functional G1 cell cycle 
checkpoint, are dependent on their G2 cell cycle checkpoint to mediate 
cell cycle arrest and DNA repair following DNA damage. The addition of a 
CHK1 or ATR inhibitor in conjunction with a DNA damaging agent may 
selectively kill tumour cells over normal tissue. 
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1.6 Checkpoint 1 kinase (CHK1) 
1.6.1 Structure and activity of CHK1 
CHK1 gene is found on chromosome 11 at 11q24.2 and comprises 16 coding 
exons (Sanchez et al., 1997). It encodes a protein kinase that has an N-terminal 
kinase domain, linker, regulatory domain and C-terminal domain (Patil et al., 
2013). The crystal structure was first published in 2000 by Chen et al and is 
shown in Figure 1-10 (Chen et al., 2000). Checkpoint 1 kinase (CHK1) is a 
protein kinase that has a number of roles in cell cycle regulation. 
 
Figure 1-10 Crystal structure of CHK1 protein 
 
Ribbon diagram of the binary structure of CHK1 with AMP-PNP. Shows 
α  helices (blue), β strands (cyan), catalytic loop (orange) and activation 
loop (red). Ball and stick model of AMP-PNP. Protein termini are labelled N 
and C. Taken from (Chen et al., 2000). 
  
Chk1 Kinase Domain Structure
683
Figure 1. Chk1KD Crystal Structure and Com-
parison with PhK
(A) A ribbon diagram of the binary complex
structure of Chk1 with AMP-PNP showing
secondary structural elements and loops dis-
cussed in the text. The a helices are shown
in blue, b strands in cyan, catalytic loop in
orange, activation loop in red. AMP-PNP and
sulfate ion are shown as ball and stick mod-
els. The triphosphate moiety of AMP-PNP is
not modeled due to lack of electron density
and the ribose ring is in C29-endo pucker con-
formation. The protein termini are denoted
by N and C. The figure was prepared with
Molscript (Kraulis, 1991).
(B) Stereodiagrams comparing theCa tracing
of the Chk1KD (open) and PhK (closed). The
Chk1 (purple) and PhK (blue) structures were
superimposed using the C-terminal lobes as
a reference. The Ca tracing of MC-peptide of
PhK is colored orange. Glu110 of PhK and
Arg(P23) of MC-peptide are shown as ball
and stick models. The N-terminal lobes (resi-
dues 2–90 of Chk1KD and residues 14–108
of PhK) can be aligned with an rms deviation
of 1.1 A˚ between positions of Ca atoms. The
C-terminal lobes (residues 91–276 of Chk1KD
and 110–290 of PhK) superimposed with an
rmsdeviation forCa atomsof 0.9 A˚, excluding
aG and connecting loops. The N-terminal
lobe of Chk1KD can be rotated z158 around
the hinge region near Glu91,whose side chain
almost overlaps with the corresponding side
chain of Glu110 in PhK, to the position of
the N-terminal lobe of PhK. The figure was
prepared with Molscript.
strands of b6 and b9 due to a twist at Phe155 between C-terminal lobe through two ion pairs; one is the invari-
ant kinase ion pair between Glu177 and Arg253, theb9 and b10. Phe155 forms backbone hydrogen bonds
with Gly125 in b6 and Arg162 in b11. Between b10 and other is between Lys180 and Glu248. This extra ion pair
restrains the movement of aEF, and in turn the move-b11 is a b turn formed through backbone interaction
between Tyr157 and Arg160. These interactions pack ment of the C terminus of the activation loop. Interest-
ingly, Lys180 and Glu248 are only conserved amongtheN terminus of the activation loop against the catalytic
loop, and position the highly conserved Arg156 and known vertebrate Chk1 proteins.
Phosphorylation of the activation loop provides a neg-Glu161 whose side chains interact with the invariant
His122 of aE and His185 that precedes aF, respectively. ative charge to cluster a set of positively charged side
chains, thereby stabilizing the active conformations ofTogether, these interactions anchor the N-terminal part
of the activation loop to the core of the C-terminal lobe. both the activation and catalytic loops (Johnson et al.,
1996). In Chk1KD, a cluster of positive charges are con-The center of the activation loop interacts with the re-
mainder of the C-terminal lobe through two backbone tributed from Lys54, Arg129, Arg162, and Lys166 with-
out phosphorylation in the activation loop. A sulfate ionhydrogen bonds between Leu164 and Phe184. The C
terminus of the activation loop is supported by aEF, lies close to the corresponding phosphate position of
the phosphothreonine (Thr197) in cyclic AMP–depen-which is anchored at two positions to the core of the
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1.6.2 Characteristics of CHK1 
The characteristics and attributes of Chk1 are as follows: 
• CHK1 deficiency is embryonic lethal 
• CHK1 is activated by ATR 
• CHK1 is activated by ATM 
• CHK1 activation leads to cell cycle arrest 
• CHK1 activates DNA repair via RAD51 
• CHK1 activates downstream cyclin-dependent kinases 
• CHK1 acts as a spindle checkpoint regulator 
 
Figure 1-11 The role of ATR, ATM, CHK1 and CHK2 in cell cycle control.  
The upstream activators of ATR, ATM, CHK1 and CHK2 and the 
downstream mediators of DNA damage-induced cell cycle checkpoints. 
Arrows denote activation and ball-ended-bars denote inhibition 
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1.6.3 CHK1 deficiency is embryonic lethal 
CHK1 is a very important protein in the embryonic development of cells. Liu et 
al demonstrated that Chk1-deficient embryonic stem cells have a defective 
G2/M checkpoint (Liu et al., 2000a). The cells respond in an abnormal fashion to 
DNA damage from ionising radiation. Chk1 deficiency in embryonic stem cells 
gives rise to a proliferation defect and subsequent cell death. In mice Chk1 
deficiency is associated with peri-implantation embryonic lethality. There are no 
documented syndromes in humans associated with CHK1 deficiency which 
suggests that it might be associated with embryonic-lethality in humans too. 
 
1.6.4 CHK1 is activated by ATR 
CHK1 can be activated by two DNA damage signalling kinases – ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia mutated and Rad3-
related (ATR) (see Figure 1-11). Liu et al showed that ATR activates CHK1 by 
phosphorylation. The development of a clone of cells with defective ATR 
(kinase-dead) inhibited CHK1serine345 phosphorylation in response to UV 
radiation (Liu et al., 2000b). The phosphorylation of CHK1 is essential for its 
activation and subsequent downstream effects. Dart et al demonstrated that 
ATR is recruited to chromatin during S-phase within the normal cell cycle in the 
absence of DNA damage (Dart et al., 2004). During DNA replication there is 
stalling of replication forks, if the DNA damage prevents DNA polymerase and 
other associated enzymes completing the normal replicate process. Replication 
fork stalling leads to binding of replication protein A (RPA) to the exposed single 
strand of DNA and subsequent recruitment of ATR-interacting protein (ATRIP) 
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and ATR (See figure 1-12) (Liu et al., 2012). This leads to the formation of 
nuclear foci of ATR in conjunction with binding proteins.  
 
Figure 1-12 The role of ATR at the replication fork. 
RPA binds to stalled replication forks. ATR associates with ATRIP and the 
sequestered RPA leading to its activation and phosphorylation of CHK1 at 
serine317 and serine345 and H2AX at serine319. 
 
ATR activates CHK1 by phosphorylating the CHK1 protein on serine317 and 
serine345 in an ATP-dependent process (Zhao and Piwnica-Worms, 2001).  The 
ATR specificity of these phosphorylation events was demonstrated using HEK 
293 (renal carcinoma) cells with a dominant negative kinase-active form of ATR 
and a parallel cell line with kinase-inactive ATR (Zhao and Piwnica-Worms, 
2001). In response to hydroxyurea-induced DNA damage the activating 
phosphorylation of CHK1 on serine317 and serine345 was only seen in HEK 293 
cells with kinase-active ATR. ATR also phosphorylates H2AX at serine139. 
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The essential role of ATR in the phosphorylation of CHK1 has been clarified 
further using knockdown cell lines. Cells in which ATM is depleted have been 
shown to be capable of phosphorylating CHK1, but cells in which ATR is 
depleted show no phosphorylation of CHK1 (Jamil et al., 2008). In their studies 
of ATR, Jamil et al also looked at the role of MCL-1 (myeloid cell leukaemia 
protein – a member of the Bcl-2 family of proteins). They showed that MCL-1 
appears to act as a co-regulator of ATR-mediated CHK-1 phosphorylation. 
Transfection-induced over-expression of MCL-1 in HeLa (cervical cancer – p53-
null) and HL60 (pro-myelocytic leukaemia – p53 deleted) cells led to increased 
phosphorylation of CHK1 on serine345 by ATR and an accumulation of cells in 
G2, even in the absence of DNA damage. In HeLa cells siRNA knockdown of 
MCL-1 abolished CHK1serine345 phosphorylation following etoposide-induced 
DNA damage. The authors do not comment if they examined if MCL-1 
knockdown led to abrogation of G2 arrest. 
Peasland et al demonstrated, using cells with an inducible kinase dead ATR 
(ATRKD), that both CHK1 serine345 and serine317 were phosphorylated after 
hydroxyurea and camptothecin and that the ATRKD inhibited both after 
hydroxyurea, but only serine345 after camptothecin (Peasland et al., 2011). They 
concluded that serine345 was ATR-specific, but that serine317 could be 
phosphorylated by other kinases after camptothecin, but not hydroxyurea. 
The importance of ATR in the activation of CHK1 and the downstream elements 
of the G2 checkpoint has been confirmed by other investigators. Numerous 
studies have demonstrated that caffeine and pentoxyphylline can abrogate the 
G2/M checkpoint (Wang et al., 1999, Kawabe, 2004). Liu et al showed 
abrogation of the G2 checkpoint if ATR function was impaired by ATR siRNA 
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(Liu et al., 2008) in ML-1 (myeloid leukaemia) cell lines. Liu et al also showed 
that loss of ATM did not impair the function of the G2 checkpoint; but that the 
checkpoint function did depend on DNA-PKcs. In glioma (M059) cell lines the 
G2 checkpoint was stronger in cells with wild type DNA-PKcs (M059-K) 
compared with mutant DNA-PKcs (M059-J) in response to DNA damage 
caused by a novel DNA damaging agent 2’-C -Cyano-2’-deoxy-1-B-D-arabino 
pentofuranosylcyto-sine (CNDAC). The results were replicated by depleting 
DNA-PKcs with siRNA in wild type DNA-PKcs (M059-K) glioma cells. 
 
1.6.5 CHK1 is activated by ATM 
ATM is a protein kinase deficient in ataxia-telangectasia (AT). AT is a recessive 
neurodegenerative disorder characterized by cerebellar ataxia, progressive 
neural cell death, retinal telangectasia, immunodeficiency and a predisposition 
to developing de novo cancers. In the clinical condition, AT, there is an 
inactivating mutation in the AT gene leading to a deficiency in ATM. ATM is a 
key protein in the response to double-strand breaks (DSBs) in DNA (Shiloh, 
2003). 
In the absence of DNA damage, ATM is present in cells as an inactive dimer. It 
is recruited and activated by the Mre11-Rad50-NBS1 (MRN) complex, leading 
to its autophosphorylation at serine1981. The phosphorylation of ATM breaks up 
the inactive dimer into the active monomer. ATM goes on to phosphorylate 
downstream effector substrates, including CHK1 (serine317) and CHK2 
(serine68) leading to G1, S and G2 cell cycle checkpoint activation. Loss of ATM 
function leads to the failure of cell cycle checkpoint arrest, repair of DNA and 
subsequent apoptosis. ATM activates p53 via phosphorylation of CHK2; which 
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in turn phosphorylates p53 at serine20.   This initiates G1 cell cycle arrest, 
pausing the cell cycle to allow for DNA repair (Kastan et al., 1992).  
ATM is also important in the control of G2/M cell cycle checkpoint arrest. The 
function of the ATM pathway has been demonstrated in an immortalized human 
neural stem cell line (Khanna and Jackson, 2001). If the DDR is induced by 
exposing cells to a single fraction of ionising radiation (0.25 Gy) the ATM 
pathway has been shown to be activated. The level of activation can be 
measured by the formation of γ-H2AX foci, autophosphorylation of ATMserine1981 
and phosphorylation of substrates including Smc1-serine966, Chk2-threonin68 and 
p53-serine15, which were inhibited by the ATM inhibitor KU55933 (Kudos) 
(Carlessi et al., 2009). The role of ATM in the DDR can be shown by comparing 
the response to ionizing radiation in ATM shRNA silenced and control 
immortalised neural stem cells. ATM depleted cells show impaired repair of 
DSBs with reduced formation of γ-H2AX foci; there is an associated reduction in 
cell death. 
Release from the G2/M checkpoint following DNA damage by ionising radiation 
appears to be dependent on the level of residual DSBs (Krempler et al., 2007). 
Krempler et al showed that cell cycle arrest is maintained if more than 10-20 
DSBs persist but cells are released from arrest if there are fewer DSBs. The 
persistent arrest of cells with DSBs was shown in AT cells following exposure to 
a single fraction of ionising radiation.  
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1.6.6 CHK1 activates downstream cyclin-dependent kinases and leads to 
cell cycle arrest 
Cyclin-dependent kinases (CDKs) are proteins that regulate the cell cycle and 
can mediate the effect of checkpoint signalling. The Cdc25 family of 
phosphatases allow cells to proceed through the cell cycle. There are 3 
members of the family Cdc25A, Cdc25B and Cdc25C. The Cdc phosphatases 
remove inhibitory phosphorylations on Cdk/Cyclin complexes allowing 
progression through the cell cycle (Reinhardt and Yaffe, 2009). Cdc25A 
appears to play a role at both the S-phase checkpoint and the G2/M transition 
checkpoint (Ferguson et al., 2005, Jin et al., 2003). The activating 
dephosphorylation of cdc2 (also known as CDK1) by Cdc25A that allows G2/M 
transition. Phosphorylation of Cdc25A by CHK1 targets it for proteosomal 
degradation, by the 26S proteasome, preventing its interaction with its 
cyclin/cyclin-dependent kinase substrates (Chen and Sanchez, 2004).  
A number of studies have looked at the relationship between the checkpoint 
proteins, ATM, ATR, CHK1 and CHK2, and the Cdc25 family of proteins. In one 
of these studies, U2OS (human osteosarcoma – wild type p53) cells and IMR-
90 (immortalised human fibroblasts) cells were exposed to UV light. UV light 
triggers a DNA damage response via ATR. The cell lines demonstrated a 
decline in Cdc25A phosphatase activity and the amount of protein present. 
However, there was no reduction in Cdc25B and Cdc25C activity or amount of 
either protein present (Mailand et al., 2000). 
In another experiment, Mailand et al compared the response to UV radiation 
exposure of U2OS wild type cells and U2OS cells with a conditional negative-
p53 allele and showed a similar decease in activity and amount of Cdc25A in 
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both cell lines (Mailand et al., 2000). Further experiments demonstrated that 
CHK1 was an effector of Cdc25A phosphorylation and subsequent activity. The 
CHK1-mediated response of cells to UV radiation could be abrogated by both 
caffeine (an ATM and ATR inhibitor) and the CHK1 inhibitor UCN-01. This 
suggests that Cdc25A activity in response to UV radiation is independent of the 
p53 pathway and the G1 checkpoint, but dependent on CHK1.  
Cdc25C is a protein phosphatase that controls passage from G2 into mitosis. 
CHK1 phosphorylates Cdc25C at serine216, phosphorylation leads to its 
activation and the formation of a complex with 14-3-3 proteins (regulatory 
proteins that bind to many signalling proteins). The complex is sequestered into 
the cytoplasm (Peng et al., 1997).  This in turn prevents activation of the cyclin 
B/Cdc2 mitotic kinase complex due to Cdc25C functions dephosphorylating 
Cdc2; finally resulting in G2 cell cycle arrest (Shapiro and Harper, 1999) and 
suppression of mitotic entry (Duensing et al., 2006). If Cdc25C is mutated so as 
to not allow phosphorylation on serine216 cells fail to arrest in G2. Peng et al 
demonstrated in HeLa and Jurkat (T cell leukaemia, mutated p53) cells that the 
CHK1 protein phosphorylates Cdc25C at serine216 this leads to cell cycle arrest 
to allow for DNA repair (Peng et al., 1997). Sorensen et al sought to inhibit 
CHK1 in a U2OS cell line using UCN-01 (Sorensen et al., 2003). Inhibition of 
CHK1 (300 nM UCN-01 for 1 hour) led to increase in the expression of Cdc25A 
protein and an increase in the activity of Cdc25A as determined by an increase 
in Cyclin A and Cyclin E expression.  
Wee1 is a kinase that phosphorylates cdc2 and Cdk2 (Lee et al., 2001). This 
has an inhibitory effect. Wee1 is directly phosphorylated on serine642 by CHK1; 
this phosphorylation promotes its association with 14-3-3 proteins. The 
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association of Wee1 with 14-3-3 proteins increases its catalytic activity and 
promotes its inhibitory phosphorylation of cdc2. 
 
1.6.7 CHK1 activates HRR DNA repair via RAD51 and BRCA2 
As described in section 1.3.4, HRR is critical for the error-free repair of DSB and 
stalled replication forks. BRCA2 and RAD51 are key proteins in this process. It 
has been shown that activated CHK1 promotes the association of RAD51 with 
chromatin (Sorensen et al., 2005). Activated CHK1 phosphorylates RAD51 on 
threonine309. The experiments that support the interaction between CHK1 and 
RAD51 include co-immunoprecipitation of a CHK1/RAD51 complex, which can 
be abrogated by hydroxyurea treatment. 
The importance of the threonine309 phosphorylation site has been confirmed by 
site-directed mutagenesis of RAD51threonine309A in Hek 293 cells, which prevents 
its phosphorylation. Cells with a mutated threonine309A RAD51 are more 
sensitive to hydroxyurea and have increased numbers of persistent DSBs, 
indicating that activation of RAD51 by CHK1 is required for HR following DSBs. 
Sorensen et al also showed that knockdown of CHK1 by CHK1 siRNA or 
chemical antagonists UCN-01 and CEP-3891 led to persistent un-repaired 
DSBs following replication-related damage by hydroxyurea or camptothecin 
(Sorensen et al., 2005) in SPD8 (Chinese hamster cells) and SW480SN.3 
(human colorectal cancer). DSBs were quantified by pulsed-field gel 
electrophoresis of 14C-thymidine labelled DNA. Depletion or inhibition of CHK1 
in both these cell lines led to the loss of RAD51 focus formation measured by 
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immunofluorescence microscopy. The same loss of RAD51 foci formation was 
seen if CHK2 was depleted by CHK2 siRNA. 
BRCA2 delivers RAD51 to the DNA and displaces RPA from the DNA replacing 
it with RAD51. BRCA2 is a tumour suppressor protein and mutations in BRCA2 
were associated with cancer predisposition (breast, ovarian, prostate and 
pancreatic cancers). Both CHK1 and CHK2 phosphorylate the carboxyl-terminal 
domain of BRCA2 (Bahassi et al., 2008). Phosphorylation of BRCA2 facilitates 
its interaction with RAD51.  
Cells which lack the phosphorylation domain of BRCA2 (MEF (mouse embryo 
fibroblasts) - lex1/lex2) show no localisation of RAD51 to DSBs. Cells with 
mutant BRCA2 are hypersensitive to DNA damaging agents. CHK2 depletion 
leads to loss of RAD51 localisation that is associated with DNA double-strand 
breaks. 
 
1.6.8 CHK1 acts as a spindle checkpoint  
The spindle checkpoint inhibits progression into anaphase if the chromosomes 
have failed to attach correctly to the mitotic spindle (Murray, 1995). CHK1 has 
also been shown to mediate spindle checkpoint activation by phosphorylating 
Aurora B kinase (Zachos et al., 2007). Aurora B kinase subsequently 
phosphorylates histone H3 at serine10, resulting in anaphase delay to prevent 
cells acquiring defects associated with chromosome miss-segregation.  
The importance of the CHK1 protein as a spindle checkpoint regulator has been 
shown using CHK1 knockdown (siRNA) in U2OS cell lines (Carrassa et al., 
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2009), which led to an increase in giant polynucleated cells and G1 arrested 
tetraploid cells. This suggests that U2OS cells with aberrant CHK1 have 
abnormal mitosis and do not activate the spindle cell checkpoint. 
Zachos et al have shown that CHK1 is required to sustain this (Zachos et al., 
2007). Cells that are deficient in Chk1 (using CHK1 siRNA) have up to 33% 
misaligned chromosomes and subsequent chromosomal instability.  
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1.7 Biomarkers for CHK1 inhibition 
Potential biomarkers for CHK1 inhibition include cdc25A stability, Cdc25C 
serine216 and H3 at serine10. An alternative downstream biomarker for CHK1 
inhibition would be Wee1serine642 phosphorylation (Lee et al., 2001). All of these 
markers could be used as cellular proof-of-mechanism biomarkers of CHK1 
activity, and its inhibition. 
Phosphorylation of CHK1 itself is also a potential biomarker. 
Autophosphorylation of CHK1 at serine296 occurs in the presence of 
conventional cytotoxics and is abolished with CHK1 inhibition (Guzi et al., 
2011). Guzi et al demonstrated that hydroxyurea increased CHK1serine296 
phosphorylation in U2OS cells and that this was reduced in a concentration-
dependent fashion by SCH 900776 (0.06 – 2 µM for 2 hours). Bryant et al 
showed in two triple-negative breast cancer cell lines, MDA-MB-468 and SKOV-
3, that a 24 hour exposure to 31.25 to 1000 nM V158411 significantly reduced 
CHK1serine296 autophosphorylation (Bryant et al., 2014b). 
Phosphorylation of CHK1serine345 has been used as a marker of ATR activity 
(Zhao and Piwnica-Worms, 2001). However, CHK1serine345 also appears to be 
phosphorylated in the presence of some CHK1 inhibitors used alone (Parsels et 
al., 2011). Bryant et al have shown that 31.25 to 1000 nM V158411 for 24 hours 
increases CHK1serine345 phosphorylation in a dose-dependent fashion in MDA-
MB-468 and SKOV-3 triple-negative breast cancer cell lines (Bryant et al., 
2014b). This raises the possibility that it could be used as a PD biomarker, 
demonstrating that the CHK1 inhibitor is present in a cell or tumour sample. The 
pre-clinical data pertaining to the CHK1 phosphorylation and its potential as a 
biomarker in pre-clinical studies is explored in more detail in Section 3.1. 
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H2AX has also been used extensively as a biomarker (Redon et al., 2010). 
Histone H2AX is phosphorylated on serine139 in response to DSBs in the 
chromatin that adjoins the damage (Rogakou et al., 1998). The disadvantage of 
H2AX as a biomarker for CHK1 activity is that it is not specific to CHK1. H2AX 
is part of the final common pathway to both homologous recombination and 
non-homologous end-joining. Therefore a number of potential control 
mechanisms for these DNA repair pathways may be implicated including 
ATR/CHK1, but also ATM/CHK2 and DNA-PK/JNK (Mukherjee et al., 2006, van 
Attikum and Gasser, 2005). 
H2AX was used as a biomarker by Daud et al in the phase I clinical trial of SCH 
900776 in combination with gemcitabine (Daud et al., 2010). They performed an 
ex vivo assay using patient plasma taken at the same time as PK samples. 
Plasma was diluted (1:4) and applied to K562 cells, following fixation H2AX 
levels were measured by flow cytometry. The authors concluded that there was 
prolonged bioactivity of SCH 900776 as quantified by H2AX levels. This 
correlated in H2AX levels seen in biopsies of normal skin taken at matched time 
points. 
Geminin has been suggested as a potentially useful biomarker of cells arrested 
in S phase. Perez et al performed a pre-clinical validation study demonstrating 
that geminin, as quantified by both immunohistochemistry (IHC) and flow 
cytometry, increased in MDA-MB-231 breast cancer cells arrested in S phase 
by 0.1 ng/ml and 1 ng/ml SN-38 (Perez et al., 2006). Levels of staining by IHC 
correlated with those by flow cytometry. They used geminin staining as a 
biomarker in a phase I study of UCN-01 in combination with cisplatin. Tumour 
biopsies from cutaneous skin metastases were performed in 3 out of 7 patients. 
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Geminin staining (by IHC) was seen in 2-8% of tumour cells prior to treatment, 
geminin staining significantly increased following the administration of 30 mg/m2 
cisplatin suggesting cells were arresting in S, but this increase was abrogated 
by 33.75 mg/m2/day UCN-01 (as 72 hour continuous infusion) suggesting that 
the S phase checkpoint was abrogated leading to cells progressing into G1. 
Neither the phase I trial of LY2603618 in combination with pemetrexed or 
pemetrexed and cisplatin published any biomarker data (Weiss et al., 2013, 
Calvo et al., 2014). The three phase I studies of PF-0477736 in combination 
with gemcitabine (2010) and AZD7762 in combination with gemcitabine (2011) 
or AZD7762 in combination with irinotecan (2011) presented in abstract form at 
ASCO have not presented any biomarker or pharmacodynamic data (Brega et 
al., 2010, Ho et al., 2011, Sausville et al., 2011). 
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1.8 Chemistry of CHK1 inhibitors 
This brief section seeks to explain the structures and chemistry of CHK1 
inhibitors to date, where this has been published. The relative potency of the 
inhibitors and the type of assay that has been used to determine this is also 
discussed. 
 
1.8.1 UCN-01 
UCN-01 is a staurosporine analogue that initially was identified as a protein 
kinase C inhibitor (Courage et al., 1995). The structure is shown in Figure 1-13. 
It was also shown to have activity against a range of other kinases including 
CHK1 and PDK1.  
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Figure 1-13 Structures of CHK1 inhibitors 
A: UCN-01 (Courage et al., 1995), B: PD-321852 (adapted from patent 
application WO2008007113 A2), C: AZD7762 (Zabludoff et al., 2008), D: 
CHIR-124 (Tse et al., 2007b), E: SCH 900776 (Guzi et al., 2011), F: SAR-
020106 (Walton et al., 2010), G: CCT244747 (Walton et al., 2012), H: GNE-
900 (Blackwood et al., 2013) 
 
1.8.2 PD-321852 
PD-321852 is a phenyl-carbazole (4-(2,6-dichloro-phenyl)-9-hydroxy-6-(3- 
methylamino-propyl)-6H-pyrrolo[3,4-c]carbazole-1,3-dione) kinase inhibitor 
developed by Pfizer and University of Auckland (New Zealand) (Parsels et al., 
2009). The structure is shown in Figure 1-13. It is a UCN-01 analogue with a 
greater specificity and potency for CHK1 than UCN-01. However, the authors 
indicate that it does have activity against other kinases (not specified) and these 
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may account for some of its effects. Its IC50 in a cell-free inhibition assay for 
CHK1 is 5 nM. 
 
1.8.3 PF00477736 
PF00477736 (Pfizer) is a novel diazepinoindolone, an ATP-competitive small 
molecular CHK1 inhibitor with a Ki for Chk1 of 0.49 nM (Blasina et al., 2008). 
The structure of PF00477736 has not been published. It has a 100-fold 
selectivity for CHK1 over CHK2. Other kinases that were inhibited by 
PF00477736 with a less than 100-fold selectivity included VEGF2R, Aurora-A, 
FGFR3, Flt3, Fms, Ret and Yes. However, despite the apparent ability of 
PF00477736 to inhibit Aurora-A in a kinase assay it did not appear to 
demonstrate this effect in vitro as it did not induce the blockade of cytokinesis or 
cell proliferation. In pre-clinical studies, the cellular potency of PF00477736 was 
measured by assessing cells entering mitosis (histone H3 phosphorylation by 
spectral dot-blot analysis) (Blasina et al., 2008). The cellular EC50 by this 
method was 45 nM. 
 
1.8.4 AZD7762 
AZD7762, a thiophene carboxamide urea [3-(carbamoylamino)-5-(3-
fluorophenyl)-N-[(3S)-3-piperidyl]thiophene-2-carboxamide] (AstraZeneca). It is 
an ATP-competitive inhibitor of both Chk1 (Ki = 3.6 nM, IC50 = 5 nM in in vitro 
assays) and CHK2 (IC50 = <10 nM) with a similar potency (Zabludoff et al., 
2008). The cellular IC50 was calculated by measuring the ability of AZD7762 to 
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inhibit the CHK1 mediated phosphorylation of cdc25C. AZD7762 has a less 
than 10 fold selectivity against other kinases including CAM kinases and Src-
like kinases. The structure is shown in Figure 1-13.  
 
1.8.5 CHIR-124 
CHIR-124 (Chiron) [(S)-3-(1H-benzo[d]imidazol-2-yl)-6-chloro-4-(quinuclidin-3-
ylamino) quinolin-2(1H)-one] (Figure 1-13) is a novel quinolone-based small 
molecular inhibitor of CHK1 with an IC50 = 0.3 nM (Tse et al., 2007b).  This was 
determined in a cell-free kinase assay examining the ability of CHK1 to inhibit 
cdc25C phosphorylation. CHIR-124 also has some limited activity against 
PDGFR, FLT3 and GSK3, but with 10 to 100-fold higher IC50 values. 
 
1.8.6 CEP-3891 
CEP-3891 (Cephalon) was developed as a more specific small molecular 
inhibitor of CHK1 (Sorensen et al., 2003). The cellular IC50 (determined by the 
reduction in Cdc25A phosphorylation) of CEP-3891 is 4 nM. Other kinases 
inhibited by CEP-3891 included TrkA (9 nM), MLK1 (42 nM) and VEGFR2 (164 
nM). No structure of CEP-3891 has been published.  
 
1.8.7 XL9844 
XL9844 (EXEL-9844 – Exelixis Inc) is a very potent oral aminopyrazine inhibitor 
of both CHK1 and CHK2 (Ki 2.2 nM and 0.07 nM, respectively) (Matthews et al., 
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2007). No structure has been published. These Ki results were determined in a 
cell-free radiolabelled-ATP competitive assay. The inhibition of both CHK1 and 
CHK2 was shown to be reversible with competition with increasing 
concentrations of ATP. XL9844 also inhibited VEGFR2 (IC50 = 12 nM) and Flt-4 
(IC50 = 6 nM). 
 
1.8.8 SCH 900776 
SCH 900776 (MK-8776) (Schering Plough/Merck) is a pyrazolo[1,5-
a]pyrimidine-based compound (Figure 1-13) that acts a potent inhibitor of CHK1 
(Kd = 2 nM, IC50 = 60 nM in a cell-free kinase assay). SCH 900776 does not 
inhibit CHK2 (IC50 = 1.5 µmol/L) and is a weak CDK2 (IC50 = 160 nM) inhibitor 
(Guzi et al., 2011). 
 
1.8.9  SAR-020106 
SAR-020106 (Sareum) is a pyrazolo[1,5-a]pyrimidine (Figure 1-13) inhibitor of 
CHK1 with an  IC50 of 13.3 nM when tested against the isolated recombinant 
CHK1 enzyme in a cell-free assay (Matthews et al., 2009). The compound is 
available when delivered intravenously. It has an IC50 for CHK2 and CDK1 of > 
10 µM. Other kinases that were modestly inhibited included FLT3, IRAK4, Met, 
MST2, p70S6K, Ret, RSK1 and TrkA. 
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1.8.10 CCT244747 
CCT244747 (Figure 1-13) is a novel oral CHK1 inhibitor developed by the 
Institute for Cancer Research in London and Sareum Pharmaceuticals (Walton 
et al., 2012). It has been developed from the compound SAR-020106. Its IC50 
against recombinant CHK1 is 8 nM.  It shows >75 times selectivity against FLT3 
and >1000 fold selectivity against CHK2 and CDK1. It has been shown to have 
a cellular IC50 for CHK1 of 29-170 nM when looking at the cellular abrogation of 
the G2 checkpoint in a mitosis induction assay. Mouse xenograft models of 
human tumours have confirmed that clinically relevant concentrations of 
CCT244747 are detectable following oral administration with an oral 
bioavailability of 62%. 
 
1.8.11 LY2603618 
LY2603618 is an intravenous selective CHK1 inhibitor developed by Eli-Lilly 
(King et al., 2014). It has an in vitro kinase activity against Chk1 of 7 nM in a 
cell-free assay. The structure has not been published. 
 
1.8.12 GNE-900 
GNE-900 (9H-Pyrrole[2,3-b:5,4-c’]dipyridine-6-carbonitrile,3-[4-(1-piperidinyl 
methyl)phenyl]) (Figure 1-13) is a potent and selective orally bioavailable 
inhibitor of CHK1 developed by Genentech by high-throughput screening of 
their small molecule library (Blackwood et al., 2013). It is an orally bioavailable 
ATP-competitive small molecular inhibitor of CHK1 with an IC50 for CHK1 in a 
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cell free kinase assay of 1.1 nM. It has a 300-fold selectivity compared to 
kinases that regulate other parts of the cell cycle; Aurora, PLK and CDK 1/2. 
 
1.8.13 V158411 
V158411 is a novel inhibitor of both CHK1 and CHK2. The structure of V158411 
has not been published. Its molecular weight is 538 kDa. Its IC50 in an in vitro 
kinase assay was 3.5 nM (CHK1) and 2.5 nM (CHK2) (Bryant et al., 2014a). In 
a cellular assay in HT29 (colorectal cancer, p53 mutated) cells, V158411 
inhibited the phosphorylation of CHK1serine296 with an IC50 of 48 nM and 
CHK2serine516 with an IC50 of 904 nM. There is no information in the public 
domain about the activity of V158411 against a wider kinase panel including 
other kinases such as FLT3. 
 
1.8.14 Other CHK1 inhibitors 
There is no published information on the structure or chemistry of a number of 
CHK1 inhibitors including LY2606368, GDC-0425 or ARRY575. 
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1.9 CHK1 inhibitors 
The pre-clinical evidence for the use of Chk1 inhibitors as single agents in 
clinical trials is less developed and less numerous than the data for their use in 
conjunction with conventional cytotoxic therapy (see Section 1-11). Only a few 
CHK1 inhibitors appear to be cytotoxic as single agents in cell line and animal 
studies. It is unclear whether those inhibitors that are cytotoxic as single agents 
mediate this cytotoxicity through their direct effect on CHK1 or by other 
mechanisms. Further work needs to be done to look at tumour and patient 
characteristics that may make tumours and patients suitable for treatment with a 
CHK1 inhibitor as a monoagent and this is explored further in Chapter 6. 
The first pre-clinical data on a CHK1 inhibitor to be published was with UCN-01 
which entered Phase 1 clinical trials in 1995. Subsequently, 10 CHK1 inhibitors 
have been developed with greater potency and a higher specificity for CHK1. 
Most of these ‘second generation’ inhibitors are ATP-competitive. The majority 
of these compounds are administered i.v., though a number of oral compounds 
are under development. Table 1-2 outlines those CHK1 inhibitors being 
developed and their stage of development. 
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Name of 
compound and 
Company 
 
Pre-clinical 
data published 
 
Development 
phase 
 
Route and trial 
Combination 
Dose-limiting toxicity Future 
Development 
Multiple kinases including CDKs and Chk1 
 
UCN-01 
 
Yes (Courage 
et al., 1995, 
Dai et al., 
2002, Mack et 
al., 2003) 
 
Phase 1 – 2 trials 
(short and long 
infusions) 
(Sausville et al., 
2001, Dees et al., 
2005) 
IV single agent in 
AST 
Hypotension and 
hyperglycaemia 
Stopped – no 
further 
development 
planned 
Phase 1 (Lara et 
al., 2005, Perez et 
al., 2006) 
IV in combination 
with cisplatin in 
AST 
Neutropenic sepsis 
and SVT 
Stopped – no 
further 
development 
planned 
Phase 1 (Hotte et 
al., 2006) 
IV in combination 
with topotecan in 
AST 
Neutropenia, 
thrombocytopenia 
and hyperglycaemia 
Stopped – no 
further 
development 
planned 
Phase 2 IV in combination 
with topotecan in 
ovarian cancer 
Hyperglycaemia Stopped – no 
further 
development 
planned 
Chk1 and Chk2 inhibitor 
AZD7762 
- Astra Zeneca 
 
Yes (Zabludoff 
et al., 2008, 
Morgan et al., 
2010, Mitchell 
et al., 2010b, 
McNeely et al., 
2010) 
 
2 Phase 1 trials 
(Sausville et al., 
2011, Sausville et 
al., 2014, Seto et 
al., 2013) 
IV in combination 
with gem in AST 
Myocardial ischaemia 
and neutropenia 
2 Phase 1 
studies 
published – 
development 
stopped due to 
toxicity 
Phase 1 (Ho et al., 
2011) 
IV in combination 
with irinotecan in 
AST 
Myocardial ischaemia ASCO 2011 
abstract 
Selective Chk1 inhibitors 
PF00477736 
- Pfizer 
 
Yes (Blasina 
et al., 2008) 
 
Phase 1 (Brega et 
al., 2010) 
 
IV in combination 
with gem in AST 
Thrombocytopenia 
and neutropenia 
ASCO 2010 
abstract 
Stopped – no 
further 
development 
planned 
PD-321852 
- Pfizer 
Yes (Parsels 
et al., 2009) 
 
Pre-clinical 
 
IV compound. No clinical trials Stopped – no 
further 
development 
planned 
SCH900776 (MK-
8776) 
Yes (Montano 
et al., 2012, 
Phase 1 (Daud et 
al., 2010) 
IV in combination 
with gem in AST 
SVT and 
thrombocytopenia 
Closed - ASCO 
2010 abstract 
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- Schering Plough Guzi et al., 
2011) 
 
Phase 1 IV in combination 
with cytarabine in 
leukaemia 
 Closed -
awaiting 
publication 
LY2603618 
- Eli-Lily 
Yes (Wang et 
al., 2014) 
Phase 1 (Weiss et 
al., 2013, Calvo et 
al., 2014) 
 
Phase II active 
IV in combination 
with pemetrexed 
or gemcitabine in 
NSCLC 
IV in combination 
with pemetrexed 
and cisplatin in 
NSCLC 
 Phase I closed 
and 1 study 
published 
 
Phase II – in 
follow up 
LY2606368 
- Eli-Lily 
 
No 
 
Phase 1 
 
IV single agent in 
AST 
 
 
Phase 1 – 
finishing Feb 
2012 
CHIR-124 
(Chiron/Novartis) 
Yes (Tse et 
al., 2007b, 
Tao et al., 
2009) 
Pre-clinical IV   
XL844 (Exelixis) Yes (Matthews 
et al., 2007) 
Phase 1 Oral in 
combination with 
gem in AST and 
lymphoma 
 Phase 1 - 
terminated 
SAR020106 
(Sareum) 
Yes (Walton et 
al., 2010) 
Pre-clinical IV   
GDC-0425 
(Roche/Genentec
h) 
No Phase 1 IV in combination 
with gem in AST 
 Phase 1 
recruiting 
CEP3891 
(Cephalon) 
Yes 
(Syljuasen et 
al., 2004) 
Pre-clinical IV   
CCT244747 
(ICR/Sareum) 
Yes (Walton et 
al., 2012) 
Pre-clinical Oral   
ARRY575 (GDC-
0575) (Array 
Pharma/Genente
ch) 
No Pre-clinical Oral   
V158411 
- Vernalis 
Yes (Bryant et 
al., 2014a 
and Bryant et 
al., 2014b) 
Pre-clinical IV  
 
 
Table 1-2 CHK1 inhibitors under development. 
IV – intravenous; AST – advanced solid tumours; Gem – gemcitabine. 
Additional data from http://clinicaltrials.gov 
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1.10 Assay methods used in pre-clinical research 
The effects of CHK1 inhibitors, alone and in combination with cytotoxic agents 
has been evaluated by different methods and each method has advantages and 
disadvantages and measures subtly different outcomes. 
Several 96-well plate assays can be employed, these are quick, simple and 
relatively high throughput, but don’t distinguish between growth arrest and cell 
kill. That is, a GI50 value could reflect 50% cell kill followed by growth of the 
remaining treated cells at the same rate as untreated control or a slowing of the 
growth rate such that the treated cells underwent one less cell doubling than the 
controls or a mixture of these 2 outcomes. Quantification of cell number and or 
viability in these assays can be via quantitative protein stain e.g. 
sulphurhodamine B (SRB) (Skehan et al., 1990). However, cells treated with a 
cytotoxic agent may continue to grow in size if not number (unbalanced cell 
growth due to nuclei containing multiple copies of DNA, but with the cell failing 
to divide) leading to an over-estimate of cell number in the treated cells 
(Keepers et al., 1991, Martin and Clynes, 1993) 
Alternative methods are measurement of cellular (mitochondrial) 
dehydrogenase activity by following the reduction of tetrazolium salts to 
coloured formazan products, this is the principle of MTT, MTS, XTT, Alamar 
blue assays and is said to reflect viable cells only but may also be influenced by 
unbalanced cell growth. Cellular ATP has also been coupled to chemi-
luminescence detection (Cell Titerglo) as a means to quantify viable cells as an 
endpoint in 96-well plate assays. Although the ATP and dehydrogenase assays 
would be predicted to produce similar results, recent comparison of the 
literature on drug sensitivity determined by these 2 methods in large 
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overlapping panels of cell lines revealed poor concordance of the data 
(Weinstein and Lorenzi, 2013). 
Perhaps a more reliable method of quantitation is to measure DNA (Promega 
kit), but this is a relatively new method and has not been widely adopted. The 
most robust way of measuring growth inhibition is by direct cell counting but 
again this will not distinguish between a slowing of the growth rate and cell 
killing. The most reliable method of assessing cell kill is by measurement of the 
clonogenic potential, i.e., the ability of cells to form colonies after treatment 
compared to control. However, this is very time-consuming and requires larger 
volumes of reagents, making it costly and not all types of cells form countable 
colonies. Even though this method may offer some advantages over others, 
cells that have arrested, but are alive will fail to form colonies and so will falsely 
be assumed to have died. The methods that have been used to assess CHK1 
inhibitor effects needs to be taken into account when interpreting the data. 
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1.11 Single agent activity of CHK1 inhibitors 
There is relatively little published data on the single agent cytotoxicity of CHK1 
inhibitors. Only 2 inhibitors, UCN-01 and LY2606368, have been taken into 
early phase clinical trials as single agents. In the early development of UCN-01 
its main effects were thought to be mediated by its inhibition of protein kinase C 
(PKC) (Courage et al., 1995). Courage et al demonstrated that UCN-01 had 
growth inhibitory effects in A549 (NSCLC – wild type p53) and MCF7 (breast 
cancer – wild type p53) cell lines that were independent of PKC. Growth 
inhibition with UCN-01 was similar in PKC depleted and untreated control cells 
(GI50 0.033 µM and 0.034 µM respectively in A549 cells, GI50 0.0178 µM and 
0.0175 µM respectively in MCF7 cells).  
300 nM and 1 µM XL9844 did not have any significant single-agent activity in 
clonogenic assays in 4 cancer cell lines (PANC-1 (pancreatic cancer – p53 
mutated), AsPC-1 (pancreatic cancer – p53 mutated), SKOV3 (ovarian cancer – 
wild type p53) and HeLa) (Matthews et al., 2007). The authors hypothesise that 
this may be due to insufficient constant exposure to the CHK1 inhibitor. 
Blackwood et al found that the orally bioavailable CHK1 inhibitor GNE-900 had 
little effect as single agent (GI50 in HT29 cells is 8.7 µM) (Blackwood et al., 
2013). There is no published single agent data with PF00477736, CEP-3891 or 
SAR-020106. 
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1.11.1 AZD7762 
AZD7762 (100 nM for 24 hours) did not affect the proliferation of HCT116 
(colorectal cancer – wild type p53) in a 96 well plate assay (absorbance assay 
measuring DNA content) (McNeely et al., 2010). Zabludoff et al present a small 
amount of in vivo data with single agent AZD7762 in mouse xenografts studies 
(Zabludoff et al., 2008). They demonstrate that AZD7762 (25 mg/kg BD every 3 
days) caused a modest reduction in the growth of SW620 (colorectal – mutated 
p53) xenografts compared to vehicle. 
 
1.11.2 PD-321852 
PD-321852 had modest single-agent activity in four pancreatic cell lines 
(MiaPaCa2, M-Panc96, BxPC3 and Panc1 (all p53 mutated)) using clonogenic 
assays (Parsels et al., 2009). Cells were treated for 24 hours in media 
containing PD-321852 prior to plating out into drug-free media for 12 to 14 days. 
They describe a ‘threshold’ toxic (the highest non-toxic) concentration of 100 
nM and minimal toxicity at 300 nM in all 4 pancreatic cell lines.  
 
1.11.3 CHIR-124 
No single agent in vitro data has been published with CHIR-124. However, 
there is in vivo data (Tse et al., 2007b). In mouse models, CHIR-124 (10 or 20 
mg/kg i.v. daily on days 2-7) alone had no effect on MDA-MB-435 (breast 
cancer cell line – p53 mutated) xenografts. 
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1.11.4 SCH 900776 
Montano et al report a wide range of sensitivities to single-agent SCH 900776 
(Montano et al., 2012). They demonstrate that a number of cell lines were 
sensitive to SCH 900776 in 96-well plate growth assays stained with Hoechst 
33258 including HCC2998 (colonic cancer (p53 mutated) GI50 = 500 nM), U2OS 
(GI50 = 550 nM), A498 (GI50 = 500 nM) and TK-10 (renal cell cancer (p53 
mutated) GI50 = 230 nM) cancer cell lines. However, a number of cell lines are 
resistant to a 24 hour exposure to SCH 900776 with a GI50 > 10 µM. These 
included MDA-MB-231 (breast cancer cell line – p53 mutated), MCF-10A 
(immortalised breast cell line), HCT116, HCT15 (colorectal cancer – p53 
mutated) and SW620 cell lines. The authors do not comment on any potential 
factors that might contribute to the sensitivity to SCH 900776. In animal studies 
in mice bearing xenografts (A2780 (ovarian cancer – p53 wild type) and 
MiaPaca) SCH 900776 showed little single agent activity (Guzi et al., 2011). 
 
1.11.5 V158411 
The sensitivity of cell lines to single-agent V158411 has been explored by 
Vernalis (Bryant et al., 2014a, Bryant et al., 2014b). Work has demonstrated 
that triple-negative breast cancer cells (HCC1937 (BRCA1-mutated, p53 
mutated), MDA-MB-157 (p53 mutated), MDA-MB-231, MDA-MB-453 (p53 
mutated) and MDA-MB-468 (p53 mutated)), ovarian (SKOV-3 and A2780), 
leukaemia (MV4:11 (p53 wild type), HL60, and Jurkat) and lymphoma (U937 
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(p53 wild type) and Raji (p53 mutated)) cell lines are sensitive to single agent 
V158411. 
HL60, Jurkat, MV4:11, Raji and U937 cell lines had GI50 of less than 1 µM 
following a 72 hour exposure to V158411 in a 96-well plate growth inhibition 
assay (Titer glo). (Bryant et al., 2014a, Bryant et al., 2014b). The sensitivity to 
V158411 appeared to show no correlation with their p53 status. It also did not 
appear to correlate with their known sensitivity to chemotherapy (gemcitabine 
and cisplatin). 
A response to V158411 in sensitive cell lines appears to correlate with the 
degradation of CHK1 (Bryant et al., 2014a). There was also time-dependent 
phosphorylation of H2AX. Measurement of CHK1 and γ-H2AX in cells treated 
with V158411 for 24 hours revealed that cells that were not sensitive to 
V158411 showed degradation of CHK1, but no increase in γ-H2AX foci 
formation. 
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1.12 Synthetic lethality with CHK1 inhibitors 
Synthetic lethality is used to describe a situation where the inactivation of two 
pathways independently is not cytotoxic, but when both pathways are targeted 
or one is constitutively inactive there is significant cytotoxicity. Combining CHK1 
inhibitors with other inhibitors targeting DNA damage repair has been employed 
as a potential strategy to exploit synthetic lethality. 
 
1.12.1 CHK1 and Myc 
There are a number of publications that have focused on the potential utility of 
CHK1 inhibitors in Myc-amplified cancers. Myc is an oncogene amplified in a 
number of cancers including lymphomas (cMyc), neuroblastomas (MYCN) and 
a few breast and lung cancers. It has been noted that CHK1 is up-regulated in 
cMyc-overexpressing murine and human lymphomas (Hoglund et al., 2011a). 
The authors have also noted that CHK2 deficiency (or CHK2 inhibition with the 
dual CHK1/CHK2 inhibitor AZD7762) in cMyc-amplified lymphomas is 
synthetically lethal (Hoglund et al., 2011b). CHK1 inactivation, by either siRNA 
or by a novel experimental CHK1 inhibitor ‘Chekin’ (developed by Abbott 
laboratories, no further details of Chekin are available), resulted in cytotoxicity in 
cMyc-amplified cell lines. The mechanism is thought to be due replication stress 
induced by a myc amplification-associated hyperproliferative state, causing 
increased dependence on the S/G2 checkpoints. 
This work was supported by a second study by Ferrao et al which examined the 
effect of single agent PF00477736 on Eµ-myc lymphoma cell lines (Ferrao et 
al., 2011). The authors compared the effect of PF00477736 in colony forming 
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assays in soft agar on p53-wild type ARF null Eµ-myc lymphoma cell lines and 
p53-null ARF null Eµ-myc lymphoma cell lines. The p53-wild type cell lines were 
significantly more sensitive to 24 hour exposure to PF0047736 than the p53-null 
cell line (GI50 0.31 µM and 2.46 µM respectively). This is contrary to the 
expectation that dysfunctional p53 will render a cell more sensitive to a CHK1 
inhibitor. 
CCT244747 has also been shown to have single agent activity against MYCN-
associated neuroblastoma. In a hemi-zygotic transgenic mouse overexpressing 
MYCN (Walton et al., 2012). 7-day continuous oral administration of 100 mg/kg 
CCT244747 led to 79% tumour volume reduction (as assessed by MRI) 
compared to vehicle treated controls 
 
1.12.2 CHK1 and PARP 
Mitchell et al demonstrated that combining CHK1 inhibitors (UCN-01 and 
AZD7762) with the PARP inhibitor, PJ34, caused a synergistic impairment of 
cell viability in colony forming assays (Mitchell et al., 2010a). MCF7, 4T1 (p53 
mutated), SKBR3 (p53 mutated) and BT474 (p53 mutated) breast cancer lines 
were exposed to vehicle, 3 µM PJ34, 50 nM UCN-01 or 25 nM AZD7762 or the 
combination of UCN-01 or AZD7762 + PJ34 for 48 hours. In 4T1, SKBR3 and 
BT474 cells, PJ34, 25 nM AZD7762 and 50 nM UCN-01 alone killed ~10% of 
cells. The combination of AZD7762 and PJ34 or UCN-01 was at least additive 
with between 20-25% cells killed. In Panc-1, MiaPaca2 (pancreatic cancer – 
p53 mutated) and MCF7 cells single agent PJ34, AZD7762 and UCN-01 killed 
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less than 10% of cells, but in combination showed synergism with 25-30% cell 
death. 
The authors demonstrated that both UCN-01 and AZD7762 promoted H2AX 
and increased PARP 1 activity. If PARP function was inhibited with PJ34, there 
was loss of CHK1 inhibitor-mediated H2AX phosphorylation and activation of 
ERK 1/2. However, PJ34 is highly cytotoxic as a single agent at concentrations 
that do not significantly inhibit PARP so the cytotoxicity may have been due to 
off-target effects. There was synergism between CHK1 inhibitors and PARP 
inhibitors in cell lines with both low basal ERK 1/2 activity (MCF7) and high 
basal ERK 1 and 2 activity (MDA-MB-231 and Panc1 cell lines) suggesting that 
ERK1/2 activation is not the sole mediator of sensitivity to the combination of 
CHK1 and PARP inhibitors. 
The use of a PARP inhibitor in combination with a CHK1 inhibitor and 
radiotherapy is considered in section 1-14. 
 
1.12.3 CHK1 and MEK inhibitors 
The MAPkinase pathway is frequently up-regulated in cancer promoting 
proliferation and inhibiting apoptosis. MEK and ERK are important components 
of this pathway Therefore, the combination of a CHK1 inhibitor (UCN-01) and 
MEK inhibitor (PD184352 - a MEK1/2 inhibitor developed by Pfizer) has been 
examined in 3 myeloma cell lines (8226 (mutated p53), H929 (wild type p53) 
and U266 (mutated p53)). Co-administration of 150 nM UCN-0 for 24 hours 
following 30 minutes with 10 µM PD184352 alone resulted in a marked increase 
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in cell death in myeloma cell lines (Dai et al., 2002). There appeared to be 
synergism with fewer than 25% apoptotic cells with either drug alone and 
between 50 and 75% apoptosis with the drugs in combination. The combination 
of UCN-01 and PD184352 was also effective at inducing apoptosis in cell lines 
resistant to doxorubicin (8226/Dox40), resistant to melphalan (8226/LR5) and 
dexamethasone (MM.1R) 
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1.13 CHK1 inhibitors in combination with chemotherapy 
The majority of pre-clinical data that has been published with CHK1 inhibitors 
has been with conventional cytotoxic therapy and in particular with gemcitabine, 
topoisomerase inhibitors and platinum compounds. 
 
1.13.1 CHK1 inhibitors and gemcitabine  
The combination of gemcitabine and a CHK1 inhibitor has been examined by a 
number of investigators. Gemcitabine causes chain termination during DNA 
replication leading to S phase arrest. This arrest is dependent on CHK1 and 
allows cells a chance to repair gemcitabine-mediated DNA damage. Using a 
CHK1 inhibitor in combination with gemcitabine may potentiate cytotoxicity by 
overriding the checkpoint, causing the cell to try to progress through the cell 
cycle with damaged DNA. 
Parsels et al demonstrated the sensitisation of a panel of pancreatic cancer cell 
lines (MiaPaCa2, BxPC3 and M-Panc-96) to gemcitabine by PD-321852 in 
clonogenic assays (Parsels et al., 2009). Pancreatic cell lines were chosen as 
gemcitabine is the first choice chemotherapy both in the adjuvant and 
metastatic context for pancreatic cancer. Cells were treated with gemcitabine 
and PD-321852 concomitantly for 24 hours before being seeded out in drug free 
media. There was a 13-fold (MiaPaCa2), 17-fold (M-Panc-96) and 6-fold 
(BxPC3) reduction in the gemcitabine IC50 by co-incubation with PD-321852.  
The authors also showed that in pancreatic cells treated with PD-321852 and 
gemcitabine there was predictable stabilisation of Cdc25A. The degree of 
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stabilization varied between different cell lines. In addition there was loss of the 
CHK1 protein itself following treatment with 100 nM or 300 nM PD-321852 for 
24 hours. The degree of loss of the CHK1 protein correlated with the relative 
degree of sensitisation of the pancreatic cell lines to PD-321852 in combination 
with gemcitabine. The reduction in CHK1 protein levels was also seen in cells 
treated with PD-321852 alone. 
As with studies with other CHK1 inhibitors, PD-321852 inhibited the formation of 
gemcitabine-induced RAD51 foci. In some cells treated with PD-321852 γ-H2AX 
staining persisted for longer than in cells treated with gemcitabine alone. This 
correlated with an accumulation of cells in S-phase. However, there was 
variation in the γ-H2AX staining between different cell lines leading to concern 
that γ-H2AX may not be a reliable marker of CHK1 inhibition in all cell lines. The 
authors suggest that a more reliable marker of CHK1’s downstream effects may 
be the measurement of γ-H2AX in combination with RAD51 foci accumulation. 
However, changes in γ-H2AX expression are not specific to activation of CHK1.  
γ-H2AX is a common downstream element of the ATM, ATR and DNA-PKcs 
pathways (Redon et al., 2010). 
As a monoagent, the highly specific CHK1 inhibitor, PF00477736 did not 
change the cell cycle, but abrogated gemcitabine-induced S-phase arrest with 
an increase in the number of cells G2-M and G0-G1 as S-phase measured by 
flow cytometry (Blasina et al., 2008). An increase in apoptosis (Tunnel assay) 
was observed with the combination of PF00477736 and gemcitabine compared 
to gemcitabine alone. 
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In further experiments, 30 nM gemcitabine was shown to cause S-phase arrest, 
but no appearance of γ-H2AX in a western blot, 360 nM PF00477736 alone did 
not increase γ-H2AX levels, but the combination of the two agents led to 
increased S-phase arrest and significant increase in γ-H2AX levels (Blasina et 
al., 2008). 
100 nM AZD7762 for 24 hours, a dual CHK1 and CHK2 inhibitor, significantly 
potentiated (approximately 10-fold potentiation) the cytotoxicity of gemcitabine 
(2 hour exposure) in HCT116 cells in 96-well plate growth inhibition assays 
(absorbance assay measuring DNA content) (McNeely et al., 2010). In addition, 
the percentage of apoptotic cells (determined by cell morphology) increased 
from 6% with 2 µM gemcitabine for 2 hours alone to 26% with gemcitabine and 
100 nM AZD7762. Confirmation that this was CHK1, rather than CHK2 came 
from knockdown experiments where CHK1 siRNA, but not CHK2 siRNA, 
produced similar effects to AZD7762. 
Similar studies were conducted by Zabludoff et al, who confirmed that 300 nM 
AZD7762 sensitises SW620 cell lines to gemcitabine in 96-well plate assays 
(Zabludoff et al., 2008). There was a significant (20-fold sensitisation) shift in 
the GI50; 24.1 nM with gemcitabine alone compared to 1.08 nM with 
gemcitabine and 300 nM AZD7762. 
300 nM and 1 µM XL9844 have been shown to significantly potentiate (on 
average 2 to 4-fold with 300 nM XL9844 and 5 to 10-fold with 1 µM XL9844) 
gemcitabine-mediated cytotoxicity in PANC-1, AsPC-1, SKOV3 and HeLa cell 
lines in clonogenic assays (Matthews et al., 2007). In PANC-1 cells 0.3 – 3 µM 
XL9844 abrogated Cdc25A phosphorylation induced by 30 nM gemcitabine for 
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24 hours in western blot assays. In an ELISA, XL9844 in combination with 100 
nM gemcitabine increased γH2AX expression in a concentration-dependent 
fashion in PANC1 cells treated either simultaneously or sequentially with both 
drugs for 24 hours. 
XL9844 also enhanced the antitumour activity of gemcitabine in PANC-1 
xenografts in athymic mice (Matthews et al., 2007). 400 mg/kg Gemcitabine 
was administered intravenously every 4 days (4 doses total) and 100 or 300 
mg/kg XL9844 twice orally following each dose of gemcitabine to mice. 
Maximum tumour growth inhibition (TGI) was 74% with gemcitabine alone and 
91% and >100% with 100 mg/kg and 300 mg/kg XL9844 respectively. 
In animal studies in mice bearing xenografts (A2780 and MiaPaca) SCH 
900776 showed little single agent activity (Guzi et al., 2011). However, in these 
xenograft models SCH 900776 potentiated gemcitabine cytotoxicity and caused 
a dose-dependent tumour regression with doses between 8 and 32 mg/Kg of 
SCH 900776. The tumours were 23% of their starting volume when treated with 
150 mg/Kg gemcitabine in combination with 32 mg/Kg of SCH 900776. There 
was no potentiation of gemcitabine related myelotoxicity even with the highest 
dose of SCH 900776. Very limited PK data is presented in this paper. 
CCT244747 was shown to enhance the cellular cytotoxicity (see Table 1-3) of 
SN38, gemcitabine, etoposide, carboplatin, 5FU and ionising radiation in SRB 
cytotoxicity assays in a panel of cell lines (HT29, SW620, MiaPaCa-2 and Calu6 
(NSCLC, p53 mutated)) (Walton et al., 2012). The greatest sensitisation was 
observed with gemcitabine. Cell lines were continuously exposed in 96-well 
plates to the combination of a fixed concentration of cytotoxic agent (at the GI50 
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of the agent) and variable concentration of CCT244747 for 96 hours prior to 
staining with SRB. CCT244747 also abrogated SN38 and gemcitabine-induced 
S phase arrest in HT29 and SW620 cell lines and etoposide-induced G2 arrest 
in the HT29 cell line.  
Drug  HT29 SW620 MiaPaCa-2 Calu6 
     
SN38 1.9 +/- 0.14 2.6 +/- 0.6 5.0 +/- 0.82 1.4 +/- 0.24 
Gemcitabine 8.5 +/- 1.6 12.2 +/- 2.7 16 +/- 6.3 5.6 +/- 0.96 
Etoposide 1.9 +/- 0.63 4.9 +/- 2.2   
CDDP 
(carboplatin) 
1.8 +/- 0.32 4.2 +/- 0.87   
5FU 2.2 +/- 0.2 4.9 +/- 0.8   
IR (1 hour 
prior) 
3.9 +/- 0.32 4.5 +/- 1.2   
IR (1 hour 
delay) 
3.0 +/- 0.67 4.9 +/- 1.6   
Table 1-3 Potentiation index of CCT244747 in combination with cytotoxic 
agents  
Adapted from (Walton et al., 2012). The potentiation index is the ratio of 
SRB GI50/combination GI50 where the combination GI50 is the 
concentration of CCT244747 that causes 50% cell growth inhibition with a 
fixed concentration (the GI50) of the cytotoxic agent. 
 
CCT244747 was also shown to significantly enhance the anti-tumour activity of 
gemcitabine in vivo. 100 mg/kg Gemcitabine (i.v. on days 0, 7 and 14) alone or 
in combination with 75 mg/kg CCT244747 (p.o. on days 0, 7 and 14) was 
administered to mice bearing HT29 tumour xenografts. Growth of the tumours 
was delayed by an additional 8.7 days in the combination treated mice 
compared to those treated with gemcitabine alone. 
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100 nM SAR-020106 potentiates gemcitabine cytotoxicity in the HT29, SW620 
and Colo205 (colorectal cancer, p53 mutated) cells (Walton et al., 2010). 
Potentiation factors were 3.0, 12 and 29 respectively in 96-well SRB cell 
proliferation assays with a 24 hour simultaneous exposure to SAR-020106 and 
gemcitabine followed by 96 hours in drug-free media. Co-treatment with 0.01 to 
5 µM SAR-020106 and 20 nM gemcitabine for 24 hours was also associated 
with increased expression of γ-H2AX and PARP cleavage indicative of DNA 
damage and apoptosis in western blot assays with concentrations of SAR-
020106 greater than 1 µM. 
Studies with GNE-900 in HT29 cells revealed a 93-fold sensitisation of 
gemcitabine following a continuous 72 hour exposure cell proliferation assays 
(Blackwood et al., 2013). Cell number was assessed by DNA content (Promega 
kit). In in vivo studies Sprague-Dawley rats the addition of 25 mg/kg GNE-900 
(as a single dose on day 2) to 30 mg/kg gemcitabine (as a single dose on day 
1) did not cause additional bone marrow toxicity compared to gemcitabine 
alone. 
V158411 potentiates the cytotoxicity of gemcitabine in a triple-negative breast 
cancer cell line (MDA-MB-468) (Bryant et al., 2014b). Potentiation was 
observed in both p53 wild type and p53 mutated cell lines, but the effect was 
greatest in p53-mutant cell lines. 
Gemcitabine potentiation is seen with both ATR inhibitors and WEE1 inhibitors. 
Prevo et al showed that the selective and potent ATR inhibitor VE-821 
significantly potentiated the cytotoxicity of gemcitabine in a panel of pancreatic 
cell lines (MiaPaCa-2, PSN-1 and PancM (all with p53 mutations) under both 
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norm-oxic and hypoxic conditions (Prevo et al., 2014). Significant potentiation of 
gemcitabine has also been seen with WEE1 inhibitors in sarcomas (Kreahling et 
al., 2013). The authors demonstrated that the WEE1 inhibitor MK1775 had 
significant synergy with gemcitabine in a panel of sarcoma cell lines (U2OS 
(osteosarcoma, p53 wild type), MG63 (osteosarcoma, p53 null), A673 (Ewing’s 
sarcoma, p53 null) and HT1080 (fibrosarcoma, p53 wild type) irrespective of 
p53 status. The results have been replicated in in vivo studies. 
The variable potentiation of gemcitabine by CHK1 inhibitors in contrast to the 
apparent robust and reproducible potentiation by ATR inhibitors and WEE1 
inhibitors has led to a suggestion that ATR and WEE1 maybe operating by a 
pathway that is independent of CHK1 
 
1.13.2 CHK1 inhibitors and topoisomerase poisons 
CHK1 inhibitors have been used in conjunction with topoisomerase poisons 
because the poisons lead to persistent SSB and DSB as described in section 
1.4.2. 
Zabludoff et al utilised AZD7762 in combination with camptothecin (Zabludoff et 
al., 2008). In HT29 cells the 70 mM camptothecin (for 2 hours) induced G2 
arrest (determined by staining for phospho-histone H3) was abrogated by 
AZD7762 (concentration range 6 nM to 12.5 µM). These authors also examined 
the sensitivity of MDA-MB-231 cells to the combination of topotecan and 300 
nM AZD7762. Cells were treated in 96-well plates for 24 hours with both 
topotecan and AZD7762 and then a further 24 hours with AZD7762 alone then 
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drug free media for 72 hours before measuring DNA content (Promega kit). 
There was significant 15-fold enhancement of the cytotoxicity of topotecan with 
AZD7762 (GI50 2.25 µM with topotecan and 150 nM with topotecan + 300 nM 
AZD7762). 
In this study, Zabludoff et al also showed that the combination of 25 mg/kg 
AZD7762 (2 and 14 hours after irinotecan) with 25 or 50 mg/kg irinotecan (4 
doses at 3 day intervals) produced a significant reduction in the growth of 
SW620 xenografts in athymic mice (Zabludoff et al., 2008). There were 13 
complete tumour regressions in 18 mice, compared to irinotecan alone where 
there were no complete regressions. Sensitisation was independent of 
irinotecan dose. 
In 96-well plate assays in which cells were incubated with drugs for 48 hours 
prior to staining for DNA content (Promega kit), CHIR-124 potentiated the 
cytotoxicity of camptothecin in a synergistic manner (isobologram analyses) in 4 
cell lines with mutated p53: MDA-MB-231, MDA-MB-453, SW-620 and CoLo205 
(Tse et al., 2007b). These authors also demonstrated that while UCN-01 and 
100 nM CHIR-124 alone did not affect the cell cycle they abrogated 20 nM SN-
38 induced S and G2 arrest over a 24 hour period in MDA-MB-435 cells. 
In combination with 5 mg/kg camptothecin (i.v. QDS on days 1-5) and 10 or 20 
mg/kg CHIR-124 (i.v. daily on days 2-7) significantly reduced MDA-MB-435 
tumour growth compared to mice treated with vehicle or camptothecin alone. 
This was accompanied by an increased level of apoptotic nuclear morphology 
observed by fluorescence microscopy in tumour sections (Tse et al., 2007b). 
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In contrast, UCN-01 and SCH 900776 did not potentiate SN38 (Montano et al., 
2012) in MDA-MB-231 cells, MDA-MB-231 (with shRNA knockdown of CHK1) 
or MCF10A treated concomitantly for 24 hours in 96-well plates with SN38 
alone or in combination with 50 nM UCN-01 or 1 µM SCH 900776 followed by 
drug-free media for 5 to 7 days.  
SAR-020106 has been shown to abrogate etoposide-induced G2 cell cycle 
arrest of HT29 cells with an IC50 of 55 nM (Walton et al., 2010). Maude et al 
demonstrated that treatment with 300 nM UCN-01 for 8 hours and 500 nM CEP-
3891 for 8 hours following 24 hours exposure to 50 nM etoposide significantly 
increased the fraction of U2OS, HeLa and SaOS2 (osteosarcoma, p53 deleted) 
killed compared to etoposide alone (Maude and Enders, 2005). In U2OS cells 
there was 6-fold potentiation with UCN-01 and 8-fold potentiation with CEP-
3891; in HeLa cells 7.6-fold and 7.5-fold respective potentiation and in SaOS2 
cells 8-fold and 6 fold potentiation. 
 
1.13.3 CHK1 inhibitors and platinum compounds 
CHK1 inhibitors have been used in combination with platinum-based 
compounds because the formation of platinum-DNA adducts that cause 
intrastrand and interstrand cross-links prevent DNA replication and ultimately 
lead to apoptosis (see Section 1.3.4) (Raymond et al., 1998) (Siddik, 2003). . 
10, 25, 50 and 100 nM UCN-01 enhanced the cytotoxicity (colony-forming 
assay) of cisplatin in AA8 (Chinese Hamster Ovary – (CHO)) cells exposed to 
cisplatin for 2 hours followed by 12 hours in combination with UCN-01 (Bunch 
 
 
71 
and Eastman, 1996). There was 3-fold enhancement with 25 nM UCN-01 and 
10-fold enhancement with 100 nM. Bunch et al then showed in Chinese 
hamster ovary (CHO) cell lines that UCN-01 abrogated cisplatin-mediated G2 
cell cycle arrest (Bunch and Eastman, 1996) and potentiated cisplatin 
cytotoxicity (by at least 3-fold) at concentrations (50 and 300 nM for 1 or 6-day’s 
continuous exposure) that were not cytotoxic as a single agent. 
A 6 hour treatment with 50 and 300 nM UCN-01 abrogated G2 arrest mediated 
by 5 µg/ml cisplatin treatment for 1 hour in AA8 cells. In AA8 cells 50 nM UCN-
01 resulted in a 10-fold potentiation of the cytotoxicity of 2 µg/ml cisplatin and 
60-fold potentiation of 10 µg/ml cisplatin. 
Further work by this group (Eastman et al., 2002) demonstrated that 250 nM 
ICP-1 and 50 nM UCN-01 enhanced growth inhibitory effect of cisplatin in 
breast cancer cell lines with defective p53 (MDA-MB-231) compared to p53 wild 
type cells (MCF10A). They also confirmed earlier studies (Bunch and Eastman, 
1996), that 50 nM UCN-01 for 22 hours after cisplatin and 250 nM ICP-1 22 
hours after cisplatin abrogates G2 cell cycle checkpoint arrest mediated by 20 
µM cisplatin for 2 hours. 
The sequence of chemotherapy administration and CHK1 inhibitors appears to 
be important. Mack et al treated NSCLC cell lines A549 and H596 (p53 
mutated) with UCN-01 either before or after cisplatin treatment (Mack et al., 
2003). Cells were treated for 3 hours with variable concentrations of cisplatin, 
UCN-01 was used for 24 hours at its single agent IC50 concentration (250 nM in 
A549 cells and 1000 nM in H596 cells); cells were then left in drug free media 
for 72 hours before proliferation was assessed using an MTT assay. Median 
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effect analysis revealed that if UCN-01 was administered after cisplatin, the 
effect was synergistic, compared with a less than additive effect when UCN-01 
was administered before cisplatin. This was confirmed by analysis of cell cycle 
arrest by flow cytometry in A549 and Calu-1 (NSCLC - p53 null) cell lines (3 
hour treatment with cisplatin, followed by 24 hours in drug-free media and then 
24 hours with 100 nM UCN-01) and by assessment of apoptosis by nuclear 
morphology. There was a decrease in the proportion of cells in G2 and an 
increase in apoptotic cells. The synergism of cisplatin and UCN-01 by median 
effect analysis was most marked in cell lines with mutated p53. However, these 
data from studies using UCN-01 should be treated with caution as UCN-01 also 
inhibits several CDKs as well as CHK1 so cell cycle arrest and cytotoxicity may 
be due to direct CDK inhibition rather than through CHK1 inhibition. 
In contrast to studies with UCN-01 CHK1 knockdown with siRNA in HeLa cells 
did not enhance the cytotoxicity of cisplatin, oxaliplatin or carboplatin in colony 
forming assays, although ATR and Rad9 knockdown did significantly enhance 
cisplatin cytotoxicity (Wagner and Karnitz, 2009). The authors then examined 
the ability of 20 or 80 nM AZD7762 to potentiate cisplatin (concomitantly with 
AZD7762 for 24 hours) cytotoxicity in clonogenic assays in the HeLa cells. 
Again, there was no significant potentiation of cisplatin cytotoxicity. These 
results were confirmed in other cell lines with a range of platinum compounds 
and CHK1 depletion by siRNA; there was no potentiation of cisplatin in 
HCT116, U2OS and A549 and of oxaliplatin in HCT116 cells.  
Similarly co-exposure to 50 nM UCN-01 or 1 µM SCH 900776 with cisplatin for 
24 hours in a 96-well plate growth inhibition assay did not significantly 
potentiate cisplatin in 3 breast cell lines (MDA-MB-231, MDA-MB-231Chk1-/- 
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(CHK1 deleted to check for off-target effects) and MCF10A) by either (Montano 
et al., 2012). This raises the possibility that cell survival following platinum-
related damage is independent of CHK1 and casts some doubt as to the 
potential use of CHK1 inhibitors in combination with platinum chemotherapy. 
V158411 also potentiates the cytotoxicity of gemcitabine and cisplatin in a triple-
negative breast cancer cell line (MDA-MB-468 p53-defective) (Bryant et al., 
2014b). V158411 appears to potentiate carboplatin and cisplatin sensitivity in 
SKOV-3 ovarian cell lines, but has no effect on the sensitivity of SKOV-3 cells to 
oxaliplatin. 
 
1.13.4 CHK1 inhibitors and taxanes 
There is relatively little pre-clinical data with CHK1 inhibitors in combination with 
taxanes. PF00477736 enhanced the anti-tumour effect of docetaxel, another 
taxane, (Zhang et al., 2009). The authors examined the combination of 15 
mg/kg or 30 mg/kg docetaxel (i.p. 3 doses at day 1, 8 and 15) and 7.5 mg/kg or 
15 mg/kg PF00477736 (i.p. given as 2 doses, 1 with docetaxel and 12 hours 
later) in CoLo205 and MDA-MB-231 xenografts. 30 mg/kg docetaxel alone 
caused complete regression of MDA-MB-231 tumours in the xenograft model so 
only 15 mg/kg docetaxel was used in combination with PF00477736. In the 
MDA-MB-231 xenografts there was 14 days growth delay with 7.5 mg/kg 
PF00477736 and 36 days growth delay with15 mg/kg PF00477736 (p < 0.05 
with both regimens). In the CoLo205 xenografts there were 3 complete 
responses with the combination of PF00477736 and docetaxel whereas when 
docetaxel was used alone all xenografts progressed after an initial response.  
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1.14 CHK1 inhibitors in combination with radiotherapy 
CHK1 inhibitors have been postulated to be potential radiosensitisers. CHK1 
was found to be up-regulated for up to 3 hours after radiation exposure in 
DU145 (p53 mutated prostate cancer) and HT29 (Mitchell et al., 2010b). When 
the cell lines were exposed to a CHK1 inhibitor, AZD7762, for 1 hour before and 
24 hours after radiation exposure there was marked increased radiation 
cytotoxicity compared to irradiation alone. The effects were greatest in p53 
mutated cell line but remained significant in p53 wild type cell lines (Dose 
Modifying Factor (DMF) of 1.58 and 1.11 respectively). Flow cytometry 
confirmed that AZD7762 abrogated G2 cell cycle arrest following radiation 
exposure and caused IR-induced γ-H2AX foci to persist. However, this affect 
was only seen in certain cell lines (HT29 and H460 (NSCLC, wild type p53)) so 
may need to be interpreted with caution. 
The use of a combination of a CHK1 inhibitor, chemotherapy and radiation has 
been explored in pancreatic cell lines. This is felt to be clinically relevant as the 
gold-standard treatment in locally advanced pancreatic cancer is chemo-
radiation. AZD7762 in combination with radiation sensitised pancreatic cell lines 
(MiaPaCa-2, Mpanc96) in an additive fashion as shown in the table below 
(Table 1-4) (Morgan et al., 2010).  
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 Radiation alone Gemcitabine 
and radiation 
AZD7762 and 
radiation 
AZD7762, 
Gemcitabine and 
radiation 
     
Radiation 
enhancement 
ratio 
1 1.2 +/- 0.07 
(p<0.05) 
1.5 +/- 0.08 
(p<0.05) 
1.9 +/- 0.16 
(p<0.05) 
     
Table 1-4 Radiation enhancement ratios with AZD7762 
Adapted from Mitchell et al., 2010b. The radiation dose that led to 10% 
survival in the absence of AZD7762 divided by the radiation dose that led 
to 10% survival in AZD7762 treated cells. 
 
The application of 300 nM UCN-01 for 1 hour to U2OS cells prior to exposure to 
ionising radiation (single 10 Gy fraction) reduced and delayed the expected 
radiation-induced degradation of Cdc25A (Sorensen et al., 2003). These results 
were replicated using CEP-3891 (a CHK1 inhibitor (Cephalon) with greater 
specificity for CHK1 than UCN-01); 500 nM CEP-3891 for 1 hour and using 
CHK1 siRNA to silence CHK1 activity in the U2OS cancer cell line. 
Using a U2OS model (Syljuasen et al., 2004) demonstrated that CEP-3891 
abrogates IR-mediated S and G2 cell cycle arrest and that this leads, after a 
delay of 24 hours, to an increase in the number of cells showing nuclear 
fragmentation. This nuclear fragmentation was distinct from apoptosis and 
occurred at an earlier time point in the presence of CEP-3891 compared with IR 
 
 
76 
alone. They also demonstrated potentiation of IR-mediated (0-6 Gy) cytotoxicity 
with 500 nM CEP-3891 in clonogenic assays.  
A CHK1 inhibitor has been used in combination with a PARP inhibitor and 
radiotherapy. Vance et al examined the combination of a CHK1 inhibitor 
(AZD7762) and a PARP1 inhibitor (AZD2281 – olaparib) and the ability of the 
combination to radiosensitise pancreatic cell lines (Vance et al., 2011). In 
clonogenic assays they examined the ability of 100 nM AZD7762 +/- 1 µM 
AZD2281 to enhance the cytotoxicity of IR. In MiaPaCa-2 and MPanc-96 cell 
lines they demonstrated that AZD7762 alone had an enhancement ratio of 1.5 
and 2.0 respectively, with AZD2281 alone the enhancement ratios were 1.5 in 
both cell lines and with AZD7762 and AZD2281 in combination 2.4 and 3.0. 
They also sought to determine if this radiosensitisation was dependent on p53 
status in 2 isogenic cell line pairs (HCT116 (p53 +/+ and p53 -/-) and H460 (p53 
wild type and p53 dominant negative). They demonstrated that the radiation 
enhancement ratio was significantly greater in the cell lines with a defective p53 
phenotype with all 3 treatment combinations  
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1.15 Clinical trials with CHK1 inhibitors 
 
1.15.1 UCN-01 
The first CHK1 inhibitor to enter clinical trials was UCN-01 (7-
hydroxystaurosporine). However, as explained in Sections 1-10-1 and 1-11-2, 
UCN-01 lacks specificity for CHK1, hampering the interpretation of the data. In 
the first single-agent phase I study, which recruited patients between April 1996 
and March 1997, UCN-01 was administered to 47 patients as a 72 hour 
continuous infusion (Sausville et al., 2001). UCN-01 was shown to have an 
extremely long and variable half-life of 25.9 days (range 6 to 161 days) with avid 
protein-binding in the plasma. 
An unexpected toxicity of UCN-01 was found to be profound hyperglycaemia 
due to increased peripheral insulin resistance characterized by an increase in 
immunoreactive C-peptide derived from pro-insulin (Sausville et al., 2001). 
Other side effects include hypotension, fatigue and nausea and vomiting. This 
first trial of a 72 hour infusion of UCN-01 was halted due to significant 
symptomatic dose-limiting toxicity (DLT) of hypotension and hyperglycaemia at 
53 mg/m2/day. A recent pre-clinical study by Sharma et al has shown that UCN-
01 blocks insulin’s action on endothelial cells via its blockade of 
phosphoinositide dependent kinase (Sharma et al., 2011). This may be the 
mechanism behind UCN-01’s DLT of hyperglycaemia. 
The long plasma half-life, when UCN-01 was given as a 72 hour infusion, led 
investigators to consider administration as a short infusion over 3 hours to 
reduce toxicity.  When UCN-01 was given to 24 patients as a short infusion, 
hyperglycaemia was mild and easily managed (Dees et al., 2005). However 
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again the DLT in this short infusion trial was symptomatic hypotension at 95 
mg/m2, which stopped the trial.  
Pre-clinical data suggested the potentiation of topoisomerase 1 inhibitors such 
as topotecan. A phase 1 study, in combination with topotecan, in patients with 
advanced solid malignancy combined a 3 hour infusion of UCN-01 on Day 1 
and intravenous topotecan on days 1-5 of a 21-day cycle (Hotte et al., 2006). 
Toxicity attributed to UCN-01 by the investigators in this trial included 
hyperglycaemia, fatigue and nausea and vomiting. A phase II trial of UCN-01 in 
combination with topotecan in ovarian cancer unfortunately was halted due to a 
lack of efficacy. This terminated study has not been published. 
Two phase 1 studies of UCN-01 in combination with cisplatin have also been 
performed. In the first the California Cancer Consortium delivered UCN-01 as a 
fixed dose of 45 mg/m2/day as a 72-hour infusion with the intention of escalating 
cisplatin from 20 mg/m2 to 75 mg/m2 in 5 increments (Lara et al., 2005). 
Unfortunately when the cisplatin was increased to 60 mg/m2 dose-limiting 
toxicities were seen with patient deaths due to sepsis and respiratory failure. 
The long half-life of UCN-01 was felt to be a contributory factor in the difficulties 
seen in this trial; and shorter infusions of UCN-01 at a lower dose were 
recommended for future trials. A dose of 60 mg/m2 is the established 
therapeutic dose of cisplatin where activity is seen as a mono-agent. Three 
patients had tumour biopsies before and after combination chemotherapy. 
These showed a significant reduction in CHK1 and Cdc25C protein levels 
suggesting that UCN-01 was having its anticipated pharmacodynamic effect in 
tumours. 
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In the second phase I trial in combination with cisplatin, Perez et al 
administered UCN-01 as a 72-hour infusion starting 22 hours after the infusion 
of cisplatin in patients with advanced solid malignancy (Perez et al., 2006). 
Initially 45 mg/m2/day UCN-01 was delivered, but this was decreased to 34 
mg/m2/day due to dose-limiting toxicity (hypoxia, subarachnoid haemorrhage, 
myocardial ischaemia, atrial fibrillation and hyperglycaemia). As well as 
conventional end-points of maximum tolerated dose and PK of UCN-01, this 
study looked for the pharmacodynamic end-point of S/G2 cell cycle arrest by 
measuring geminin immunohistochemistry in tumour biopsies taken at baseline, 
22 hours after cisplatin (prior to UCN-01), 24 and 72 hours after starting the 
UCN-01 infusion. Biopsy specimens showed abrogation of the S/G2 checkpoint 
following UCN-01 compared to both baseline and post-cisplatin values. 
Unfortunately this trial of UCN-01 only recruited 7 patients so assessment of the 
efficacy of UCN-01 in combination with cisplatin could not be made. The trial 
was ended as this point as it was felt impractical to administer a 72-hour 
infusion. Another factor was that data from the phase 1 single-agent trial 
delivering UCN-01 as a 3-hour infusion had become available and been shown 
to be equally efficacious as the 72 hour infusion.  
 
1.15.2 PF00477736 
No single agent studies of PF-00477736 have been performed. However, a 
phase I study of PF-00477736 in combination with gemcitabine was reported at 
ASCO 2010 (Brega et al., 2010). The study population was patients with 
gemcitabine-naïve advanced solid malignancy. 750 mg/m2 gemcitabine was 
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given as a 1-hour infusion with PF-00477736 given 20 to 24 hours after the 
gemcitabine. Both PF-00477736 and gemcitabine were given on day 1 and day 
8 of a 21-day cycle. PF-00477736 was delivered by 2 different schedules; early 
cohorts were given it over 3 hours (50 to 80 mg i.v. flat dose) whereas later 
cohorts were given PF-00477736 (80 to 340 mg i.v. flat dose) as a 24 hour 
infusion. It appears that pre-clinical data to support the longer infusion time 
came to light after the trial started (Blasina et al., 2008). 
36 patients were treated the best response was a partial response in 3 patients 
(SCC of skin, NSCLC and mesothelioma). The MTD of PF-00477736 in 
combination with 750 mg/m2 gemcitabine was 270 mg. No pharmacodynamic 
studies were performed. There was an intention to repeat the phase I study in 
combination with 1000 mg/m2gemcitabine, and to perform biomarker analysis 
with the assessment of the effect on the S/G2 checkpoint in serial tumour 
biopsies, but this has not been published. 
 
1.15.3 AZD7762 
AZD7762 has been used in combination with gemcitabine in two Phase 1 trials, 
one in American patients with advanced solid tumours and the second in 
Japanese patients (Sausville et al., 2014, Seto et al., 2013). In the study in 
American patients, first presented at ASCO 2011 (Sausville et al., 2011), 6 – 40 
mg AZD7762 (i.v. flat dose) was administered in combination with gemcitabine 
to 42 patients. Patients received a single agent run-in phase of two doses of 
single agent AZD7762, and then AZD7762 was given concomitantly with 750 or 
1000 mg/m2 gemcitabine (i.v.) on days 1 and 8 of a 21-day cycle. Unfortunately 
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2 further patients had cardiac DLTs during the single agent phase (1 grade 3 
symptomatic troponin rise and 1 grade 3 myocardial ischaemia). There was no 
evidence that gemcitabine affected the PK of AZD7762. There were 2 partial 
responses (6 mg AZD7762 with 750 mg/m2 gemcitabine and 9 mg AZD7762 
with 750 mg/m2gemcitabine) to the combination treatment in NSCLC patients 
who were gemcitabine-naïve. The study concluded that the MTD of AZD7762 in 
combination with 1000 mg/m2 gemcitabine was 30 mg. 
The Japanese study followed a similar design with a single agent run-in phase 
followed by combination treatment with AZD7762 and 1000 mg/m2 gemcitabine 
on days 1 and 8 of a 21 day cycle. 20 patients were treated. There were 2 DLTs 
in the 30 mg AZD7762 cohort. One patient developed a grade 3 rise in cardiac 
troponin and a second neutropenia and thrombocytopenia. The study concluded 
that the MTD of AZD7762 in combination with 1000 mg/m2 gemcitabine in 
Japanese patients was 21 mg. There were no complete or partial responses. 
Five patients with NSCLC achieved disease stabilisation. 
AZD772 has also been delivered in combination with irinotecan to patients with 
advanced solid tumours, though this Phase I clinical trial has only been 
published as an ASCO poster in 2011 (Ho et al., 2011) . After a single agent 
run-in phase of two doses (7 days apart) of single agent 6 – 144 mg AZD7762 
(i.v. flat dose), AZD7762 was given concomitantly with 100 or 125 mg/m2 
irinotecan (i.v.) on days 1 and 8 of a 21-day cycle. 68 patients received the 
combination therapy in total. However, the trial was halted as cardiac DLT (1 
myocardial infarction and 1 Grade 4 ventricular dysfunction) was seen during 
the single agent run-in phase in the trial. This was at the 96 mg AZD7762 with 
100 mg/m2 irinotecan dose level. There was 1 complete response to therapy in 
 
 
82 
a patient with a small cell carcinoma of the ureter and 1 partial response in a 
patient with colon cancer despite prior treatment with irinotecan. 
With five cases of myocardial DLTs between the 3 early phase trials, the 
development programme of AZD7762 has been halted. 
 
1.15.4 SCH 900776 
A phase I study of SCH 900776 (CHK1 inhibitor – Schering Plough) in 
combination with gemcitabine was also reported at ASCO 2010 (Daud et al., 
2010). 26 patients were treated with 800 mg/m2 gemcitabine followed by 10 to 
112 mg/m2 SCH 900776 (i.v.) on Day 1 and Day 8 of a 21-day cycle. The time 
period between the administration of gemcitabine and SCH 900776 was not 
specified in the abstract or poster. 4 patients showed a response to the 
combination (melanoma, sarcoma, cholangiocarcinoma and pancreatic tumour). 
The trial determined an MTD of SCH 900776 in combination with 800 
mg/m2gemcitabine of 112 mg/m2. 
In the phase I trial, SCH 900776 was given as a 15 minute infusion, but SCH 
900776 is reported to be orally bioavailable. The half-life of the IV preparation 
was between 6.24 and 9.33 hours. No pharmacodynamic data was published in 
the abstract, but the poster contained data related to γ-H2AX. Plasma samples 
from patients dosed with SCH 900776 were taken alongside pharmacokinetic 
samples, diluted with tissue medium 1:4 and administered to K562 cells grown 
in tissue culture. The cells were grown in this medium for either 2 or 24 hours 
and then fixed and stained for γ-H2AX. γ-H2AX intensity was measured by flow 
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cytometry. The clinical pharmacodynamic data correlated with the pre-clinical 
data. However, a decision has been made not to proceed with further clinical 
trials of SCH 900776 at present. 
 
1.15.5 LY2603618 
LY2603618 has been evaluated in a Phase I trial in combination with 500 
mg/m2pemetrexed in patients with advanced solid tumours (Weiss et al., 2013). 
40-195 mg/m2 LY2603618 (i.v. as a 4.5 hour infusion) was delivered as a single 
agent 7 days prior to pemetrexed and then 24 hours after pemetrexed every 21 
days. 31 patients were treated in the study. There was one partial response by 
RECIST criteria (Therasse et al., 2000) in a patient with pancreatic 
adenocarcinoma (105 mg/m2 cohort), nine other patients had stable disease 
following treatment. The MTD of LY2603618 in combination with 500 mg/m2 
pemetrexed was determined to be 150 mg/m2. DLTs were diarrhoea, 
thrombocytopenia, fatigue and reversible-infusion reactions. 
A second phase I study of LY2603618 (130-275 mg/m2 on day 2 of a 21-day 
cycle) in combination with 75 mg/m2 cisplatin (i.v. on day 1 of a 21-day cycle) 
and 500 mg/m2 pemetrexed (i.v. on day 1 of a 21-day cycle) has treated 14 
patients with advanced solid tumours (Calvo et al., 2014). No DLTs were 
reported. Two patients with NSCLC had a partial response. The recommended 
phase II dose of LY2603618 in combination with cisplatin and pemetrexed was 
275 mg/m2. 
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A further phase I study of LY2603618 (on day 2, 9, 16 of a 28 day cycle) has 
been performed in combination with 1000 mg/m2 gemcitabine (i.v. on day 1, 8 
and 15 of a 28-day cycle) in Japanese patients with advanced solid tumours, 
but has not been published. Phase Ib/II studies are ongoing or as yet 
unpublished in patients with pancreatic cancer in combination with gemcitabine, 
and in NSCLC in combination with pemetrexed. 
 
1.15.6 LY2606368 
The only ‘second generation’ CHK1 inhibitor to be taken into early phase clinical 
trials as a single agent is LY2606368. This trial has not been published but 
included expansion cohorts of patients with squamous head and neck cancer. A 
phase II clinical trial in this patient population is now being performed. 
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1.16 Aims of project 
 
To evaluate novel CHK1 inhibitor, V158411, in terms of: 
• Its effect on DNA damage-induced checkpoint function in parallel with 
chemo/radio-potentiation in a panel of cell lines characterised for their 
CHK1 expression and activity. 
• To determine the single agent cytotoxicity in the panel of cell lines.  
• To identify potential pharmacodynamic biomarkers of CHK1 activity 
suitable for measuring the activity of inhibitors in the clinic. 
• To explore the role of p53 and identify other potential determinants of 
sensitivity to CHK1 inhibitors. 
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Chapter 2 Materials and Methods 
2.1 Chemicals and Drugs 
All chemicals, including tissue culture reagents, were supplied by Sigma (Poole, 
UK) unless otherwise stated. V158411 (kindly provided by Vernalis, Cambridge, 
UK). NU7441 (Newcastle University, UK), PF00477736 (Axon Medchem, 
Groningen, Netherlands), AZD7762 (Axon MedChem), Camptothecin, 
etoposide, hydroxyurea, (hydroxyurea 2 M) stock solution were dissolved in dry 
DMSO to form a 10 mM stock solution which was aliquoted and frozen. 
Gemcitabine and cisplatin were dissolved to form a 10 mM stock solution in 
PBS and frozen in aliquots. Ionising radiation was delivered using a medical 
irradiator (Xstrahl RS320 X-irradiator, 3.15 Gy/minute dose rate) with the dose 
of ionising radiation standardised for either adherent or suspension cell lines.  
 
2.2 Cell lines and cell culture 
Human cancer cell lines were obtained from ATCC (Manassas, Virginia, USA), 
(ECACC, Porton Down, UK) or from institute archives and authenticated by 
short-tandem repeat (STR) profiling, compared to the reference ATCC profiles, 
by LGC Standards (Teddington, Middlesex, UK). All media was supplemented 
with 10% foetal calf serum (FCS) and 2 mM penicillin-streptomycin. Cells were 
verified to be free from mycoplasma infection by PCR (Mycoalert™) every two 
months. All cell lines were cultured in humidified incubators at 37oC with 5% 
CO2.  
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Name Species Tissue of 
Origin 
p53 status Provenance  Media 
      
MCF10A Human Breast Wild Type ATCC RPMI-1640 
MCF7 Human Breast Wild Type ATCC RPMI-1640 
MDA-MB-231 Human Breast Mutated ATCC RPMI-1640 
K562 Human CML Mutated ATCC RPMI-1640 
HCT116 WT Human Colon Wild Type John Lunec4 RPMI-1640 
HCT116-/-p53 Human Colon Mutated John Lunec4 RPMI-1640 
M059J Human Glioblastoma Mutated NICR DMEM 
M059J-Fus1 Human Glioblastoma Mutated NICR DMEM + 
G4181 
U2OS WT Human Osteosarcoma Wild Type John Lunec4 DMEM 
U2OS DN 
p53 
Human Osteosarcoma Dominant 
Negative2 
John Lunec4 DMEM + 
G4181 
Hep3B Human Liver Null ATCC DMEM/F123 
Huh7 Human Liver Mutated ECACC DMEM/F123 
HepG2 Human Liver Wild type ECACC DMEM/F123 
PLC/PRF/5 Human Liver Mutated ATCC DMEM/F123 
SNU.182 Human Liver Not detected ATCC RPMI-1640 
SNU.475 Human Liver Mutated ATCC RPMI-1640 
AA8 Chinese 
Hamster 
Ovary Mutated Keith 
Caldecott5 
RPMI-1640 
V3 Chinese 
Hamster 
Ovary Mutated Keith 
Caldecott5 
RPMI-1640 
XRS-6 Chinese 
Hamster 
Ovary Mutated Keith 
Caldecott5 
RPMI-1640 
EM9 Chinese 
Hamster 
Ovary Mutated Keith 
Caldecott5 
RPMI-1640 
VC8 Chinese 
Hamster 
Lung 
fibroblasts 
Wild Type Malgorzata 
Zdzienicka 
via Thomas 
Helleday6 
DMEM 
VC8-B2 Chinese 
Hamster 
Lung 
fibroblasts 
Wild Type Thomas 
Helleday6 
DMEM 
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Table 2-1 Cell lines 
Details of species, tissue of origin, p53 status and provenance. DMEM 
(Dulbecco’s modified Eagles medium), DMEM/F12 (Dulbecco’s modified 
Eagles medium/nutrient F12 ham). 14 µg/ml G418 (Life Technologies, 
Paisley, UK); 2The U20S p53DN express the p53-R248W dominant negative 
mutant p53 prepared by transfection of U20S: PG13-Luc cells (Moumen et 
al., 2005); 3Supplemented with 2 mM L-glutamine (Sigma); 4John Lunec, 
Northern Institute for Cancer Reasearch, Newcastle-upon-Tyne University, 
UK; 5Keith Caldecott, Professor of Biochemistry, Sussex University, UK; 
6Thomas Helleday, Professor of Translational Medicine and Chemical 
Biology, Karolinska Institutet, Stockholm, Sweden. 
 
2.3 Cytotoxicity assays 
 
Cytotoxicity was assessed by clonogenic assays, which measure the ability of 
single cells to survive and proliferate into colonies after cytotoxic insult. Briefly, 
cells from exponentially growing monolayers in flasks were harvested by 
trypsinisation. A single cell suspension was ensured by syringing through a 22G 
needle. Cells were counted using an automated counter (Beckman Coulter, 
Brea, California, USA). A fixed numbers of cells (between 50 and 10000, with 
an aim to have between 20 and 100 colonies to count depending on the 
cytotoxicity of the drug) were seeded in 2 ml media into the wells of a six-well 
plate. After 24 hours the media was removed and replaced with media 
containing appropriate concentrations of the drug of interest. After incubation in 
drug-containing media for 24 hours the media was removed, each well washed 
with PBS and 2 mls of drug-free media was added. The plates were incubated 
for between 8 and 21 days for colonies to form. The media was then removed, 
the cells fixed with Carnoy’s solution (25% glacial acetic acid (Fisher, 
Loughborough, UK) and 75% methanol (Fisher)), and stained with 1% crystal 
violet solution. Colonies were counted on the G-Box (Syngene, Cambridge, UK) 
with a minimum colony size of ~50 cells. 
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Cytotoxicity of drugs in K562 cells was assessed by performing clonogenic 
assays in a 3D matrix. Following counting a fixed number of cells were seeded 
using blunt needles into 2 mls of media (4:1 ratio of Methocult (Stemcell, 
Grenoble, France) and Isocove’s media (Gibco, Paisley, UK) supplemented 
0.6% L-glutamine).  After 2 weeks colonies were stained with 0.5 mls per well 
MTT (0.5% in water) (MTT changes colour following reduction with 
mitochondrial dehydrogenase in viable cells) and counted on the G-Box. 
 
2.4 Chk1 knockdown with siRNA 
To confirm whether a drug of interest is affecting the intended target, the effect 
of drug can be compared to that of cells in which the target protein has been 
silenced by an alternative method. Knockdown with siRNA relies on the 
incorporation of the siRNA into the cellular genome this is facilitated by a 
transfection agent in a process that has to occur in the absence of antibiotics. 
siRNA binds to the target RNA promoting its degradation by the cellular 
apparatus. 
MCF7 cells from exponentially growing monolayers in flasks were harvested by 
trypsinisation. A single cell suspension was ensured by syringing through a 22G 
needle. Cells were counted using an automated counter (Beckman Coulter). 1.5 
µl of siRNA (target siRNA Chk1 (Qiagen) or scrambled siRNA (Sigma)) was 
mixed with 500 µl Opti-MEM (Life Technologies) and 5 µl Lipofectamine 
RNAmax (Invitrogen) and 7 x 105 cells in 2.5 mls antibiotic-free media for each 
well of a six-well plate. Wells were seeded with no siRNA, scrambled siRNA or 
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Chk1 siRNA both for western blotting after 48 hours, 5 days and 7 days and for 
to look for cloning efficiency at each time point. 
 
2.5 Western blotting 
Western blotting allows the immunological detection, and approximate 
quantitation of cellular proteins. The first step in western blotting is the 
preparation of a lysate. A lysate is prepared from cells by mechanical removal 
of the cells from the plate, the cellular material is placed into a lysis buffer which 
extracts the proteins from the other cellular components.  The lysis buffer 
contains protease inhibitors, which prevent the breakdown of proteins. 
Subsequently cellular proteins are loaded onto a polyacrylamide matrix (gel) 
separated on the basis their size by an electrical current. The proteins are then 
transferred to a membrane and those of interest are detected by the binding of 
a specific primary antibody with signal amplification by a secondary antibody 
raised against the species of the primary antibody. The secondary antibody is 
conjugated to horseradish peroxidase which catalyses the production of light 
from a chemi-luminescent agent allowing detection of the protein. Relative 
quantities of protein can be quantified and compared to a housekeeping protein 
such as actin. 
Cells from exponentially growing monolayers in flasks were harvested by 
trypsinisation. A single cell suspension was ensured by syringing through a 22G 
needle. Cells were counted using an automated counter (Beckman Coulter). 
Fixed numbers of cells were seeded in 10 mls media onto 10 cm plates. After 
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24 hours the media was removed and replaced with media containing 
appropriate concentrations of the drug of interest for 1 hour. 
After the appropriate exposure to the drug-containing media (normally 1 hour), 
the media was removed and the cells washed with 2 mls ice cold PBS. Cells 
were scraped using a cell scraper and resuspended in 2 mls PBS. Samples 
were kept on ice. Cells were pelleted by centrifugation at 450 g for 5 minutes. 
The supernatant was removed and discarded. The pellet was resuspended in 
75 µl of Phosphosafe buffer (Merck Chemicals, Nottingham, UK) containing 
additional protease inhibitor cocktail. Each sample was sonicated for 10 
seconds and left at room temperature for 5 minutes to extract the protein. The 
samples were then spun again in a refrigerated centrifuge for 5 minutes at 
16000 g. The supernatant was removed and kept on ice, the pellet discarded. 
The protein content of the samples was quantified using a Pierce protein assay 
(ThermoScientific, Cramlington, UK) against an albumin standard curve (0.2-1.2 
ug). Plates were read on FLUOstar Omega plate reader (BMG Labtech, 
Allmendgruen, Germany). 
For Chk1 analysis 20 µg of the protein from the sample of interest was loaded 
into each well with sample buffer (4 x XT loading buffer (Bio-Rad, Hemel 
Hempstead, UK)), with water making the total volume up to 15 µl (12 and 15-
well gels) or 20 µl (10-well gels) on 4-12% TGX gels (Bio-Rad) at 200 volts for 
25 minutes (Mini-Protean Tetra Cell, Bio-Rad). For DNA-PK analysis 30 µg of 
the protein from the sample of interest was loaded into each well with sample 
buffer, with water making the total volume up to 30 µl (12 +2 well gels). on XT 
Criterion (3-8%) gels (Bio-Rad). Gels were run at 150 volts for 1 hour. All 
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samples were transferred onto HiBond C-Extra membrane (GE Healthcare, 
Little Chalfont, UK) at 100 volts (Mini-Protean Tetra Cell, Bio-Rad) on ice for 1 
hour. Following washing in TBS-tween the membrane was blocked in 5% 
bovine serum albumin (BSA) for 1 hour. Phopho-antibodies were made up in 
5% BSA and normal antibodies in 1% BSA. Antibodies used as follows: 1:1000 
Chk1 (Santa Cruz Biotechnology, Dallas, TX, USA), 1:300 ATR (Santa Cruz 
Biotechnology), 1:1000 pChk1serine296 (Abcam, Cambridge, UK), 1:1000 
pChk1serine345 (Cell Signalling Technology, Boston, MA, USA), 1:1000 DNAPK 
(Santa Cruz Biotechnology), 1:1000 pDNAPKserine2096 (Abcam), 1:100 cdc25c 
(Santa Cruz Biotechnology), 1:5000 Actin (Genscript, Piscataway, NJ, USA) 
The membrane was exposed to constantly agitated primary antibodies 
overnight at 40C. Following three 5-minute washes with TBS-tween the 
membrane was exposed to the appropriate secondary antibody (1:1000 mouse 
and 1:1000 rabbit polyclonal antibodies – DAKO, Glostrup, Denmark) in 1% 
BSA at room temperature for 1 hour. The membrane was washed a further 4 
times for 5 minutes in TBS-tween. The membrane was treated with ECL-Prime 
(GE Healthcare) for 5 minutes prior to analysis in the G-Box (Syngene, 
Cambridge UK). Bands were quantified using the software GeneTools 
(Syngene). 
 
2.6 Flow cytometry 
Flow cytometry is used to determine the fraction of cells in each phase of the 
cell cycle on the basis of size and DNA content following staining with a DNA 
dye (propidium iodide or DAPI are two examples). Cells in G2 and mitosis have 
twice the DNA content of cells in G0 or G1. Cells that display significant 
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aneuploidy cannot be analysed in this way. Many experiments to determine 
when cells are arresting, and which factors are playing a role at each stage of 
the cell cycle, require investigators to be able to trigger cell cycle arrest at 
specific points within the cell cycle. In vitro cell cycle arrest can be triggered 
using alpha-factor which arrests cells in G1, nocodazole can be used to cause 
G2 arrest (Aylon et al., 2004). 
Cells from exponentially growing monolayers in flasks were harvested by 
trypsinisation. A single cell suspension was ensured by syringing through a 22G 
needle. Cells were counted using an automated counter (Beckman Coulter). 
Fixed numbers of cells were seeded in 10 mls media onto 10 cm plates. After 
24 hours the media was removed and replaced with media containing 
appropriate concentrations of the drug of interest 1 hour 
After the appropriate exposure to the drug-containing media (normally 1 hour), 
the media was removed and the cells washed with 2 mls PBS. Cells were 
harvested by trypsinisation (1 ml trypsin-EDTA) and resuspended in 5 mls 
normal media. Cells were pelleted by centrifugation at 450 g for 5 minutes. The 
pellet was washed in 2 mls PBS, vortexed and spun again at 450 g for 5 
minutes. The pellet was resuspended in 1 ml of PBS and kept on ice. 
Samples were analysed on a BD FacsCalibur (BD Biosciences, Franklin Lakes 
NJ, USA). 500 µl of well-mixed sample was mixed with 500 µl hypotonic 
propidium iodide solution (0.025% PI (Calbiochem)) around 30 seconds prior to 
analysis. Flow cytometry data was analysed using CellQuest software (BD 
Biosciences). 
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2.7 In silico analysis of microarray expression data 
Microarrays allow the analysis of individual gene expression across the 
genome. The levels of mRNA from specific genes can be normalised to the 
mRNA levels from housekeeping genes so that the relative expression of one 
gene to another can be compared. 
The Affymetrix Human Genome U133 Plus 2.0 Array hosts 57500 DNA probes 
covering the whole human genome. The probes hybridise to complementary 
sequences of biotin-labelled cDNA, which can be detected by a fluorochome. 
The level of mRNA expression corresponds to fluorescent intensity. The NCBI 
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/projects/geo/) 
contains publically available datasets from a range of tumour sites. Datasets 
from a range of tumours where both normal tissue and tumour were available 
were chosen. Data for individual genes of interest was analysed using the 
online GEO2R tool. Background signal intensity was subtracted and data 
normalised to the housekeeping gene HPRT1. Where more than one probe was 
associated with a single gene the average expression across the probes for the 
gene of interest was used. 
 
2.8 Statistics 
All data was analysed using GraphPad Prism 6 software. Statistical significance 
(* = P < 0.05; ** = P < 0.01, ***, P < 0.001) was determined using paired, two-
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tailed t test or one-way ANOVA and either Tukey or Dunnett tests unless 
specified. 
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Chapter 3 Proof of target-drug interaction 
The aim of this section of work is to measure inhibition of CHK1 in cells and the 
impact on DNA damage-induced cell cycle arrest. Total CHK1 expression, the 
phosphorylation of target proteins within the pathway, and the downstream 
consequences of activation or inhibition of proteins following a CHK1 inhibitor 
are considered.  
 
3.1 Introduction to target-drug interaction with V158411 
Cellular total CHK1 protein levels are unlikely to be responsive to DNA damage 
in the time-scale required for checkpoint activation. This has been confirmed by 
several studies that have shown that total CHK1 protein expression, in western 
blot assays, appears to be stable or increased following treatment with cytotoxic 
agents. For example, there was no change in total CHK1 protein levels in 
SW620 cells treated with 20 nM gemcitabine for 24 hours or 100 nM SN38 for 
24 hours (Walton et al., 2010).  Stable total CHK1 protein expression was also 
seen in MCF10A and MDA-MB-231 breast cell lines treated with 0.1 and 1 mM 
hydroxyurea for 24 hours (Montano et al., 2012). However, some studies 
demonstrated that total CHK1 protein levels in U87MG gliomas cell lines 
transiently increased (over 1-2 days) following exposure to 100 µM 
temozolomide for 3 hours, but then fell over a 10 day period in drug-free media 
(Hirose et al., 2001). 
There is mixed data as to the effect of CHK1 inhibitors on total CHK1 
expression. Exposure to 0.01 to 5 µM SAR-020106 for 24 hours appeared to 
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not affect total CHK1 protein expression in SW620 cells (Walton et al., 2010). 
However, exposure to 100 or 300 nM PD-321852 for 24 hours reduced total 
CHK1 protein expression compared to untreated controls in a panel of 
pancreatic cell lines (MiaPaCa2, BxPC3, PANC-1 and M-Panc-96) (Parsels et 
al., 2009). 
As described in the introduction (section 1-5-1), most cancer cells have a defect 
in their G1 checkpoint control, but there is relatively little data comparing total 
CHK1 protein expression between different cancer cell lines. Parsels et al 
demonstrated that baseline total CHK1 protein expression was similar in their 
panel of 4 pancreatic cancer cell lines (MiaPaCa2, BxPC3, PANC-1 and M-
Panc-96) (Parsels et al., 2009). However, few other authors have presented 
data on a head to head comparison of total CHK1 expression between cell 
lines. 
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Figure 3-1 The ATR-CHK1 pathway and phosphorylation targets. 
ATR phosphorylates CHK1 at serine317 and serine345, activated CHK1 is 
autophosphorylated at serine296. Arrows denote activation and T-bars 
denote inhibition. 
 
As described in the Introduction (Section 1-6-6) Cdc25A stability, Cdc25C 
phosphorylation and phosphorylation of CHK1 itself have all been investigated 
as potential biomarkers of CHK1 activity. Downstream phosphorylation targets 
are more likely to be an indication of CHK1 function/activity and 
autophosphorylation at serine296 has been reported by several groups. 
CHK1serine296 has been demonstrated to be a site of autophosphorylation in 
response to CHK1 activation (Clarke and Clarke, 2005). CHK1 serine296 
phosphorylation in untreated cell lines is very low (Walton et al., 2010). 
CHK1serine296 phosphorylation has been shown to be induced by some types of 
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cytotoxic therapy and reduced by the addition a CHK1 inhibitor. Guzi et al 
demonstrated that hydroxyurea (at an unspecified concentration overnight) 
increased CHK1serine296 phosphorylation in U2OS cells and that this was then 
reduced in a concentration-dependent fashion by 0.06 – 2 µM SCH 900776 for 
2 hours (Guzi et al., 2011). This work was duplicated in breast cell lines 
(MCF10A and MDA-MB-231) (Montano et al., 2012). Hydroxyurea treatment for 
24 hours increased CHK1serine296 phosphorylation in a concentration-dependent 
fashion and co-incubation with 1 µM SCH900776 abolished CHK1serine296 
phosphorylation. Similarly, Walton et al showed that a 24 hour exposure to 100 
nM SN38 significantly induced CHK1serine296 phosphorylation in SW620 cells 
(Walton et al., 2010, Walton et al., 2012). Walton et al demonstrated that a 24 
hour exposure to CCT244747 at concentrations >50 nM abolishes SN-38 
induced CHK1serine296 phosphorylation in HT29 cells (Walton et al., 2012). 
Clarke and Clarke also demonstrated that CHK1 was phosphorylated by ATR at 
both serine317 and serine345 (Clarke and Clarke, 2005). Walton et al also 
observed that 24 hour exposure to SN38 increased CHK1serine317 and 
CHK1serine345 phosphorylation reflecting ATR activation. Curiously, this was 
reduced, but not abolished by concentrations >100 nM of the CHK1 inhibitor, 
CCT244747 (Walton et al., 2012). Similarly, 2 µM gemcitabine for 2 hours 
increased CHK1serine317 and CHK1serine345 phosphorylation, which was reduced 
by 100 nM AZD7762 for 24 hours following gemcitabine (McNeely et al., 2010). 
These curious results of a CHK1 inhibitor acting upstream on ATR 
phosphorylation events, was postulated by the report’s authors to be secondary 
to a global reduction in CHK1 protein. 
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In studies using AZD7762 and gemcitabine in MiaPcCa-2 pancreatic cells 
(Parsels et al., 2011), 100 nM AZD7762 for 24 hours alone increased 
CHK1serine345 phosphorylation as did 50 nM gemcitabine for 2 hours and there 
was an additive effect when AZD7762 was combined with gemcitabine. It was 
suggested that this was due to loss of feedback inhibition of PP2A (that is 
normally activated by CHK1) to repress ATR activity. Subsequently, the authors 
looked at CHK1serine345 expression in biopsies (hair follicles and colonic 
biopsies) from mice treated with 30 – 60 mg/kg gemcitabine and 5 – 40 mg/kg 
AZD7762 alone and in combination (AZD7762 3 hours after gemcitabine and 
biopsies taken after a further 3 hours). There was no significant increase in 
CHK1serine345 phosphorylation with either drug on its own, but a significant 
increase when used in combination. 
Other authors have also noted that CHK1 inhibitors increase CHK1serine345 
phosphorylation significantly. For example, Montano et al showed in MDA-MB-
231 cells that 24 hour exposure to 1 µM SCH 900776 significantly increased 31 
- 500 mM hydroxyurea–induced CHK1serine345 phosphorylation (Montano et al., 
2012). 
Alternative downstream markers of CHK1 activity have been considered, such 
as phosphorylation of H2AX, but this is the target of many kinases in response 
to DNA damage and stalled replication forks and therefore not likely to be 
specific (Redon et al 2012). CHK1 inhibition (XL9844 – 18.5 to 4500 nM for 2 
hours) in conjunction with 30 nM gemcitabine for 24 hours induces γ-H2AX in 
PANC-1 cells (Matthews et al., 2007). Simultaneous treatment with 30 nM 
gemcitabine and 1500 nM XL9844 increases γ-H2AX 4-fold. However, this is 
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not specific to the use of a CHK1 inhibitor as other cytotoxic therapy as a single 
agent induce γ-H2AX expression (Montano et al., 2012).  
Guzi et al also looked at the phosphorylation of RPA at serine33 as a marker of 
DNA damage and showed that phosphorylation was increased significantly 
when 0.06 – 2 µM SCH 900776 for 2 hours was used in conjunction with 
hydroxyurea (at an unspecified concentration overnight) (Guzi et al., 2011). 
Other potential downstream markers of CHK1 activity include Cdc25A and 
Cdc25c. Activated CHK1 precipitates the degradation of Cdc25A and Cdc25A 
degradation induced by 30 nM gemcitabine for 24 hours was prevented by 300 
to 3000 nM XL9844 for 2 hours. (Matthews et al., 2007). 
Another measure of CHK1 activity is the impact on S and G2 phase cell cycle 
arrest. As described in section 1.11.2 and 1.11.3. CHK1 inhibitors reduce 
topoisomerase I poison-induced S-phase arrest and topoisomerase II poison-
induced and cisplatin-induced G2 arrest. 50 nM UCN-01 and 300 nM SCH 
900776 abrogated S phase arrest induced by 10 nM SN-38 in MDA-MB-231 
cells (Montano et al., 2012). 
In HT29 cells 500 nM CCT244747 for 24 hours (Walton et al., 2012). 
CCT244747 alone had minimal effects on the cell cycle distribution but reduced 
the 70% accumulation of cells in G2 caused by exposure to 25 µM etoposide for 
1 hour by 30% with a corresponding increase in cells in G1 (9.6%) or S phase 
(67%, but not actively incorporating BrdUrd). Eastman et al demonstrated that 
exposure of MDA-MB-231 breast cancer cells and MCF10A breast epithelial 
cells to 20 µM cisplatin for 2 hours induced both S and G2 arrest. This was 
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significant after 24 hours and maximal after 48 hours (Eastman et al., 2002). 
This arrest was abrogated in a concentration dependent fashion by both UCN-
01 and ICP-1 in the MDA-MB-231 cell line. 
The aims of this chapter are: 
a) To characterise a panel of cell lines in terms of their CHK1 expression 
and activity after exposure to cytotoxic agents 
b) To demonstrate CHK1 inhibition by V158411 
c) To demonstrate cell cycle checkpoint abrogation by V158411. 
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3.2 Baseline cellular levels of CHK1 
In view of the lack of specificity of H2AX phosphorylation for CHK1 and because 
Cdc25A stability/Cdc25c phosphorylation could be dependent on their 
expression in different cell lines it was decided to focus on phosphorylation of 
CHK1 itself. Prior to assessing the ability of V158411 to inhibit CHK1, the 
expression of total CHK1 protein and gemcitabine-induced CHK1serine296 
phosphorylation in a panel of cell lines was assessed by western blot analysis. 
The panel consisted of human leukaemic (K562 p53 mutated), breast (MCF7 
p53 wild type, MDA-MB-231 p53 mutated), colon (HCT116 p53 wild type and 
p53 -/-), glioblastoma (M059J p53 mutated, DNA-PKcs deficient and M059J-
Fus1 p53 mutated, DNA-PKcs corrected) described in table 2-1. CHK1serine296 is 
autophosphorylated by CHK1 when it is in its activated state. Pilot experiments 
showed that a short 1 hour exposure to 1 µM gemcitabine induced a significant 
increase in pCHK1serine296 expression (data not shown). This short relatively 
high concentration exposure to gemcitabine was chosen over a longer lower 
concentration exposure as it was felt that a short exposure would be the easiest 
to use in the development of an ex vivo biomarker. 
Figure 3-2 shows the baseline expression of total CHK1 protein in un-stimulated 
samples from a panel of cell lines. A seven-fold variation in cellular levels was 
observed; expression was highest in the K562 cells and lowest in MCF7 cells. 
Representative western blots from these experiments showing the expression 
of CHK1, pCHK1serine296 and actin are shown for 9 cell lines in the panel in 
Figure 3-3. 
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Figure 3-2 Expression of total CHK1 protein 
Values are normalised to actin in a cell line panel comprising K562 (p53 
mutated), MCF7 (p53 wild type), MDA-MB-231 (p53 mutated), HCT116 ( p53 
wild type), HCT116 (p53 -/-), M059J (p53 mutated), M059J-Fus1 (p53 
mutated), U2OS (p53 mutated) and U2OS (dominant negative p53). Data 
are mean and standard deviation of at least 3 independent experiments 
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Figure 3-3 Expression of total CHK1 protein, pCHK1serine296 and actin by 
western blotting in a cell line panel. 
Cell line panel comprises K562 (p53 mutated), MCF7 (p53 wild type), MDA-
MB-231 (p53 mutated), HCT116 (p53 wild type), HCT116 (p53 -/-), M059J 
(p53 mutated), M059J-Fus1 (p53 mutated), U2OS (p53 wild type) and U2OS 
(dominant negative p53) with and without a 1 hour exposure to 1 µM 
gemcitabine. 
 
The phosphorylation of CHK1 at serine296 in matched control samples and 
samples treated for 1 hour with 1 µM gemcitabine is shown in Figure 3-4. This 
demonstrates that gemcitabine reliably up-regulates the expression of 
pCHK1serine296 in all cell lines apart from the M059J and U2OS wild type cell 
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lines. Figure 3-5 shows the ratios by which pCHK1serine296 expression is up-
regulated in treated samples compared to untreated controls. There is a wide 
range in the degree to which CHK1serine296 phosphorylation is induced (Figure 3-
5), from 1.3-fold to 8-fold, and that this does not correlate with the baseline 
expression seen in Figure 3-2. Although, pCHK1serine296 levels were still higher 
in K562 cells, similar levels were seen in HCT116 wild type and M059J-Fus1 
cell lines after gemcitabine exposure. Interestingly, both HCT116 p53 -/- and 
U2OS dominant negative p53 cells had lower baseline pCHK1serine296 levels 
than the wild type, but activation by gemcitabine did not appear to be p53-
dependent. 
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Figure 3-4 Expression of pCHK1serine296 
Values are normalised to actin in controls and paired samples 1 hour after 
1 µM gemcitabine. Cell line panel comprising of K562 (p53 mutated), MCF7 
(p53 wild type), MDA-MB-231 (p53 mutated), HCT116 (p53 wild type), 
HCT116 (p53 -/-), M059J (p53 mutated), M059J-Fus1 (p53 mutated), U2OS 
(p53 wild type) and U2OS (dominant negative p53). Data are mean and 
standard deviation of at least 3 independent experiments 
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Figure 3-5 Relative expression of pCHK1serine296 
Data in cell line panel treated with 1 µM gemcitabine compared to 
untreated controls. Cell line panel comprising of K562 (p53 mutated), 
MCF7 (p53 wild type), MDA-MB-231 (p53 mutated), HCT116 (p53 wild type), 
HCT116 (p53 -/-), M059J (p53 mutated), M059J-Fus1 (p53 mutated), U2OS 
(p53 wild type) and U2OS (dominant negative p53). Data are mean and 
standard deviation of at least 3 independent experiments 
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3.3 Confirmation of specificity of V158411 for CHK1 
A series of experiments were planned to attempt to confirm that V158411 was 
having its desired effects and single agent cytotoxicity (see section 4.1) via its 
action on CHK1 rather than on an unknown other target. It was hoped to be 
able to knock CHK1 down with siRNA, confirm this knockdown and then to 
perform clonogenic assays with the combination of CHK1 siRNA and V158411. 
Figure 3-6 demonstrates the knockdown of CHK1 in the MCF7 breast cancer 
cell line with siRNA at 48 and 120 hours after treatment. Unfortunately 
treatment with CHK1 siRNA for 7 days led to the death of too many cells for 
there to be sufficient protein recoverable for western blot analysis. 
 
Figure 3-6 Representative western blot in MCF7 breast cancer cell line. 
Expression in MCF7 (p53 wild type) cells of CHK1 and actin in untreated 
controls treated for 48 hours, 5 days and 7 days, cells treated with 
scrambled siRNA for 48 hours, 5 days and 7 days, and cells treated with 
CHK1 siRNA for 48 hours, 5 days. Note no 7 day sample with CHK1 siRNA 
as insufficient cells alive to extract protein for western blot analysis. 
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Figure 3-7 (A) quantifies this knockdown of CHK1 by siRNA in comparison to 
cell line samples treated with control scrambled siRNA. There was 80% 
knockdown after 48 hours and more than 98% knockdown after 5 days. 
 
 
Figure 3-7 Data with siRNA knockdown and clonogenic survival 
(A) siRNA knockdown of CHK1 in MCF7 (p53 wild type) breast cancer cell 
line. A comparison of samples treated with scrambled and CHK1 siRNA 
for 48 or 120 hours. (B) Clonogenic survival assay in MCF7 breast cancer 
cell line following treatment with scrambled siRNA and CHK1 siRNA. 
 
In parallel with the samples prepared for western blotting a clonogenic assay 
was performed in control cells, those treated with scrambled siRNA and with 
CHK1 siRNA for 48 hours. The results are shown in Figure 3-7 (B). This shows 
that there was no clonogenic survival after 2 weeks in cells treated for 48 hours 
with CHK1 siRNA. Therefore it was not possible to test the specificity of 
V158411 CHK1 knock-down cells. 
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3.4 Phosphorylation of CHK1 at serine345 and serine296 
The following series of experiments were performed to provide evidence that 
V158411 was inhibiting CHK1. The work was also aimed at investigating 
whether the phosphorylation of CHK1 at either serine296 or serine345 might be an 
appropriate biomarker that could be developed into a tool for use in early phase 
clinical trials. V158411 doses that were equimolar rather than equitoxic were 
used in these experiments. These equimolar concentrations were used in 
experiments examining protein expression, cell cycle and cytotoxicity. 
Hydroxyurea was used as a positive control for ATR activation and CHK1serine345 
phosphorylation. 
Representative western blots from these experiments are shown at the end of 
this section in Figures 3-12 (A and B) and 3-13 (A and B). All drug treatments 
were concomitant for 1 hour immediately prior to the preparation of lysates. The 
protein expression was normalised to the expression of actin. 
 
3.4.1 Effect of single agent V158411 on pCHK1serine296 and pCHK1serine345 
levels 
Figure 3-8 demonstrates that V158411 reduces CHK1serine296 phosphorylation in 
a concentration dependent manner in MCF7, MDA-MB-231 and K562 cell lines. 
The representative blots for pCHK1serine296, pCHK1serine345 and actin expression 
from these experiments are shown in Figure 3-13. 150 nM V158411 reduced 
the expression of pCHK1serine296 by 48% below baseline in MCF7 cells, 67% in 
MDA-MB-231 cells and 53% in K562 cell line. There was no significant inhibition 
of CHK1serine296 phosphorylation in HCT116 cells 
 
 
112 
 
Figure 3-8 Phosphorylation of CHK1serine296 with V158411 
Phosphorylation following treatment for 1 hour with 50 nM and 150 nM 
V158411 alone for 1 hour compared to untreated controls. Experiment 
performed in MCF7 (p53 wild type), MDA-MB-231 (p53 mutated), HCT116 
(p53 wild type) and K562 (p53 mutated) cell lines. CHK1serine296 normalised 
to actin and then to untreated controls. Data are mean and standard 
deviation of at least 3 independent experiments. 
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CHK1serine345 phosphorylation is increased in all 4 cell lines by the presence of 
the CHK1 inhibitor V158411. This is shown in Figure 3-9. CHK1serine345 
phosphorylation was increased in a concentration responsive manner. 150 nM 
V158411 increased the expression of pCHK1serine345 11-fold in MCF7 cells, 8-
fold in MDA-MB-231 cells, 10-fold in HCT116 cells and 6–fold in K562 cell lines. 
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Figure 3-9 Phosphorylation of CHK1serine345 after exposure to V158411.  
Phosphorylation following treatment for 1 hour with 50 nM and 150 nM 
V158411 alone for 1 hour compared to untreated controls. Experiment 
performed in MCF7 (p53 wild type), MDA-MB-231 (p53 mutated), HCT116 
(p53 wild type) and K562 (p53 mutated) cell lines. CHK1serine345 normalised 
to actin and then to untreated controls. Data are mean and standard 
deviation of at least 3 independent experiments 
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3.4.2 Effect of V158411 on gemcitabine-induced changes in pCHK1serine345 
and pCHK1serine296 phosphorylation levels 
Figure 3-10 shows the CHK1serine296 phosphorylation following a 1 hour 
treatment with gemcitabine with and without 50 nM and 150 nM V158411. 1 µM 
gemcitabine consistently increased CHK1serine296 phosphorylation in all 4 cell 
lines. The increase was 8-fold in MCF7 cells, 7-fold in MDA-MB-231 cells, 4.5-
fold in HCT116 cells and 9-fold in K562 cells. 
V158411 reduced this increase in CHK1serine296 phosphorylation in a 
concentration-dependent fashion in all cell lines apart from MDA-MB-231. 50 
nM V158411 reduced gemcitabine-induced CHK1serine296 phosphorylation from 
its stimulated level by 75% in MCF7 cells, 77% in MDA-MB-231 cells 78% in 
K562 cells and 66% in HCT116 cells. 150 nM V158411 reduced gemcitabine-
induced CHK1serine296 phosphorylation from its stimulated level by 94% in MCF7 
cells, 58% in MDA-MB-231 cells, 77% in HCT116 cells and 89% in K562 cells. 
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Figure 3-10 Phosphorylation of CHK1serine296 following exposure to 
V158411 and gemcitabine. 
Phosphorylation following treatment for 1 hour with 1 µM gemcitabine ± 
50 nM and 150 nM V158411 for 1 hour compared to untreated controls. 
Experiment performed in MCF7 (p53 wild type), MDA-MB-231 (p53 
mutated), HCT116 (p53 wild type) and K562 (p53 mutated) cell lines. 
CHK1serine 296 normalised to actin and then to untreated controls. Data are 
mean and standard deviation of at least 3 independent experiments 
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Both gemcitabine and V158411 individually increased the phosphorylation of 
CHK1serine345 and together the increase was additive in MCF7 and HCT116 cells 
but not MDA-MB-231 and K562 cells (Figure 3-11). 1 µM gemcitabine alone 
increased CHK1serine345 3-fold and this was increased to 10-fold in combination 
with 150 nM V158411 in the MCF7 cells. In HCT116 cells there was a 10-fold 
increase in CHK1serine345 phosphorylation with 1 µM gemcitabine and this was 
increased to 16-fold with the addition of 150 nM V158411. However, in K562 
cells there was no further increase in gemcitabine-induced with either V158411. 
In contrast, in MDA-MB-231 cells 50 nM or 150 nM V158411 did not increase 
CHK1serine345 phosphorylation induced by gemcitabine and in K562 there was a 
modest, and not significant, decrease in gemcitabine-induced CHK1serine345. 
The ratio between CHK1serine296 phosphorylation and CHK1serine345 
phosphorylation following treatment with 1 µM gemcitabine and 1 µM 
gemcitabine in combination with 50 nM and 150 nM V158411 was explored in 
all 4 cell lines, but no consistent relationship could reliably be found (data not 
shown). 
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Figure 3-11 Phosphorylation of CHK1serine345 following exposure to 
V158411 and gemcitabine. 
Phosphorylation following treatment for 1 hour with 1 µM gemcitabine +/- 
50 nM and 150 nM V158411 for 1 hour compared to untreated controls. 
Experiment performed in MCF7 (p53 wild type), MDA-MB-231 (p53 
mutated), HCT116 (p53 wild type) and K562 (p53 mutated) cell lines. 
CHK1serine345 normalised to actin and then to untreated controls. Data are 
mean and standard deviation of at least 3 independent experiments.  
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Figure 3-12 Example western blots in MCF7 and MDA-MB-231 cells. 
Representative western blot in (A) MCF7 (p53 wild type) cells and (B) 
MDA-MB-231 (p53 mutated) cells. Expression of ATR, pCHK1serine296, 
pCHK1serine345 and actin in untreated controls, and cells treated with 50 nM 
V158411, 150 nM V158411, 500 nM V158411, 1500 nM V158411, 1 µM 
gemcitabine, 1 µM gemcitabine + 50 nM V158411, 1 µM gemcitabine + 150 
nM V158411, 1 µM gemcitabine + 500 nM V158411, 1 µM gemcitabine + 
1500 nM V158411 and 10 mM. hydroxyurea All treatments for 1 hour prior 
to preparation of lysates. 
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Figure 3-13 Example western blots in HCT116 and K562 cells. 
Representative western blot in (A) HCT116 (p53 wild type) cells and (B) 
K562 (p53 mutated) cells. Expression of total CHK1, pCHK1serine296, 
pCHK1serine345 and actin in untreated controls, and cells treated with 50 nM 
V158411, 150 nM V158411, 1 µM gemcitabine, 1 µM gemcitabine + 50 nM 
V158411, 1 µM gemcitabine + 150 nM V158411, and 10 mM hydroxyurea. 
All treatments for 1 hour prior to preparation of lysates. 
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3.5 Cell cycle perturbation by cytotoxic agents 
Having demonstrated a clear effect of V158411 on phosphorylation targets 
indicative of CHK1 inhibition it was important to demonstrate that this translated 
into abrogation/attenuation of cell cycle arrest at the S and G2 checkpoints. 
K562 cells were used in the initial experiments and then MDA-MB-231 breast 
cancer cells and HCT116 colorectal cancer cells were used in subsequent 
experiments. MCF7 breast cancer cells were not used as this cell line displays 
significant aneuploidy meaning that the quantification of flow cytometry data is 
unreliable. Although, S-phase data was collected, specific staining for cells in S-
phase such as BrdU was not used. Therefore, the S-phase data is not included 
here as it is less reproducible than the data with regard to G2 fraction.  
 
3.5.1 The effect of conventional cytotoxics and IR on cell cycle 
distribution in K562 cells 
Prior to looking at the abrogation of cell cycle arrest by V158411 it was 
important to determine which conventional cytotoxic agents (gemcitabine, 
cisplatin, hydroxyurea, camptothecin, etoposide and IR) caused a reliable 
increase in the G2 fraction of cycling cells. These experiments were performed 
in K562 CML cell line. 
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Figure 3-14 Analysis of cell cycle distribution by flow cytometry in K562 
CML cells following cytotoxic therapy. 
Untreated controls (Nil) and cells treated with 2 Gy IR (IR), 10 µM cisplatin 
(Cis), 1 µM gemcitabine (Gem), 500 µM hydroxyurea (Hu), 10 µM 
camptothecin (Cpt) and 5 µM etoposide (Etop) at baseline, 6 hours, 12 
hours and 24 hours after cytotoxic exposure. K562 (p53 mutated) cell line 
doubling time approximately 12-14 hours. 
 
Figure 3-14 demonstrates that 2 Gy IR and 10 µM cisplatin cause modest G2 
cell cycle arrest and were taken forward for future work both in K562 and other 
cell lines. None of the agents caused a significant S-phase arrest and 
gemcitabine, hydroxyurea, camptothecin and etoposide do not cause a 
significant increase in the G2 fraction in K562 cells and so were not taken 
forward for future work. 
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3.5.2 Dose response of K562 cells to ionising radiation 
Following the initial demonstration of G2 arrest following exposure to 2 Gy IR a 
further experiment in K562 cells was performed to ascertain if higher doses of 
IR led to a greater proportion of cells arresting in G2. Figure 3-15 shows the 
results of this experiment with 2, 4, 6, 8 and 10 Gy IR in comparison to un-
irradiated control cells. Rather, than being dose-dependent, the G2 arrest was 
time-dependent with maximum arrest observed at 12 and 24 hours. As 2 Gy is 
the standard dose in fractionated radiotherapy, 2 Gy of IR 24 hours prior to 
analysis was chosen as the dose to use in future work. 
 
Figure 3-15 Analysis of cell cycle distribution by flow cytometry in K562 
CML cells following IR. 
Untreated controls and cells treated with 2 Gy, 4 Gy, 6 Gy, 8 Gy and 10 Gy 
IR at baseline, 6 hours, 12 hours and 24 hours after IR. K562 (p53 mutated) 
cell line doubling time approximately 12-14 hours. 
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3.6 Effect of V158411, ionising radiation and cisplatin on cell cycle 
distribution 
A 24 hour exposure to 50nM, 150 nM and 500 nM V158411 has been shown in 
western blot experiments (see Section 3-5) to cause a concentration-dependent 
reduction in CHK1serine296 phosphorylation justifying the duration of treatment 
used in these experiments. The following experiments were performed in K562, 
MDA-MB-231, HCT116 cell lines. Cells were treated with ionising radiation and 
then exposed to drug-free medium, 50 nM V158411, 150 nM V158411 or 500 
nM V158411 for 24 hours hour prior to flow cytometry. In combination with 
cisplatin (based on the data presented in Figure 3-14), cells were co-treated 
with 1 µM cisplatin with plain medium, 50 nM V158411, 150 nM V158411 or 500 
nM V158411 for 24 hours prior to flow cytometry.  
Representative histograms from the experiments are shown in Figure 3-16 for 
K562 cells, Figure 3-17 for MDA-MB-231 and Figure 3-18 for HCT116 wild type 
cells. Analysis of this data is in the subsequent sections. 
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Figure 3-16 Representative example of flow cytometry in K562 cells. 
Top row (L to R): untreated control, 50 nM V158411, 150 nM V158411 and 
500 nM V158411. Middle row: 2 Gy IR, 2 Gy IR + 50 nM V158411, 2 Gy IR + 
150 nM V158411 and 2 Gy IR + 500 nM V158411. Bottom row: 1 µM 
cisplatin, 1 µM cisplatin + 50 nM V158411, 1 µM cisplatin + 150 nM 
V158411 and 1 µM cisplatin + 500 nM V158411. K562 (p53 mutated) cell 
line doubling time approximately 12-14 hours. Minimum of 10000 events 
collected for each cytogram. 
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Figure 3-17 Representative example of flow cytometry in MDA-MB-231 
cells. 
Top row (L to R): untreated control, 50 nM V158411, 150 nM V158411 and 
500 nM V158411. Middle row: 2 Gy IR, 2 Gy IR + 50 nM V158411, 2 Gy IR + 
150 nM V158411 and 2 Gy IR + 500 nM V158411. Bottom row: 1 µM 
cisplatin, 1 µM cisplatin + 50 nM V158411, 1 µM cisplatin + 150 nM 
V158411 and 1 µM cisplatin + 500 nM V158411. MDA-MB-231 (p53 mutated) 
cell line doubling time approximately 40 hours. Minimum of 10000 events 
collected for each cytogram 
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Figure 3-18 Representative example of flow cytometry in HCT116 wild type 
cells. 
Top row (L to R): untreated control, 50 nM V158411, 150 nM V158411 and 
500 nM V158411. Middle row: 2 Gy IR, 2 Gy IR + 50 nM V158411, 2 Gy IR + 
150 nM V158411 and 2 Gy IR + 500 nM V158411. Bottom row: 1 µM 
cisplatin, 1 µM cisplatin + 50 nM V158411, 1 µM cisplatin + 150 nM 
V158411 and 1 µM cisplatin + 500 nM V158411. HCT116 (p53 wild type) cell 
line doubling time approximately 16-18 hours. Minimum of 10000 events 
collected for each cytogram 
 
3.6.1 The effect of V158411 alone on G2 cell cycle fraction in cell lines 
The impact of a 24 hour exposure to 3 concentrations of V158411 (50 nM, 150 
nM and 500 nM) was determined in K562, MDA-MB-231 and HCT116 by flow 
cytometry. The results are shown in Figure 3-19. V158411 caused a 
concentration-dependent depletion of the G2 fraction of cells in all 3 cell lines 
that was significant at all 3 concentrations of V158411 (p = 0.034, p = 0.041, 
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and p = 0.0003 respectively (paired t-tests)) and in K562 cells with 150 nM and 
500 nM V158411 (p = 0.003 and p = 0.0007 (paired t-test)) and 500 nM 
V158411 (paired t-test). There was a much smaller reduction in the G2 fraction 
in MDA-MB-231 cells, which was only significant with 50 nM V158411 (p = 0.04 
(paired t-test)). This reduced effect is likely to be because the cell cycle in MDA-
MB-231 cells is much longer at around 40 hours than in K562 cells (12-14 
hours) and in HCT116 cells (16-18 hours). 
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Figure 3-19 Flow cytometry in K562, MDA-MB-231 and HCT116 wild type 
cells 
Untreated samples, 50 nM V158411, 150 nM V158411 and 500 nM V158411. 
% change in G2 fraction is calculated as the change in G2 fraction 
compared to time = 0 normalised to untreated controls. Cell line doubling 
time in K562 (p53 mutated) 12-14 hours, MDA-MB-231 (p53 mutated) 40 
hours and HCT116 (p53 wild type) 16-18 hours. Data are mean and 
standard deviation of at least 3 independent experiments 
 
 
130 
 
3.6.2 The effect of ionising radiation +/- V158411 on G2 cell cycle fraction 
in cell lines 
In parallel with the flow cytometry experiment with V158411 alone, the effect of 
V158411 on the cell cycle perturbation by 2 Gy IR was determined in K562, 
MDA-MB-231 and HCT116 cells. Cells were treated with 2 Gy IR alone or in 
combination with 50 nM V158411, 150 nM V158411 and 500 nM V158411 for 
24 hours prior to cell cycle analysis by flow cytometry. The results shown in 
Figure 3-20. 
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Figure 3-20 Flow cytometry in K562, MDA-MB-231 and HCT116 wild type 
cells 
Untreated samples, 2 Gy IR, 2 Gy IR + 50 nM V158411, 2 Gy IR + 150 nM 
V158411 and 2 Gy IR + 500 nM V158411. % change in G2 fraction is 
calculated as the change in G2 fraction compared to time = 0 normalised 
to untreated controls. Cell line doubling time in K562 (p53 mutated) 12-14 
hours, MDA-MB-231 (p53 mutated) 40 hours and HCT116 (p53 wild type) 
16-18 hours. Data are mean and standard deviation of at least 3 
independent experiments. 
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This demonstrates that 2 Gy IR does cause an increase in the G2 fraction in all 
3 cell lines, but this is only statistically significant in K562 (p = 0.022 (paired t-
test)). Nevertheless V158411 abrogated what G2 arrest there was in all 3 cell 
lines in a concentration-dependent manner in K562 and HCT116, but not MDA-
MB-231 cells. 
In K562 cells V158411 abrogated the IR-mediated increase in the G2 fraction in 
a concentration dependent manner at concentrations ≥ 150 nM (p = 0.004 and 
p = 0.003 (paired t-test) at 150 and 500 nM, respectively). All 3 concentrations 
of V158411 (50 nM, 150 nM and 500 nM) cause significant abrogation of IR-
mediated G2 cell cycle arrest in HCT116 cells (p = 0.030, p = 0.009, and p = 
0.037 respectively (paired t-tests)). 
In the MDA-MB-231 cell line there was only a very small increase in the G2 
fraction with 2 Gy IR, which was not statistically significant but the G2 fraction 
was significantly reduced by 500 nM V158411 (p = 0.005 (paired t-test)). 
 
3.6.3 The effect of cisplatin +/- V158411 on G2 cell cycle fraction in cell 
lines 
As with IR, in parallel with the flow cytometry experiment with V158411 alone, 
cells from the 3 cell lines (K562, MDA-MB-231 and HCT116) were treated with 
1 µM cisplatin on its own or in combination with 50 nM V158411, 150 nM 
V158411 and 500 nM V158411. The results are shown in Figure 3-21. 
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Figure 3-21 Flow cytometry in K562, MDA-MB-231 and HCT116 wild type 
cells 
Untreated samples, 1 µM cisplatin, 1 µM cisplatin + 50 nM V158411, 1 µM 
cisplatin + 150 nM V158411 and 1 µM cisplatin + 500 nM V158411. % 
change in G2 fraction is calculated as the change in G2 fraction compared 
to time = 0 normalised to untreated controls. Cell line doubling time in 
K562 (p53 mutated) 12-14 hours, MDA-MB-231 (p53 mutated) 40 hours and 
HCT116 (p53 wild type) 16-18 hours. Data are mean and standard 
deviation of at least 3 independent experiments. 
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1 µM cisplatin increased the G2 cell cycle fraction in all 3 cell lines, but this was 
only significant in K562 cell line (p = 0.041 (paired t-test)). 150 nM and 500 nM 
V158411 significantly abrogated this cisplatin-mediated arrest in K562 cells (p = 
0.009 and p = 0.003 respectively (paired t-test)). There appeared to be a trend 
towards a reduction in the G2 fraction following cisplatin treatment with 
increasing concentrations of V158411 in K562 cells, but this was not statistically 
significant. Likewise there was a trend in the HCT116 cell line, but none of the 
changes reached statistical significance. There was no change in MDA-MB-231 
cells.  
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3.7 Discussion 
Table 3-1 shows a summary of the data from 4 cell lines in which the 
investigations in this chapter were focussed and acts a summary of the 
expression of CHK1, phosphorylation of CHK1 in response to V158411 +/- IR 
and cisplatin and the effect of V158411 +/- IR and cisplatin on the cell cycle.  
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 MCF7 MDA-MB-231 HCT116 K562 
     
CHK1 protein levels 
(untreated) Low Low-medium Medium High 
CHK1serine296 untreated Low Low Low High 
% CHK1serine296 reduction 
with V158411 (untreated 
cells) 
30-90 65-80 25* 50 
% CHK1serine296 increase 
with 1 µM gemcitabine 400/800 200/700 800/500 200/900 
% reduction by V158411 
of gemcitabine induced 
CHK1serine296 increase 
50-100 60* 80-100 80-100 
% CHK1serine345 increase 
with V158411 (untreated 
cells) 
1000-2000 300-700 500-1000 500* 
% CHK1serine345 increase 
with 1 µM gemcitabine 200 2500 1500 1500 
%CHK1serine345 increase 
with V158411 and 1 µM 
gemcitabine 
200-800 2500 2000-3000 1000-1500* 
% reduction in G2 fraction 
with V158411 alone  - 10 70-90 50-80 
% increase in G2 fraction 
with 2 Gy IR) - 135 120 110 
% reduction by V158411 
of IR-induced G2 
accumulation  
- 0-100* 300-400* 200-400 
% increase in G2 fraction 
with 1 µM cisplatin - 110 110 120 
% reduction in G2 fraction 
with V158411 and 1 µM 
cisplatin (%) 
- 0-100* 300-400* 0-400 
Table 3-1 Summary of baseline characteristics and changes in response 
to V158411 +/- IR and Cisplatin in MCF7, MDA-MB-231, HCT116 and K562 
cancer cell lines. 
% change in G2 fraction: G2 fraction (treated)/ G2 fraction (untreated) x100 
Values included in the table are mean. * no concentration response. 
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The data presented show a wide range of baseline total CHK1 protein 
expression between cell lines. Data in this chapter are largely generated using 
MCF7, MDA-MB-231, HCT116 and K562 cancer cell lines which had low, low-
medium, medium and high levels of basal CHK1 protein expression, 
respectively. 
There is relatively little published data comparing CHK1 levels between cell 
lines. In contrast to our data, Parsels et al showed that total CHK1 expression 
was similar in a panel of 4 pancreatic cancer (Parsels et al., 2009). The 
differences observed in the data reported here could reflect tissue specific 
differences as a wide panel of cell lines were used (CML, breast, colon, GBM 
and osteosarcoma). In the two breast cancer cell lines used, MCF7 and MDA-
MB-231, the baseline CHK1 protein levels were quite similar. More research is 
required to examine the variability in a wider panel of cell lines within tumour 
types, between tumour types and in different normal tissues. Furthermore, work 
is required to examine the heterogeneity of expression of total CHK1 expression 
by immunohistochemistry (IHC) in normal tissue and tumour samples from 
patients. 
The data presented shows that greater than 90% CHK1 knockdown can be 
achieved with siRNA in MCF7 cancer cells, but this was not compatible with 
survival in clonogenic studies, precluding proposed studies to determine the 
specificity of V158411 for CHK1. In MCF7 cells 150 nM V158411 reduced 
CHK1serine296 phosphorylation by approximately 50% and led to around 30% 
clonogenic survival (see Section 4-2), suggesting that only partial CHK1 
knockdown may be required for a significant reduction in cell survival. 
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Other studies have not been published with respect to CHK1 knockdown in 
MCF7 cells; however, Zenvirt et al knocked CHK1 down in U2OS cells with 
siRNA with a significant reduction in cell survival in the absence of 
chemotherapy (Zenvirt et al., 2010). It would be interesting to explore whether 
lower concentrations of siRNA or alternative methods of siRNA transfection 
prevented this phenomenon. Work by other members of the group has explored 
the effect of ATR modulation in fibroblasts (GM847 cells) transduced via SV-40 
with a doxycycline-inducible FLAG-tagged kinase-dead ATR (Peasland et al., 
2011). The cells always express ATR and when induced by doxycycline ATR 
expression increases; the ATR is not active and acts as a dominant-negative. 
ATR kinase-dead cells did not grow in cell culture until ATR was re-expressed. 
Further data from the group has shown that MCF7 cells only grow when ATR 
was re-expressed by shRNA ATR. 
To develop a pharmacodynamic assay for CHK1 inhibition the ideal situation 
would be to measure a downstream phosphorylation events in the absence of 
an additional activating agent. Autophosphorylation of CHK1 is likely to be most 
specific as it is largely independent of accessory proteins. A low level of 
endogenous CHK1 activity (CHK1serine296 phosphorylation) was detected in all 
untreated solid tumour cell lines at consistently low levels. With only low levels 
of endogenous CHK1serine296 phosphorylation there is only a small dynamic 
range to detect inhibition in an assay. This may explain why other authors have 
not presented data on how exposure to other CHK1 inhibitors as single agents 
modulate the phosphorylation of CHK1serine296. However, in K562 CML cells 
endogenous levels were significantly higher and reductions in phosphorylation 
were more easily detected. Concentrations of 150 nM V158411 on its own for 1 
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hour reduced CHK1serine296 phosphorylation by 50% in MCF7 cells, 70% in 
MDA-MB-231 cells, 25% in HCT116 cells and 60% in K562 cells. 
A more sensitive strategy is to examine the reduction in phosphorylation of 
CHK1serine296 following DNA damage. This increases the dynamic range for the 
detection of inhibition. The data presented here show that gemcitabine 
increased CHK1serine296 phosphorylation by 8-fold, 7-fold, 4.5-fold and 9-fold in 
MCF7, MDA-MB-231, HCT116 and K562 cells respectively and that 50 nM 
V158411 inhibited the gemcitabine-induced increase by ~80% and 150 nM 
V158411 completely abolished gemcitabine-induced phosphorylation, reducing 
it to significantly below baseline in all cell lines apart from MDA-MB-231 cells 
where there was a 2.3 fold reduction from the stimulated level. A short 1 hour 
treatment was chosen as this could be potentially used in the development a 
biomarker assay of ex vivo CHK1 activation for clinical use that required an ex 
vivo treatment. This confirmed that this is an appropriate concentration and 
duration to be used in the subsequent experiments and in the development of a 
potential ex vivo biomarker. 
The data with V158411 is in line with published data showing exposure to 
cytotoxic agents increased CHK1serine296 phosphorylation. Montano and Guzi 
demonstrated that CHK1serine296 phosphorylation was increased in U2OS cells, 
MDA-MB-231 breast cancer cells and MCF10A breast cells by an overnight 
treatment with hydroxyurea (Guzi et al., 2011, Montano et al., 2012). Walton et 
al showed that 100 nM SN38 for 24 hours also increased CHK1serine296 
phosphorylation in HT29 cancer cells (Walton et al., 2012). 
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The data presented here is also in keeping with that presented by Montano et al 
with SCH 900776 in U2OS, MDA-MB-231 and MCF10A cell lines where SCH 
900776 abrogated the hydroxyurea-mediated increase in CHK1serine296 
phosphorylation in a concentration-dependent fashion (Montano et al., 2012, 
Guzi et al., 2011). This is also supported by the data pertaining to CCT244747 
which at concentrations > 100 nM abolished the SN-38-mediated increase in 
CHK1serine296 phosphorylation (Walton et al., 2012). 
CHK1serine296 phosphorylation is a potential biomarker for CHK1 inhibitor activity 
especially after either co-treatment with a cytotoxic agent or following an ex vivo 
stimulation with gemcitabine. The antibody used in these experiments for the 
CHK1serine296 epitope is only suitable for use in western blotting. It could be used 
with western blots with PBMCs from in vivo animal experiments or from patients 
in early phase clinical trials. 
However, new antibodies for CHK1serine296 are now available and it would be 
interesting to explore whether these could be used in other applications.  
CHK1serine345 phosphorylation is an alternative marker of interest. It is markedly 
elevated in the presence of V158411. There was a 11-fold, 8-fold, 10-fold and 
6-fold increase of pCHK1serine345 in MCF7, MDA-MB-231, HCT116 and K562 
cells respectively 1 hour after the administration of 150 nM V158411. This is in 
line with the data presented by Montano demonstrating that SCH 900776 
increased CHK1serine345 phosphorylation (Montano et al., 2012).  
Surprisingly, V158411 did not cause any further increase in CHK1serine345 
phosphorylation compared to gemcitabine alone in MDA-MB-231 and K562 
cancer cell lines. In MCF7 cancer cells the increase was less than that with 
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V158411 alone; however, in HCT116 there was a 3-fold increase in 
CHK1serine345 phosphorylation by gemcitabine and V158411 compared to 
V158411 alone which may have been merely additive. 
The pattern of increase in CHK1serine345 phosphorylation was very different with 
V158411 alone compared to co-treatment with gemcitabine and V158411. With 
V158411 alone CHK1serine345 phosphorylation was greatest in MCF7 > HCT116 
> K562 = MDA-MB-231. Whereas with co-treatment with gemcitabine and 
V158411 CHK1serine345 phosphorylation was greatest in MDA-MB-231 > HCT116 
= K562 > MCF7. This presumably reflects cell-specific differences in the relative 
contribution to ATR activation via the stalling of replication forks with 
gemcitabine or via the inhibition of dephosphorylation events when CHK1 is 
inhibited. 
CHK1serine345 phosphorylation may be useful as a demonstration of CHK1 
inhibition in biopsy specimens in either in vivo experiments or from patients in 
early phase clinical trials, but it should be remembered that this reflects an 
effect on ATR activity that is not necessarily CHK1-specific. 
The CHK1serine345 antibody used in our work and that of a number of other CHK1 
inhibitors is also suitable for flow cytometry and IHC. Parsels et al demonstrated 
that induction of Chk1serine345 phosphorylation as measured by IHC (in skin 
biopsies and hair follicles from mice) can reliably be used as a biomarker of 
Chk1 activity in mice treated with a combination of AZD7762 and gemcitabine 
(Parsels et al., 2011). From my own experience I would favour work using skin 
biopsies as hair follicles are difficult to collect, vary widely between subjects and 
are require considerable dexterity to process. 
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Flow cytometry in K562 cells demonstrated that G2 cell cycle arrest occurs after 
at least 6 hours (maximum at around 24 hours) consistently after treatment with 
cisplatin (10 µM until analysis at 6 hours, 12 hours and 24 hours) or 2 Gy IR 
(and increasing the IR dose caused no further cell cycle disturbance). Other 
cytotoxic therapy, camptothecin and gemcitabine, may have caused S phase 
arrest as documented by other authors (Tse et al., 2007b, Montano et al., 
2012). However, quantifying S phase arrest without specific methods such as 
BrdU staining is unreliable. 
Since only cisplatin and IR caused convincing S or G2 cell cycle arrest in the 
K562 cells only these agents were investigated in the other cells. Only modest 
cell cycle effects were observed 24 hours after treatment with a DNA damaging 
agent in all cell lines. 
Eastman and colleagues observed more marked G2 arrest than reported here 
after 20 µM cisplatin for 2 hours in MDA-MB-231 cancer cells (Eastman et al., 
2002). We used a lower concentration of cisplatin for a longer duration; 10 µM 
in initial experiments and then 1 µM in subsequent experiments for durations of 
up to 24 hours compared to 20 µM for 2 hours. 
Of note, in contrast to experiments performed by Walton et al, we did not show 
a significant increase in the proportion of cells in G2 24 hours after treatment 
with etoposide (Walton et al., 2012). Walton et al. used HT29 colorectal cells 
and treated them with 25 µM etoposide for 1 hour compared to our experiment 
where we used 5 µM etoposide for 6, 12 and 24 hours. 
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Single agent V158411 caused a significant concentration dependent reduction 
in the proportion of cells in G2 in both K562 and HCT116 cells. There was a 
much more modest reduction in MDA-MB-231 breast cancer cells. This did not 
correlate with the extent of inhibition of CHK1serine296 phosphorylation seen with 
single agent V158411 in these cell lines. The greatest inhibition of CHK1serine296 
phosphorylation by V158411 was seen in MDA-MB-231 cancer cell lines where 
there was the most modest reduction of cells in G2 cell cycle arrest. This is in 
contrast to the effects seen on the cell cycle with other single agent Chk1 
inhibitors, UCN-01, CHIR-124, SCH 900776 and CCT244747, where no 
significant changes in the cell cycle distribution were seen (Tse et al., 2007b, 
Montano et al., 2012, Walton et al., 2012). 
Based on the data for both 296 and 345 phosphorylation where the effect was 
most pronounced in MCF7 and HCT116 cells and modest in MDA and K562 
cells it was somewhat predictable that V158411 would have very little effect on 
cell cycle arrest in MDA-MB-231 cancer cells compared to HCT116 cells. 
However, the profound effect of V158411 on the cell cycle of K562 cells would 
not have been predicted by the CHK1 phosphorylation data. 
V158411 abrogated DNA damage-induced G2 cell cycle arrest in K562, and 
HCT116 in a concentration-dependent manner. This mimics the perturbation of 
etoposide-induced G2 arrest seen in HT29 colorectal cancer seen by Walton et 
al with CCT244747 (Walton et al., 2012). Walton et al do not quantify the 
degree of G2 cell cycle arrest seen with 25 µM etoposide for 1 hour or the extent 
of abrogation with the single concentration of 500 nM CCT244747 for 23 hours 
following etoposide that they use, but present the flow cytometry histograms.  
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In MDA-MB-231 G2 arrest was very modest such that significant inhibition by 
V158411 was difficult to measure. Other studies have used MDA-MB-231 cells 
and have demonstrated cisplatin-induced G2 arrest that was abrogated by both 
UCN-01 and ICP-1 (Eastman et al., 2002). In these studies the MDA-MB-231 
cells were exposed to 20 µM cisplatin for 2 hours, left in drug-free media for 24 
hours before a 30 or 48 hour exposure to UCN-01 and ICP-1. This longer 
exposure to UCN-01 and ICP-1 may have led to the more significant abrogation 
of G2 cell cycle arrest; though the authors do not quantify this and simply give a 
visual representation of the data. 
The absence of significant changes in the cell cycle distribution with single 
agent V158411 in MDA-MB-231 breast cancer cells in contrast to the other cell 
lines may be because the length of a cell cycle in K562 cells is 12-16 hours, in 
HCT116 cells 20-30 hours and in MDA-MB-231 cells 45-55 hours. So the K562 
and HCT116 cells will all have gone through at least one cell cycle in 24 hours 
whereas only about half of the MDA-MB-231 cells will have been through one 
cell cycle. This is in line with the data presented by Eastman, albeit with a 
shorter, 2 hour exposure to a higher, 2 µM, concentration of cisplatin where 
significant increases in the G2 fraction were not seen at 24 hours, but also after 
30 and 48 hours (Eastman et al., 2002). Flow cytometry has not been 
performed at 48 hours as it was decided to keep to the same time points across 
cell lines to ensure the data was comparable rather than to tailor the time points 
to the duration of the cell cycle in each cell line. These data supports the 
mechanism that V158411 is acting via CHK1 to modulate the G2 checkpoint. 
CHK1 levels and phosphorylation and checkpoint activation after DNA damage 
vary across the cell lines and do not necessarily predict cell cycle effects after 
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DNA damage. Pilot experiments demonstrated that while gemcitabine induced 
CHK1 phosphorylation after just 1 hour there was no effect of cisplatin until at 
least 16 hours. However, gemcitabine failed to induce cell cycle arrest and 
therefore cell cycle perturbations was investigated after IR and cisplatin. The 
use of different agents in these 2 experiments was pragmatic, but could be seen 
as a weakness and does not allow direct comparison between the experiments. 
Because IR and cisplatin were the only agents to consistently cause G2 arrest in 
the panel these were investigated alongside gemcitabine in cytotoxicity studies 
with V158411 in the next chapter. 
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Chapter 4 Cytotoxicity of V158411 
Having determined that V158411 inhibits CHK1 autophosphorylation at 
serine296 almost completely at 150 and 500 nM and that this is associated with 
the abrogation of cell cycle arrest after DNA damage (IR and cisplatin).  The 
impact of V158411, alone and in combination with DNA damaging agents 
(gemcitabine, cisplatin and IR), on cell survival was examined. 
 
4.1 CHK1 inhibitors and cell viability 
The majority of pre-clinical studies with CHK1 inhibitors have explored their 
potential to be used as chemosensitisers in combination with conventional 
cytotoxics. The rationale for these studies as described in section 1-5-1 is that 
cell cycle arrest is needed to allow repair of DNA damage before it becomes 
cytotoxic. In cancer cells that have lost G1 cell cycle control there is greater 
dependence on the CHK1-mediated S and G2 checkpoint control.  
The rationale for single agent therapy with CHK1 inhibitors is less strong. Not 
surprisingly therefore, there is relatively little published data regarding the 
single-agent activity of ‘second generation’ CHK1 inhibitors. Some investigators 
have demonstrated that certain cell lines are sensitive to single agent CHK1 
inhibitors, but currently it is not clear what determines sensitivity. This will be 
explored in greater depth in chapters 5 and 6. 
The dual CHK1/CHK2 inhibitor 100 nM AZD7762 for 25 hours alone showed 
minimal cytotoxicity in a panel of cell lines clonogenic assays (Mitchell et al., 
2010b). The most sensitive cell lines in this panel were SF-295 (glioblastoma - 
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57% survival), and MiaPaca2 (65% survival). There was greater than 70% 
survival with all the remaining cell lines (HT29, DU145, A549, H460, PC-Sw and 
1522 (normal skin fibroblasts)). 
In contrast Montano et al demonstrated that SCH 900776 was significantly 
cytotoxic as a single agent in 4 cell lines within a wider panel (Montano et al., 
2012). Cell lines were exposed to SCH 900776 for 24 hours in 96 well plates 
followed by a 5 to 7 day incubation in drug-free media. A fluorescent DNA stain, 
Hoechst 33258, was used to assess cell proliferation. Most cell lines tolerated 
concentrations of up to 10 µM SCH 900776 for 24 hours, however 4 (A549, 
U2OS, TK-10 and HCC2998) showed significant cytotoxicity following exposure 
to 500 nM SCH 900776.  
In studies with the dual CHK1/CHK2 inhibitor XL9844, Matthews et al 
demonstrated a modest effect of the drug on clonogenic survival. The effect 
was greatest in HeLa cells where a 24 hour exposure to 300 nM XL844 reduced 
survival by 32% (Matthews et al., 2007). 
As described in the Introduction (section 1-13); in most pre-clinical studies 
CHK1 inhibitors have been used in conjunction with gemcitabine or 
topoisomerase I poisons. Varying degrees of chemosensitisation have ben 
observed and often related to p53 status. In a panel of human cancer cell lines 
(p53 mutant SW620 and MDA-MB231 cells and paired HCT116 cells with and 
without p53) AZD7762 increased the growth inhibitory effects (MTT assay) and 
cytotoxicity of both gemcitabine and topotecan, with more pronounced 
potentiation in cells with mutated p53. (Zabludoff et al., 2008). At a 
concentration of 300 nM AZD7762 potentiated the effect of gemcitabine more 
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than 20-fold in p53 mutated SW620 cells and the effect of topotecan 15-fold in 
p53 mutant MDA-MB-231 cells. The potentiation of gemcitabine was confirmed 
using clonogenic survival assays in p53 wild type and mutated HCT116 cells 
exposed for 2 hours to gemcitabine, then 24 hours with or without 100 nM 
AZD7762 followed by drug-free media for 10-14 days prior to colony counting. 
In these studies AZD7762 increased the cytotoxicity of 1 µM gemcitabine 40-
fold in the p53 mutant HCT116 cells compared to 10-fold in the p53 wild type 
HCT116 cells. 
Data were confirmed in SW620 xenograft models where 60 mg/kg gemcitabine 
(i.v.) was administered every 3 days and 12.5 or 25 mg/kg AZD7762 (i.v.) 4 and 
16 hours after each gemcitabine dose increased the inhibition of tumour growth 
by gemcitabine by >70% by AZD7762. However, the most remarkable data was 
obtained with the combination of AZD7762 with irinotecan in the SW620 model, 
with complete tumour regressions being observed in all mice treated with 50 
mg/kg irinotecan and 25 mg/kg AZD7762 (two doses 2 and 14 hours after the 
irinotecan). 
There is also some mixed cytotoxicity data with CHK1 inhibitors in conjunction 
with platinum compounds (that cause DNA cross-links) and a single study in 
conjunction with taxanes (spindle poisons). Eastman and Bunch demonstrated 
that the prototype CHK1 inhibitor 50 nM UCN-01 significantly potentiated 
cisplatin-induced growth inhibition in AA8 CHO cells and in MDA-MB-231 
(Bunch and Eastman, 1996, Eastman et al., 2002). Cells were treated for 2 
hours with cisplatin, then had 22 hours in drug-free media prior to 24 hours in 
UCN-01 prior to estimating growth by DNA content 6 days later. However, in 
other studies the clonogenic survival of HeLa cells treated with cisplatin was not 
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impaired by 24 hour co-exposure with 20 and 80 nM AZD7762 (Wagner and 
Karnitz, 2009). In similar studies there was no potentiation of cisplatin-induced 
growth inhibition in human breast cancer MDA-MB-231, MDA-MB-231CHK1-/- or 
immortalised human breast fibroblasts MCF10A cells by either 50 nM UCN-01 
or 1 µM SCH 900776 co-exposure for 24 hours followed by 5-7 days in drug-
free medium (Montano et al., 2012). However, in this study there was 
substantial sensitisation to hydroxurea by both CHK1 inhibitors in all 3 cell lines, 
even those lacking CHK1. 
Somewhat curiously, PF00477736 has been shown to sensitise xenografts to 
the taxane docetaxel (Zhang et al., 2009). In the xenograft model of CoLo205 
and MDA-MB-231, mice were administered 15 or 30 mg/kg docetaxel intra-
peritoneal (i.p.) once on day 1, 8 and 15 with or without 7.5 or 15 mg/kg 
PF00477736 (i.p.) concomitantly with the docetaxel and a second dose after a 
delay of 6 hours. There was significant tumour growth delay in both xenografts 
with the combination compared to single agent docetaxel or PF00477736. 
There is far less published pre-clinical data concerning radio-potentiation with 
CHK1 inhibitors than there is with combination therapy with other 
chemotherapeutic agents. As described in section 1.14 promising levels of 
radiosensitisation have been observed with UCN-01, AZD7762 and CEP-3891 
both in vitro and in vivo but so far this has not translated into clinical studies of 
CHK1 inhibitors in combination with IR. 
There is data supporting the notion that radiosensitisation by CHK1 inhibitors 
will be greater in p53 null/mutant cells. 100 nM AZD7762 for 1 hour prior to IR 
and 24 hours after a single fraction of IR (range 0-14 Gy), significantly 
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radiosensitised DU145 1.6-fold, HT29 and H460 with a dominant negative p53 
1.58-fold in colony forming assays (Mitchell et al., 2010b). Significantly in 
matched H460 cells with wild type p53 radiosensitisation was only 1.11-fold (not 
significant) and there was no significant radiosensitisation in 1522 (normal 
human fibroblasts) sensitisation is 1.05 fold, in A549 NSCLC cells sensitisation 
is 1.2-fold. 
In a separate paper, Yang et al demonstrated that AZD7762 was an effective 
radiosensitiser in H23 (p53 mutated radio-sensitive) and PC14PE6 (p53 wild 
type radio-resistant) NSCLC cell lines (Yang et al., 2011). Cells were treated 
with 100 nM AZD7762 for 1 hour before and 24 hours after exposure to a range 
of doses of IR (0 – 7 Gy). They also developed a mouse xenografts model of 
PC14PE6 NSCLC with brain metastases and showed that 25 mg/kg AZD7762 
(i.v.) prolonged the median survival time following whole brain irradiation (15 
Gy) delivered 1 hour after AZD7762. Median survival was 30 days with no 
treatment, 40 days with IR alone and 51 days with IR + AZD7762 (p = 0.05 
compared to IR alone). 
There is mixed evidence as to whether a CHK1 inhibitor should be administered 
concomitantly with cytotoxic therapy or after a delay. Zabludoff compared the 
effect of AZD7762 on the cytotoxicity of gemcitabine in isogenic p53 +/+ and 
p53 -/- HCT116 cells in a colony-forming assay (Zabludoff et al., 2008). Cells 
were treated with variable gemcitabine concentrations for 2 hours followed by 
either immediate 24 hour treatment with 100 nM AZD7762 for 24 hours 
immediately or after a 24 hour incubation in drug-free media. The 
chemosensitisation was greatest in this assay if 100 nM AZD7762 was 
delivered immediately after the 2 hour exposure to gemcitabine. Further work 
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was performed using 100 nM AZD7762 for 24 hours in combination with 50 nM 
gemcitabine for 2 hours in 3 different scheduling regimens in a panel of 
pancreatic cell lines (MiaPaCa-2, M-Panc96, BxPC3 and Panc-1) (Parsels et 
al., 2011). The authors demonstrated that the best schedule depended on the 
concentration of gemcitabine used. 50 nM gemcitabine for 2 hours is relatively 
non-toxic to the pancreatic cell lines and in this scenario there was greatest 
chemo-potentiation (4.5-6 fold) if AZD7762 was given immediately after 
gemcitabine. However, if higher concentrations of gemcitabine were used a 
delay of 24 hours led to greater potentiation. These authors had observed 
similar effects with PD-321852 in MiaPaCa-2 and Panc-1 cells (Parsels et al., 
2009). The authors suggest that at higher concentrations of gemcitabine the 
cells have arrested in early-S phase and time needs to have elapsed for the 
cells to have escaped the S phase arrest for cytotoxicity to be potentiated by the 
agent targeting the G2 checkpoint. 
Walton et al showed in vitro studies with SW620 cells that co-exposure to 
gemcitabine (fixed concentration of IC50) and the CHK1 inhibitor SAR-020106 
(variable concentrations – not specified) for less than 24 hours did not enhance 
gemcitabine cytotoxicity but enhancement was observed if the co-exposure was 
for at least 48 hours (Walton et al., 2012). Studies in mice revealed that 
concomitant administration of the CHK1 inhibitor SAR-020106 with gemcitabine 
or irinotecan was more effective at delaying the growth of SW620 mouse 
xenografts (Walton et al., 2010). 4 doses of 60 mg/kg gemcitabine (i.v.) or 3 
doses of 12.5 mg/kg irinotecan (i.p.) were delivered every 3 or 7 days 
respectively. 40 mg/kg SAR-020106 (i.p.) was delivered either 1 hour before 
(concomitant schedule) or 24 hours after (delayed schedule) the cytotoxic 
therapy. The growth delay with concomitant administration of gemcitabine and 
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SAR-020106 was 8.5 days compared to 6.3 days when SAR-020106 was 
delivered on the delayed schedule. 
In contrast, pre-clinical studies by Montano with SCH 900776 led the early 
phase clinical trial team to deliver SCH 900776 24 hours after gemcitabine 
(Montano et al., 2012, Daud et al., 2010). Montano et al compared the 
sensitivity of MDA-MB-231 cells to either simultaneous treatment with 
hydroxyurea and 2 µM SCH 900776 for 24 hours or 2 µM SCH 900776 was 
only added for the last 6 hours of the 24 hour incubation period. The authors 
showed that there was a 50-fold decrease in the IC50 of hydroxyurea with both 
regimens. However if the same concentrations of both drugs were used 
concurrently for only 6 hours there was no cytotoxicity. It is unclear how this 
pre-clinical evidence led the early phase investigators to use a schedule where 
there was a 24 hour delay between the delivery of gemcitabine and SCH 
900776. This may be based on unpublished data. 
The approach of delaying the administration of the CHK1 inhibitor for a defined 
period after the cytotoxic agent is supported by data with GNE-900 (Blackwood 
et al., 2013). The authors administered 20 mg/kg GNE-900 orally concomitantly 
with 60 mg/kg gemcitabine (i.p.) or after 8, 16, 24, 36 or 48 hours to mice 
bearing HT-29 xenografts. Maximal chemosensitisation was seen with a 24 
hour gap between gemcitabine and the CHK1 inhibitor with what the authors 
describe as a therapeutic window between 16 and 36 hours. There was no 
effect when GNE-900 was given concomitantly with gemcitabine or with a delay 
of 8 or 48 hours. 
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With respect to the scheduling of a CHK1 inhibitor in conjunction with IR, 
Mitchell and colleagues comment in their discussion that, in pilot in vitro studies 
that they do not include in detail in their publication, treatment with 100 NM 
AZD7762 after IR was more effective at enhancing the effect of IR than 
treatment with AZD7762 for 24 hours prior to IR (Mitchell et al., 2010b). 
The aims of this chapter are: 
a) To determine the cytotoxicity of single agent V158411 in a panel of cell 
lines. 
b) To determine the chemosensitisation by V158411 of cell lines to 
gemcitabine and cisplatin. 
c) To determine the radiosensitisation of cell lines by V158411 
d) To establish the schedule dependency of radiosensitisation using the 
same cell lines in which the effects of V158411 on CHK1 phosphorylation 
and cell cycle kinetics had been determined. 
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4.2 Single agent cytotoxicity of V158411 
CHK1 inhibitors may be useful as single agent therapies as well as in 
combination with traditional cytotoxics or radiotherapy. To determine if V158411 
had single agent activity in the 4 cancer cell lines (MCF7, MDA-MB-231, 
HCT116 and K562 cells) investigated in Chapter 3, the clonogenic survival 
following a 24 hour exposure to increasing concentrations of V158411 was 
assessed (Figure 4-1). The LC50 values ranged from 114 nM in MCF7 cells to 
511 nM in MDA-MB-231 cells (Table 4-1).  
 
Figure 4-1 Cytotoxicity of single agent V158411 
Cytotoxicity assays (clonogenic) in MCF7 (p53 wild type), MDA-MB-231 
(p53 mutated), HCT116 (p53 wild type) and K562 (p53 mutated) cancer cell 
lines. Data are mean +/- SEM of 3 independent experiments. Within each 
experiment there were at least 2 replicates. 
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Cell Line and p53 status V158411 LC50 (nM): mean and 
(SD) 
V158411 LC90 (nM): mean 
and (SD) 
   
MCF7 (p53 wild type)  113.8 (40.3) 986.9 (152.3) 
MDA-MB-231 (p53 
mutant)  
511.3 (64.5) 1411.2 (56.7) 
K562 (p53 mutant)  152.5 (87.2) 482.1 (524.5) 
HCT116 (p53 wild type)  476.4 (41.2) 1453 (99.9) 
   
Table 4-1 LC50 and LC90 values of V158411 
Data from cytotoxicity assays (clonogenic) in MCF7 (p53 wild type) and 
MDA-MB-231 (p53 mutated) breast cancer, HCT116 (p53 wild type) 
colorectal and K562 (p53 mutated) CML cancer cell lines. Mean and 
standard deviation from at least 3 experiments. 
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4.3 The effect of V158411 concentration and exposure duration on 
cytotoxicity 
To assess whether a shorter duration exposure to a higher concentration of 
V158411 or a longer exposure to a lower concentration would result in higher 
cytotoxicity, MCF7 and HCT116 cells were treated for 24, 72 or 120 hours with 
V158411 in clonogenic assays. The concentrations of V158411 were chosen so 
that the total exposure/AUC (area under the curve) given over the varying time 
periods would be constant; that is 50 nM x 24 hours, 16 nM x 72 hours, 10 nM x 
120 hours; 150 nM x 24 hours, 50 nM x 72 hours, 30 nM x 120 hours and finally 
500 nM x 24 hours, 166 nM x 72 hours and 100 x 120 hours (Figure 4-2).  
 
Figure 4-2 Cytotoxicity assay (clonogenic) exploring dose 
duration/intensity. 
Clonogenic survival of MCF7 (p53 wild type) and HCT116 (p53 wild type) 
cells following treatment with V158411: 50 nM x 24 hours, 16 nM x 72 
hours, 10 nM x 120 hours; 150 nM x 24 hours, 50 nM x 72 hours, 30 nM x 
120 hours; 500 nM x 24 hours, 166 nM x 72 hours, 100 nM x 120 hours. 
Summary of 3 independent experiments Data are mean +/- SEM of 3 
independent experiments. Within each experiment there were at least 2 
replicates. 
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Greatest cytotoxicity is seen with a shorter (24 hours versus 72 hours versus 
120 hours) exposure to a higher concentration of V158411 in both MCF7 and 
HCT116 cell lines. A 24 hour exposure is significantly more cytotoxic than a 72 
hour exposure in both MCF7 and HCT116 cells (p = 0.019 and p = 0.006 
respectively (paired t-test)). However, there is no statistically significant 
difference between a 72 hour exposure and 120 hour exposure in both MCF7 
and HCT116 cell lines (p = 0.124 and p = 0.084 respectively (paired t-test)). 
As expected cytotoxicity was both concentration and time-dependent. Within 
each group of equivalent AUC the highest concentration for the shortest time 
was more cytotoxic than lower concentrations for longer exposure period. This 
was true for MCF7 at a total AUC of 50 nM for 24 hours and for HCT116 cells at 
all AUCs. Time dependency was more apparent in MCF7 cells where 50 nM for 
24 hours was less cytotoxic than when the exposure was extended to 50 nM for 
72 hours and 150 nM for 24 hours was less cytotoxic than 166 nM for 72 hours. 
In HCT116 although 50 nM for 24 hours was less cytotoxic than 50 nM for 72 
hours, there was less difference between 150 nM for 24 hours and 166 nM for 
72 hours.   
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4.4 Chemo-potentiation 
The majority of the pre-clinical literature with CHK1 inhibitors has focused on its 
use in combination with gemcitabine, topoisomerase I poisons and platinum 
compounds. For the purposes of this project V158411 was used in combination 
with either gemcitabine or cisplatin in the MCF7 (p53 wild type) and MDA-MB-
231 (p53 mutated) breast cancer cell lines. 
 
4.4.1 Single agent cytotoxicity of gemcitabine and cisplatin 
Prior to performing combination cytotoxicity studies with V158411 the single 
agent cytotoxicity of gemcitabine and cisplatin in MCF7 and MDA-MB-231 cell 
lines was assessed in clonogenic assays after 24 hour drug exposure (Figure 4-
3). The drugs had similar cytotoxicities in both cell lines with MDA-MB-231 
cancer cells being marginally more sensitive (Table 4-2).  
 
Cell Line MCF7: mean and (SD) MDA-MB-231: mean and (SD) 
   
Gemcitabine LC50 (nM) 21 (15.0) 17 (8.3) 
 Gemcitabine LC90 (nM) 205 (127.9) 100 (140.7) 
 Cisplatin LC50 (µM)  2 (n/a)  1.3 (0.52) 
Cisplatin LC90 (µM) 23 (n/a) 18 (n/a) 
   
Table 4-2 LC50 and LC90 values of gemcitabine and cisplatin. 
Data from MCF7 (p53 wild type) and MDA-MB-231 (p53 mutated) breast 
cancer cell lines. Mean and standard deviation from at least 3 experiments 
where data is available. 
 
 
159 
 
 
Figure 4-3 Cytotoxicity of single agent gemcitabine and cisplatin in MCF7 
and MDA-MB-231 breast cancer cell lines. 
Cytotoxicity assays (clonogenic) in MCF7 (p53 wild type), MDA-MB-231 
(p53 mutated). Data are mean +/- SEM of 3 independent experiments. 
Within each experiment there were at least 2 replicates. 
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4.4.2 Combination of gemcitabine with 50 nM and 150 nM V158411 
The ability for V158411 to potentiate the cytotoxicity of gemcitabine in MCF7 
and MDA-MB-231 breast cancer cell lines was assessed in clonogenic assays. 
Cells were co-exposed to increasing concentrations of gemcitabine and 2 
concentrations of V158411, 50 nM and 150 nM (representing the approximate 
LC50 and a lower than LC50 concentration to explore synergism) for 24 hours 
and colonies allowed to form in fresh, drug-free medium 10 days later (Figure 4-
4 and Figure 4-5). 
Neither concentration of V158411 potentiated the cytotoxicity of gemcitabine in 
either cell line. There was no statistically significant difference in the LC50 values 
in either cell line when V158411 was used in addition to gemcitabine. 
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Figure 4-4 Cytotoxicity of gemcitabine +/- V158411 in MCF7 cells. 
MCF7 (p53 wild type) breast cancer cell line treated with gemcitabine 
alone or in combination with 50 nM V158411 or 150 nM V158411 for 24 
hours. Upper graph: Absolute survival; lower graph: survival normalised 
to DMSO or 50 nM or 150 nM V158411 alone control. Data are mean +/- 
SEM of 3 independent experiments. Within each experiment there were at 
least 2 replicates. 
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Figure 4-5 Cytotoxicity of gemcitabine +/- V158411 in MDA-MB-231 cells. 
MDA-MB-231 (p53 mutated) breast cancer cell line treated with 
gemcitabine alone or in combination with 50 nM V158411 or 150 nM 
V158411 for 24 hours. Upper graph: Absolute survival; lower graph: 
survival normalised to DMSO or 50 nM or 150 nM V158411 alone control. 
Data are mean +/- SEM of 3 independent experiments. Within each 
experiment there were at least 2 replicates. 
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4.4.3 Combination of cisplatin with 50 nM and 150 nM V158411 
The ability for V158411 to potentiate the cytotoxicity of cisplatin in MCF7 and 
MDA-MB-231 breast cancer cell lines was assessed in clonogenic assays. Cells 
were co-exposed to increasing concentrations of cisplatin and 2 concentrations 
of V158411, 50 nM and 150 nM for 24 hours (Figure 4-6 and Figure 4-7). 
As can be seen in both figures (Figure 4-6 and Figure 4-7) neither concentration 
of V158411 potentiated the cytotoxicity of cisplatin in either cell lines. There was 
no statistically significant difference in the LC50 values in either cell line when 
V158411 was used in addition to cisplatin. 
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Figure 4-6 Cytotoxicity of cisplatin +/- V158411 in MCF7 cells. 
MCF7 (p53 wild type) breast cancer cell line treated with cisplatin alone or 
in combination with 50 nM V158411 or 150 nM V158411 for 24 hours. 
Upper graph: Absolute survival; lower graph: survival normalised to 
DMSO or 50 nM or 150 nM V158411 alone control. Data are mean +/- SEM 
of 3 independent experiments. Within each experiment there were at least 
2 replicates.  
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Figure 4-7 Cytotoxicity of cisplatin +/- V158411 in MDA-MB-231 cells. 
MDA-MB-231 (p53 mutated) breast cancer cell line treated with cisplatin 
alone or in combination with 50 nM V158411 or 150 nM V158411 for 24 
hours. Upper graph: Absolute survival; lower graph: survival normalised 
to DMSO or 50 nM or 150 nM V158411 alone control. Data are mean +/- 
SEM of 3 independent experiments. Within each experiment there were at 
least 2 replicates. 
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4.5 Radio-potentiation 
The ability of V158411 to potentiate the cytotoxicity of ionising radiation (IR) in 
MCF7 and MDA-MB-231 cell lines was assessed. Cells were treated with 
V158411 or control DMSO for 2 hours prior to exposure to IR and for a further 
22 hours after exposure. 
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Figure 4-8 Cytotoxicity of IR +/- V158411 in MCF7 cells. 
MCF7 (p53 wild type) breast cancer cell line treated with 0-10 Gy IR alone 
or in combination with 50 nM V158411 or 150 nM V158411 for 24 hours. 
Upper graph: Absolute survival; lower graph: survival normalised to 
DMSO or 50 nM or 150 nM V158411 alone control. Data are mean +/- SEM 
of 3 independent experiments. Within each experiment there were at least 
2 replicates. 
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Figure 4-9 Cytotoxicity of IR +/- V158411 in MDA-MB-231 cells. 
MDA-MB-231 (p53 mutated) breast cancer cell line treated with 0-10 Gy IR 
alone or in combination with 50 nM V158411 or 150 nM V158411 for 24 
hours. Upper graph: Absolute survival; lower graph: survival normalised 
to DMSO or 50 nM or 150 nM V158411 alone control. Data are mean +/- 
SEM of 3 independent experiments. Within each experiment there were at 
least 2 replicates. 
0 2 4 6 8 10
1
10
100
0
Dose IR (Gy)
%
 C
lo
no
ge
ni
c 
Su
rv
iv
al
No V158411
50 nM V158411
150 nM V158411
0 2 4 6 8 10
1
10
100
0
Dose IR (Gy)
%
 C
lo
no
ge
ni
c 
Su
rv
iv
al
No V158411
50 nM V158411
150 nM V158411
 
 
169 
 
V158411 enhanced IR-induced cytotoxicity in both cell lines (Figure 4-8 and 
Figure 4-9) at both 50 nM and 150 nM, but this was only significant in the MDA-
MB-231 cancer cell line (MCF7 p = 0.059, MDA-MB-231 p = 0.023 (ANOVA)). 
Radiotherapy is most commonly administered in 2 Gy fractions, so radiation 
enhancement ratios (RER) at 2 Gy IR were calculated for both cell lines (Table 
4-3). There was no statistically significant difference between 50 nM and 150 
nM V158411 in the enhancement of IR in either cell line. 
 
 MCF7 MDA-MB-231 
RER: mean and 
(SD) 
p-value RER: mean and 
(SD) 
p-value 
 
No V158411 
versus 50 nM 
V158411 
1.70	  (0.147)	  
 
0.05 1.242	  (0.039)	  
 
0.006 
No V158411 
versus 150 nM 
V158411 
1.91	  (0.247)	   0.038 1.46	  (0.219)	   ns 
Table 4-3 RER (mean and SD) with V158411. 
RER in MCF7 (p53 wild type) and MDA-MB-231 (p53 mutated) cancer cell 
lines. ns – not significant. p values calculated by paired t-tests. Summary 
of data from at least 3 independent experiments.  
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4.6 The effect of dose schedule on the cytotoxicity of V158411 in 
combination with ionising radiation 
In the previous experiments when V158411 was used in combination with IR; it 
was delivered for 2 hours prior to, and 22 hours immediately after IR. It is 
unclear whether this is the best strategy for enhancing the cytotoxicity of IR. In 
early phase clinical trials some CHK1 inhibitors (as a 1 to 3 hour infusion) have 
been used concomitantly with conventional chemotherapy and others following 
a 24 hour delay. 
An experiment was designed to assess whether there was any difference in the 
ability of V158411 to enhance the cytotoxicity of IR depending on the dosing 
schedule. Since MDA-MB-231 and MCF7 cells behaved similarly in previous 
experiments, for the scheduling experiments a different cell line, HCT116 was 
introduced to replace the MDA-MB-231 cell line. MCF7 and HCT116 cells were 
exposed to V158411 for 24 hours prior to 2 Gy IR or for 24 hours immediately 
after 2 Gy IR, or for 24 hours following a 24 hour delay after IR (Figure 4-10). 
In both cell lines 2 Gy IR caused an approximately 50% reduction in survival. In 
MCF7 cells, pre-treatment with V158411 prior to IR was less effective than 
treatment either immediately after IR, but nevertheless caused a concentration-
dependent significant increase in cytotoxicity compared to IR alone (1.4 fold at 
50 nM, 2.7 fold at 150 nM). 
In HCT116 cells, pre-treatment with V158411 appeared to protect cells from IR, 
with survival being significantly greater than with IR alone (50 nM V158411 
(32% increase in survival) p = 0.0004 and 150 nM V158411 (12% increase in 
survival) p = 0.014 respectively (paired t-test)). In MCF7 cells co-treatment and 
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delayed post IR exposure to V158411 caused similar radiosensitisation that was 
approximately 2 fold at 50 nM and 3 fold at 150 nM (p = 0.0085 and p = 0.0153 
respectively (paired t-test)). Radiosensitisation by V158411 in HCT116 cells 
was modest and not statistically significant, being around 1.2-fold at 150 nM 
and negligible at 50 nM (p = 0.16 and p = 0.13 respectively (paired t-test)). 
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Figure 4-10 Cytotoxicity of IR +/- V158411 in different dose schedules. 
The effect of dose schedule of V158411 and ionising radiation. A and B in 
MCF7 (p53 wild type) breast cancer cell line and C and D in HCT116 (p53 
wild type) colorectal cancer cell line. Black bars  - cells treated with 2 Gy 
IR alone, purple bars – cells treated for 24 hours with V158411 prior to 2 
Gy IR, dark blue bars – cells treated with V158411 for 24 hours 
immediately after 2 Gy IR, light blue bars – cells treated with V158411 for 
24 hours after a 24 hour delay following the delivery of 2 Gy IR. Data are 
mean +/- SEM of 3 independent experiments. Within each experiment 
there were at least 2 replicates. 
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C. HCT116 V158411 (50 nM)
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B. MCF7 V158411 (150 nM)
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D. HCT116 V158411 (150 nM)
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4.7 Discussion 
The sensitivity (LC50) of the four cell lines examined to single agent V158411 
ranged from 114 nM (MCF7 – breast cancer) to 511 nM (MDA-MB-231 - breast 
cancer). There seems to be a threshold concentration (50 nM) below which very 
little cytotoxicity is seen in any of the four cell lines; this is despite the fact that 
there is greater than 50% inhibition of CHK1serine296 phosphorylation in 3 of 4 
(MDA-MB-231, HCT116 and K562) of the cell lines with 50 nM V158411 (see 
Table 4-4). There is discordance between the inhibition of CHK1serine296 
phosphorylation and cytotoxicity; the cell lines with the greatest inhibition of 
CHK1serine296 phosphorylation at the lowest concentration of V158411 (MDA-
MB-231) are the cell line in which V158411 is the least cytotoxic. Interestingly, 
MCF7 cells were the cells in which endogenous CHK1 activity was most 
resistant to inhibition by V158411, but were the most sensitive cell line in 
cytotoxicity assays. 
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Cell Line V158411 CHK1 inhibition Cell death 
    
MCF7 50 nM 32% 34% 
150 nM 53% 60% 
MDA-MB-231 50 nM 52% 6% 
150 nM 67% 30% 
K562 50 nM 53% 10% 
150 nM 55% 54% 
HCT116 50 nM 40% 2% 
150 nM 17% 9% 
Table 4-4 CHK1 inhibition with V158411 and relationship to single agent 
cytotoxicity. 
CHK1 inhibition data (% reduction in CHK1serine296 following 1 hour 
treatment with 50 and 150 nM V158411) from section 3.4. Cytotoxicity in 
single agent assay with 50 and 150 nM V58411. 
 
There are a limited number of studies published with CHK1 inhibitors used as 
single agents so comparisons between this data with V158411 and the literature 
are restricted. However, in studies with the dual CHK1/2 inhibitors AZD7762 
and XL9844 only modest cytotoxicity was observed and this is restricted to a 
few cell lines. Mitchell et al demonstrated minimal cytotoxicity with the dual 
CHK1/CHK2 inhibitor AZD7762 in a panel of cancer cell lines (Mitchell et al., 
2010b). A lack of significant single agent activity was also seen with another 
dual CHK1/CHK2 inhibitor, XL9844, where in clonogenic assays the most 
significant reduction in survival following a 24 hour exposure to 300 nM XL844 
was a 32% reduction in survival in HeLa cells (Matthews et al., 2007). Similarly, 
Montano et al showed that a 24 hour exposure to 500 nM SCH 900776 was 
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cytotoxic to 4 (A549, U2OS, TK-10 and HCC2998) out of wider panel of cancer 
cell lines (Montano et al., 2012). The cytotoxicity of V158411 as a single agent 
in U2OS cells is considered in section 5-2. 
This over 3-fold factor range in sensitivity (single-agent CHK1 cytotoxicity) 
within tumours from a common tissue of origin suggests that factors other than 
the tissue of origin play a role in determining sensitivity to V158411. It has been 
hypothesised that cancers with a defective G1 cell cycle checkpoint will be more 
sensitive to CHK1 inhibitors.  However, MCF7 breast cancer cells have a 
normal p53 phenotype and MDA-MB-231 breast cancer cells have a mutated 
p53 so in this case p53 status does not appear to be the main determinant of 
sensitivity to single-agent V158411. This is not an isogenic cell line pair so 
comparing the two different cell lines has to be approached with caution; 
experiments using isogenic-paired cell lines are considered in Chapter 5. p53 is 
a commonly mutated in cancer, but is only one part of the complex apparatus 
that is involved in the control of the G1 checkpoint. Other components of the G1 
checkpoint control pathway may play a role in determining the sensitivity of cells 
to CHK1 inhibitors. Other potential determinants of sensitivity to CHK1 inhibitors 
that have been considered by other authors include Myc, Ras, ERK 1/2, MEK, 
JNK-p38 MAP kinase and these will be considered in more detail in Chapter 6 
(Hoglund et al., 2011b, Mitchell et al., 2010a, Xia et al., 1995).  
The experiment looking at the duration for which V158411 should be 
administered as a single agent demonstrates that the peak concentration of 
V158411 is the important determinant of cytotoxicity in both MCF7 and HCT116 
cancer cell lines. In both cell lines, a shorter exposure to V158411 (24 hours) 
resulted in greater cytotoxicity than the same AUC spread over 3 or 5 days. 
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Most other studies with CHK1 inhibitors have not explored exposures to CHK1 
inhibitors that are longer than 24 hours in clonogenic assays or considered 
whether the concentration of a CHK1 inhibitor or duration of exposure are the 
most important determinant of cytotoxicity, particularly as a single agent. 
Blasina et al examined a variable length exposure to PF00477736 and 
gemcitabine (continuous co-exposure followed by drug-free media for a total of 
96 hours) in growth inhibition (MTT) assays in HT29 cells (Blasina et al., 2008). 
They showed that cytotoxicity was seen with as short as an 8 hour exposure 
(~25% cell death) to the drugs and this increased in a linear fashion with longer 
exposures (12, 24 and 48 hours). In SW620 cells SAR-020106 (concentration 
not specified) enhanced gemcitabine (at the IC50) cytotoxicity to the greatest 
extent if the co-exposure was for at least 48 hours (Walton et al., 2012). 
Information regarding the relative importance of concentration versus duration 
or AUC may be relevant to the design of in vivo pre-clinical experiments and 
clinical trials. The data presented in this chapter suggests that less frequent 
administration of V158411 to achieve higher peak plasma concentrations may 
be more efficacious than frequent administration that achieves lower peak 
plasma concentrations. This would have to be modulated based on the toxicity 
seen in normal tissues with different regimens and would need to be tailored to 
allow normal tissues to adequately recover. All other experiments examining the 
cytotoxicity of V158411 either alone or in combination with cytotoxic therapy or 
IR have used a 24 hour exposure to V158411 rather than any longer 
treatments. 
 
 
177 
Disappointingly, there was no significant chemo-potentiation with either 
gemcitabine or cisplatin in either MCF7 or MDA-MB-231 breast cancer cell 
lines. In combination with cisplatin, there was a suggestion of antagonism 
between V158411 and cisplatin with a non-significant resistance to cisplatin in 
combination with V158411. 
This was unexpected as the majority of studies with alternative CHK1 inhibitors 
have shown significant chemo-potentiation of both gemcitabine and cisplatin (as 
described in sections 1.11.1 and 1.11.2). Possible explanations for some of 
these differences perhaps lie in the type of assay (clonogenic, apoptosis or 
growth inhibitory), longer co-exposures in growth inhibition assays, and the type 
of inhibitor that was used (CHK1 or CHK1/CHK2). In all the combination studies 
with V158411 the data was normalised to the cytotoxicity seen with V158411 
alone. It is not clear from all the studies in the literature whether the combination 
cytotoxicity data has been normalised to that seen with the CHK1 inhibitor 
alone. It is possible that some of the effects may have been the measurement 
of additive effects. 
Blasina et al demonstrated potentiation of gemcitabine cytotoxicity in human 
cancer cell lines (20-fold in SW620 cells and 10-fold in HCT116wild type p53) and 
CoLo205 xenografts (43% potentiated tumour growth inhibition (TGI) with 20 
mg/Kg PF00477736 OD and 75% TGI with 20 mg/Kg PF00477736 BD) with the 
selective CHK1 inhibitor PF00477736 (Blasina et al., 2008). Studies examining 
the dual CHK1/CHK2 inhibitor 300 nM AZD7762 in conjunction with 
gemcitabine used a 24 hour co-treatment followed by a further 24 hour 
exposure to AZD7762 alone (Zabludoff et al., 2008). Growth was assessed 
using a colorimetric assay based on tetrazolium salt reduction (MTT). Recently 
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it has been shown that, data regarding drug sensitivity using this type of assay 
are different from other 96-well plate assays based on ATP content (Weinstein 
and Lorenzi, 2013). Neither assay truly represents cytotoxicity, and the data 
presented in this chapter based on clonogenic assays may more faithfully 
represent cell killing. Alternatively, it could be that longer exposure periods are 
needed to enhance the cytotoxicity of gemcitabine and cisplatin, or that an 
inappropriate schedule of cytotoxic and V158411 were used. 
Most scheduling data with CHK1 is based on chemotherapy combinations, in 
particular with gemcitabine. In colony forming assays in HCT116 cells 100 nM 
AZD7762 caused the greatest sensitisation if given immediately after a 2 hour 
exposure rather than following 24 hours in drug free media (Zabludoff et al., 
2008). In further studies using AZD7762 and PD-32152 the best dosing 
schedule was dependent on the concentration of gemcitabine used. With low 
concentrations of 50 nM gemcitabine greatest sensitisation (4.5 to 6-fold) was 
seen if 100 nM AZD7762 was delivered immediately after a 2 hour treatment 
with gemcitabine. However, if higher concentrations of gemcitabine were used, 
delayed treatment with gemcitabine gave greater (8 to 10-fold) enhancement of 
gemcitabine cytotoxicity (Parsels et al., 2011, Parsels et al., 2009). 
Matthews et al, like ourselves, measured colony formation following a 24 hour 
co-exposure to a CHK1 inhibitor (100 and 300 nM XL9844) with 0 to 80 nM 
gemcitabine followed by 7-10 days in drug-free media, and showed 
chemosensitisation in all 4 cancer cell lines PANC-1 (3-fold with 300 nM 
XL9844), AsPC-1 (16 to 20-fold with 300 nM XL9844), SKOV-3 (6-fold with 300 
nM XL9844) and HeLa (8-fold with 300 nM XL9844) tested (Matthews et al., 
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2007). However, none of the cell lines used the Matthews study were the same 
as the ones used here, so a direct comparison cannot be made 
One potential reason for the lack of gemcitabine potentiation by 50 nM or 150 
nM V158411 is that in the cell lines investigated here, gemcitabine did not 
cause measurable cell cycle perturbation and hence inhibition of cell cycle 
checkpoints by V158411 would be predicted to have an insignificant effect. 
However, cisplatin did cause a G2 arrest and therefore the effect of V158411 on 
cisplatin cytotoxicity was evaluated. Unfortunately no chemosensitisation was 
seen. There is mixed data in the literature regarding cisplatin potentiation by 
CHK1 inhibitors. 
With the prototype non-specific inhibitor, UCN-01 there was potentiation of 
cisplatin-mediated cytotoxicity in AA8 CHO cells (3-fold) and MDA-MB-231 
breast cancer cells (2-fold) treated for 2 hours with cisplatin and after a 24 hour 
period in drug free media with 24 hours with 50 nM UCN-01 (Bunch and 
Eastman, 1996, Eastman et al., 2002). However, the more specific AZD7762 
(20 and 80 nM 24 hour co-treatment) failed to potentiate cisplatin-mediated 
cytotoxicity (clonogenic assays) and 1 µM SCH 900776 (24 hour co-treatment) 
failed to potentiate cisplatin-induced growth inhibition (Hoechst fluorescent 
assay) in MDA-MB-231 and other cell lines (Wagner and Karnitz, 2009, 
Montano et al., 2012). 
The studies in Chapter 3 showed that IR also cause cell cycle perturbation that 
was reduced by V158411 and in the studies presented in this chapter V158411 
did enhance IR-induced cytotoxicity. There was significant radio-potentiation in 
both MCF7 and MDA-MB-231 breast cancer cell lines with radiation 
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enhancement ratios at 2 Gy following 50 nM V158411 of 1.93 and 1.30 
respectively. This is similar to the level of radio-potentiation in multiple cancer 
cell lines DU145 (DMF = 1.6), HT29 (DMF = 1.7), and H460 with dominant 
negative p53 (DMF = 1.58) treated with 100 nM of the dual CHK1/CHK2 
inhibitor AZD7762 (Mitchell et al., 2010b). Further work has been performed by 
Yang et al using AZD7762 as a radiosensitiser in a NSCLC cancer cell line 
(PC14PE6) and in a xenograft model (Yang et al., 2011). In the xenograft model 
of NSCLC brain metastases, they demonstrated significantly prolonged median 
survival following IR in combination with AZD7762. Unfortunately there is no 
other published data using any of the other selective CHK1 inhibitors as 
radiosensitisers 
The data from the scheduling experiments in both MCF7 and HCT116 cell lines 
with V158411 and IR suggest that V158411 should be administered 
concomitantly with the IR or after a 24 hour delay rather than 24 hours prior to 
IR. This is similar to the finding that treatment with 100 nM AZD7762 after IR 
and showed greater enhancement of radiation toxicity than before IR (Mitchell 
et al., 2010b). 
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Chapter 5 Determinants of sensitivity to CHK1 inhibitors 
Our understanding of the role of p53 in carcinogenesis has evolved; it was 
initially thought to be an oncogene because of high expression in tumours, more 
recently it has been shown that the high expression of a dominant negative 
mutant p53 and that p53 is actually a tumour suppressor gene (Massague, 
2004). As shown in Figure 1.8 it plays a key role in the DDR – signalling to cell 
cycle control/programmed cell death (Bouwman and Jonkers, 2012). It is 
activated by CHK1 and CHK2 and by ATM both directly and via CHK2. As can 
be seen from Table 2-1 in Chapter 2 the majority of cancer cell lines used in 
pre-clinical cancer research do have a mutated p53. However, the functional 
implications of the p53 mutation are not always known.  
 
5.1 p53 status as a determinant of sensitivity to single agent V158411 
Despite the strong rationale for CHK1 inhibitors to have the greatest effect in 
p53 disrupted cells there is mixed data in the literature as to whether p53 status 
is an important determinant for sensitivity to CHK1 inhibitors, either as single 
agents or in combination with conventional cytotoxic therapy. UCN-01, ICP-1, 
PF00477736, and AZD7762 caused significantly greater sensitisation of cells 
with a mutated p53 (Blasina et al., 2008, Tse et al., 2007b, Zabludoff et al., 
2008, Eastman et al., 2002). However, other studies have shown that CHK1-
mediated cytotoxicity is independent of p53 (Guzi et al., 2011, Hirose et al., 
2001). 
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In studies growth inhibition assays (in which DNA content was the endpoint) 
250 nM ICP-1 or 50 nM UCN-01 caused a significant, 7-fold, enhancement of 
cisplatin-mediated growth inhibition in MDA-MB-231 cells with mutant p53 that 
was not observed in MCF10A (immortalised breast epithelial cells p53 wild type) 
cells (Eastman et al., 2002).  Similarly, in cell counting assays Blasina et al 
demonstrated a greater degree of sensitisation by 180, 360 and 540 nM 
PF00477736 administered 24 hours after 1 nM gemcitabine continuously for 96 
hours and 2.5 nM camptothecin continuously for 24 hours significantly 
enhanced (3-fold at 24 hours) in the p53 mutated HT29 cells compared to the 
p53 wild type HUVEC (human umbilical vein epithelial) (Blasina et al., 2008). 
Similarly radiosensitisation by AZD7762 was greater in p53 mutant cells: HT29, 
du145 and Mia-Paca (DMFs 1.6 to 1.7-fold) compared to p53 wild type normal 
fibroblasts (DMF = 1.05) and A549 cells (DMF = 1.2) (Mitchell et al., 2010b) 
However, in these studies the phenotype of the compared cells was very 
different and factors other than p53 status most likely also contributed to the 
differential sensitisation. More reliable data can be generated using paired 
isogenic cell lines that differ only in their p53 status. 
The potentiation of gemcitabine (2 hour exposure, varying concentration) by 
100 nM AZD7762 for 24 hours was investigated in a HCT116 cell line pair (p53 
+/+ and p53 -/-) by a colony-forming assay (Zabludoff et al., 2008). While both 
cell lines were equally sensitive to monoagent gemcitabine, 100 nM AZD7762 
caused a greater sensitisation in the p53 -/- cells compared to the wild type 
cells. In growth inhibition (SRB) studies SAR-020106 caused a 2.3-fold greater 
sensitization of gemcitabine and 4.5-fold greater sensitization of SN38 an 
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A2780 cells with functionally inactivated (by HPV16E6) p53 than p53 wild type 
A270 cells (Walton et al., 2010).  
Using the same pair of HCT116 cell lines radiosensitisation (0, 2, 3, 4 and 6 Gy) 
by 300 nM UCN-01 continuous exposure for 3 days was dependent on p53 
status in clonogenic assays (Petersen et al., 2010). In the p53-/- the LC90 was 
4.6 Gy which was reduced to 3.8 Gy with UCN-01, but in the wild type cells the 
LC90 was 3.9 Gy without 3.8 Gy with UCN-01. Similarly radiosensitisation in 
matched H460 cells was greater than in cells with a dominant negative p53 
(DMF = 1.58) compared to the wild type (DMF = 1.11). However, in U2OS with 
a tetracyclin-inducible dominant negative cells p53-independent 
radiosensitisation was seen with both 100 nM UCN-01 for 24 hours and 500 nM 
CEP-3891 for 24 hours (Petersen et al., 2010).  
In contrast, investigations in p53-deficient U87MG-E6 glioma cell lines, that 
were relatively resistant to temozolomide compared to wild type U87MG 
controls, revealed that 25-100 nM UCN-01 for 4 days enhanced temozolomide 
cytotoxicity 5-fold in clonogenic assays with both cell lines (Hirose et al., 2001).  
The p53 status has also been investigated with respect to cell cycle checkpoint 
activation. For example, 250 nM ICP-1 failed to affect the modest cisplatin-
induced (20 µg/ml for 2 hours) G2 arrest in wild type MCF10A cells but 
significantly attenuated G2 arrest in the p53 mutant MDA-MB-231 cells 
(Eastman et al., 2002). Similarly, sequential treatment with 20 nM SN38 for 24 
hours followed by 100 nM CHIR124 for 24 hours resulted in 51% of HCT116 
wild type cells remaining in G2 arrest whereas only 15% of HCT116p53-/- cells 
remained in G2. (Tse et al., 2007b).  
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In light of these data with other CHK1 inhibitors, the cytotoxicity of V158411 as 
a single agent and in combination with gemcitabine, cisplatin and IR was 
assessed using clonogenic assays in 2 pairs of isogenic cell lines differing in 
their p53 status: one that has been used extensively in other studies with CHK1 
inhibitors (HCT116) and the other, U2OS cells transfected with the R248W 
dominant negative p53 mutant. Following on from the flow cytometry data in 
section 3.6; the ability of V158411 to reduce the G2 cell cycle fraction was 
assessed in the HCT116 isogenic cell line pair. V158411’s  abrogation of IR and 
cisplatin mediated G2 arrest was also examined. The aim was to determine if 
the novel CHK1 inhibitor, V158411, exerted differential effects on cell cycle 
distribution and cytotoxicity that was dependent on the p53 status of the cells. 
The aims of this chapter are: 
a) To determine the cytotoxicity of single agent V158411 in paired cell lines 
with different p53 status. 
b) To determine the chemosensitisation by V158411 of cell lines to 
gemcitabine and cisplatin in HCT116wild type p53 and HCT-/-p53 cancer cell 
lines. 
c) To determine the radiosensitisation of cell lines by V158411 in 
HCT116wild type p53 and HCT-/-p53 cancer cell lines. 
d) To determine the role of p53 status as a determinant of V158411-
induced cell cycle changes following radiotherapy and cisplatin in 
HCT116wild type p53 and HCT-/-p53 cancer cell lines 
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5.2 Confirmation of the p53 status of HCT116 and U2OS cells 
To confirm that the HCT116p53-/- cells with a homozygous mutation in p53 
(notated p53 -/-) lacked p53 expression and that the U2OSp53DN over-expressed 
the dominant negative mutant p53; Western blotting experiments were 
conducted. As shown in Figure 5-1 wild type HCT116p53+/+ cells expressed p53 
but a 1 hour exposure to hydroxyurea was not sufficient to induce expression, in 
contrast no p53 could be detected in lysates from HCT116p53-/- cells. As 
expected the U2OS cells transfected with the dominant negative p53 mutant 
expressed abundant p53 protein (Figure 5.2). However, unlike the U2OS wild 
type cells that showed induction of p53 and downstream p21 following exposure 
to IR, in the U2OSp53DN cells there was no induction of p21 indicating that the 
pathway was non-functional. 
 
Figure 5-1 Western blot in HCT116wild type p53 and HCT116p53-/- cells. 
Control untreated and samples treated with 10 mM hydroxyurea for 1 
hour.  Expression of p53 and actin (p21 not performed). Figure courtesy of 
Fiona Middleton. 
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Figure 5-2 Western blot in U2OS isogenic cell line pair (wild type and p53 
dominant negative). 
Control untreated and samples treated with 10 Gy IR for 6 hours. 
Expression of p53, p21, and actin. Figure courtesy of Fiona Middleton 
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5.3 Single agent cytotoxicity of V158411 in the paired cell lines 
Figure 5.3 shows the summary of the results of clonogenic assays with single 
agent V158411 in the wild type and p53-/- HCT116 cells and Figure 5.4 shows 
similar data obtained from the wild type and p53 dominant negative U2OS cells 
with a summary of the LC50 and the LC90 values given in Table 5-1. As can be 
seen from both the figures and the table there was no significant difference in 
the cytotoxicity between the wild type and p53 variant cells. 
 
 
Figure 5-3 Cytotoxicity of single agent V158411 in HCT116wild type p53 and 
HCT116p53-/- cells. 
Data are mean +/- SEM of 3 independent experiments. Within each 
experiment there were at least 2 replicates. 
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Cell Line V158411 LC50: mean and (SD) V158411 LC90: mean and 
(SD) 
   
HCT116 Wild Type  476.4 nM (46.2 nM)  1453 nM (n/a) 
HCT116 p53 Mutant 406.0 nM (63.79 nM) 1486 nM (n/a) 
U20S Wild Type 449.7 nM (1226 nM) >1500 nM (n/a) 
U2OS p53 DN 794.6 nM (n/a) >1500 nM (n/a) 
Table 5-1 LC50 and LC90 values for V158411 
HCT116wild type p53 and HCT116p53-/- cells and U2OS wild type and U2OS with 
dominant-negative p53. Mean and SD of at least 3 experiments where data 
is available. 
 
 
Figure 5-4 Cytotoxicity of single agent V158411 in U2OS wild type and 
U2OS with dominant-negative p53. 
Data are mean +/- SEM of 3 independent experiments. Within each 
experiment there were at least 2 replicates. 
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5.4 p53 status as a determinant of sensitivity to gemcitabine and 
cisplatin 
In section 4.3 there was no significant difference in the sensitivity of MCF7 (p53 
wild type) or MDA-MB-231 (p53 mutated) cells to either gemcitabine or cisplatin 
and V158411 did not significantly potentiate the cytotoxicity of either 
gemcitabine or cisplatin in either cell line. However, as these cells differed in 
many phenotypic/genotypic respects besides their p53 status it is not possible 
to say if p53 status is a determinant of sensitivity or chemopotentiation 
As a first step to investigating the potentiation by V158411 in the matched p53 
wild type and dysfunctional HCT116 cells the cytotoxicity of gemcitabine and 
cisplatin was determined by clonogenic assay in these cells. In these studies 
the HCT116p53-/- cells were approximately 1.5 to 2-fold resistant to gemcitabine 
and cisplatin (see Table 5-2). These experiments were not replicated in the 
U2OS cell line pair due to time constraints. 
 
Cell Line HCT116Wild Type p53: mean and 
(SD) 
HCT116 p53 Mutant: mean and 
(SD) 
   
Gemcitabine LC50 (nM) 4.7 (1.92) 9.2 (2.60) 
 Gemcitabine LC90 (nM) 19 (6.10) 33 (16.53) 
 Cisplatin LC50 (µM) 1.3 (3.47) 2.1 (8.04) 
Cisplatin LC90 (µM) 16 (8.02) 28 (n/a) 
   
Table 5-2 LC50 and LC90 values for gemcitabine and cisplatin in HCT116wild 
type p53 and HCT116p53-/- cells. 
Mean and SD values from 3 independent experiments where data 
available. 
 
 
190 
5.5 p53 status as a determinant of chemosensitisation by V158411 
The effect of 50 nM and 150 nM V158411 on the cytotoxicity of gemcitabine and 
cisplatin was determined the HCT116wild type p53 and HCT116p53-/- cells. V158411 
did not potentiate gemcitabine or cisplatin in either cell line (Figure 5-5 and 
Figure 5.6). 
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Figure 5-5 Cytotoxicity of gemcitabine +/- V158411 in HCT116wild type p53 
(upper graph) and HCT116p53-/- (lower graph) 
Cells treated with gemcitabine alone or in combination with 50 nM 
V158411 or 150 nM V158411 for 24 hours. Survival normalised to DMSO or 
50 nM or 150 nM V158411 alone control. Data are mean +/- SEM of 3 
independent experiments. Within each experiment there were at least 2 
replicates. 
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Figure 5-6 Cytotoxicity of cisplatin +/- V158411. HCT116wild type p53 (upper 
graph) and HCT116p53-/- (lower graph) 
Cells treated with gemcitabine alone or in combination with 50 nM 
V158411 or 150 nM V158411 for 24 hours. Survival normalised to DMSO or 
50 nM or 150 nM V158411 alone control. Data are mean +/- SEM of 3 
independent experiments. Within each experiment there were at least 2 
replicates. 
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  HCT116Wild Type p53 HCT116-/-p53 
  LC50  LC90 LC50  LC90  
Gemcitabine 
No 
V158411 
8.42 nM 27.17 7.63 nM 32.15 nM 
50 nM 
V158411  
7.07 nM 26.14 5.65 nM 27.70 nM 
150 nM 
V158411  
8.47 nM 26.63 9.66 nM 27.82 nM 
Cisplatin 
No 
V158411 
2679 nM n/a 2052 nM n/a 
50 nM 
V158411  
2905 nM 9184 nM 720.0 nM 9207 nM 
150 nM 
V158411  
2918 nM 10000 nM 2840 nM n/a 
Table 5-3 LC50 and LC90 values of HCT116 cells 
Cells treated with gemcitabine and cisplatin +/- 50 nM V158411 and 150 nM 
V158411. Data from at least 3 independent experiments. 
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5.6 p53 status as a determinant of radio-potentiation by V158411 
Modest radiosensitisation with V158411 was seen in MCF7 and MDA-MB-231 
cancer cell lines (see section 4-4). To determine if there was any impact of p53 
status on radiosensitisation; the survival of HCT116wild type p53 and HCT116p53-/- 
cells following irradiation with or without 50 nM or 150 nM V158411 was 
measured by clonogenic assay (Figure 5-7). 
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Figure 5-7 Cytotoxicity of IR +/- V158411 in HCT116wild type p53 (upper graph) 
and HCT116p53-/- (lower graph) 
Cells treated with 0-10 Gy IR alone or in combination with 50 nM V158411 
or 150 nM V158411 for 24 hours. Survival normalised to DMSO or 50 nM or 
150 nM V158411 alone control. Data are mean +/- SEM of 3 independent 
experiments. Within each experiment there were at least 2 replicates. 
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The HCT116p53-/- cells were not significantly more resistant than the HCT116wild 
type p53 cells to IR alone at the LD50 (see Table 5-4). There was a modest 
sensitisation to IR by 50 nM and 150 nM V158411 in both the wild type and p53 
-/- variants consistent with our previous data in unmatched cells. The extent of 
potentiation was similar in both wild type and p53 mutated cells.  
 
 HCT116 Wild Type HCT116-/-p53 
 LD50  LD90 LD50  LD90  
IR alone 1.80 Gy 4.72 Gy 1.64 Gy 4.82 Gy 
IR + 50 nM 
V158411  
1.64 Gy 4.07 Gy 1.45 Gy 4.23 Gy 
IR + 150 nM 
V158411  
1.54 Gy 3.81 Gy 1.24 Gy 3.75 Gy 
Table 5-4 LD50 and LD90 values of HCT116 cells 
Cells treated with IR +/- 50 nM V158411 and 150 nM V158411. Data from at 
least 3 independent experiments. 
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5.7 p53 status as a determinant of V158411-induced cell cycle changes 
 
5.7.1 Cell cycle distribution following V158411 alone 
The differences in cell cycle distribution following treatment with 150 nM 
V158411 alone for 24 hours was assessed in HCT116wild type p53 and HCT116p53-
/- cells (Figure 5-8). V158411 had no significant impact on the cell cycle 
distribution in either cell line (representative histograms are shown in Figure 5-
9). 
 
Figure 5-8 Flow cytometry in HCT116wild type p53 and HCT116p53-/- cells 
Untreated samples and 150 nM V158411. Data are mean +/- SEM of 3 
independent experiments. 
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Figure 5-9 Representative example of flow cytometry in HCT116 wild type 
and p53 mutated cells 
 
(A) HCT116 wild type untreated; (B) HCT116 wild type + 150 nM V158411 
(24 hours); (C) HCT116 p53 mutated untreated; (D) HCT116 p53 mutated + 
150 nM V158411 (24 hours). Cell line doubling time approximately 16-18 
hours. Minimum of 10000 events collected for each cytogram 
 
5.7.2 Cell cycle distribution following cisplatin or IR +/- V158411 
The cell cycle distribution following treatment with 1 µM cisplatin for 24 hours or 
IR (24 hours after 2 Gy) with and without 150 nM V158411 co-treatment with for 
24 hours was assessed in the HCT116wild type p53 and HCT116p53-/- cells (Figure 
5-11 and representative histograms are shown in Figure 5-10). 
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Figure 5-10 Representative example of flow cytometry in HCT116 cells 
 
Comparison of HCT116 wild type and p53 mutated cells; untreated, and 
treated with 2 Gy IR (24 hours pre-analysis), 1 µM Cisplatin (24 hours) +/- 
150 nM V158411 (24 hours). Cell line doubling time approximately 16-18 
hours. Minimum of 10000 events collected for each cytogram 
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In the HCT116wild type p53 cells, there was a small increase in the G2 fraction 
following both cisplatin (significant, p = 0.029 (paired t-test)) and IR (non-
significant, p = 0.129 (paired t-test)). V158411 did not change this significantly 
following either cisplatin or IR. However, in the HCT116p53-/- cells, there was a 
more substantial increase G2 arrest with both cisplatin (non-significant, p = 0.08 
(paired t-test)) and IR (statistically significant, p = 0.004 (paired t-test)). In these 
cells V158411 abrogated the cisplatin-induced G2 accumulation (non-significant, 
p = 0.36 (paired t-test)) and attenuated the IR-induced G2 arrest (non-
significant, p = 0.156 (paired t-test)).  
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Figure 5-11 Flow cytometry in HCT116wild type p53 and HCT116p53-/- cells 
Untreated samples, 1 µM cisplatin and 1 µM cisplatin + 150 nM V158411; 
untreated samples, 2 Gy IR, and 2 Gy IR + 150 nM V158411. Data are mean 
+/- SEM of 3 independent experiments. 
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5.8 Discussion 
Because of the high frequency of p53 mutations in cancer and the rationale for 
the selectivity of inhibitors of S/G2 checkpoints in p53 dysregulated cancer it 
was important to determine if V158411 cytotoxicity and sensitisation was 
dependent on p53 status. 
There was no difference in the cytotoxicity of single agent V158411 between 
HCT116wild type p53 and HCT116p53-/- cells or between U2OS and U2OSDNp53 cells, 
and V158411 did not impact on the cell cycle kinetics in the HCT116wild type p53 
and HCT116p53-/- cells.  There is no published data on the impact of p53 status 
on the sensitivity to other CHK1 inhibitors used as single agents. It is possible 
that other CHK1 inhibitors have been investigated in this way, but similarly 
negative data have not been published.  
As predicted from previously published data (El-Deiry, 2003, Ding et al., 2013), 
loss of p53 function conferred resistance to gemcitabine, cisplatin (and IR). In 
terms of chemo-resistance this was 1.5 to 2-fold, radio-resistance was not 
significant. As with the MCF7 and MDA-MB-231 breast cancer cell lines 
V158411 did not chemosensitise either HCT116wild type p53 and HCT116p53-/- 
colorectal cancer cells to gemcitabine. Although cisplatin caused a more 
pronounced G2 arrest in the HCT116p53-/- cells and V158411 had a greater 
impact on this arrest in the HCT116p53-/- cells it did not sensitise either cell line 
to cisplatin cytotoxicity. This lack of chemosensitisation is in contrast to 
observations with other CHK1 inhibitors (as described in the introduction). The 
closest study to ours was Zabludoff’s demonstrating greater gemcitabine 
potentiation by 100 nM AZD7762 in HCT116p53-/- cells (15-fold potentiation) 
compared to HCT116wild type p53 cells (10-fold potentiation) (Zabludoff et al., 
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2008). However, in that study both cell lines were equally sensitive to single 
agent gemcitabine whereas we showed that the p53-/- cell line was less 
sensitive than the wild type parental cell line (LC50 4.7 nM and 9.2 nM 
respectively) and AZD7762 is a dual CHK1/2 inhibitor. 
Consistent with the data in the breast cancer cells IR caused a G2 arrest that 
was attenuated by V158411, however this was only significant in the 
HCT116p53-/- cells. This was accompanied by a modest radio-potentiation with 
50 nM and 150 nM V158411 in both the HCT116 wild type or HCT116 p53 
mutated colorectal cancer cell lines. 
Peterson et al looked at the ability in clonogenic assays (in 10 cm plate assays 
rather than the smaller 6 well plates used in our experiments) of UCN-01 to 
radio-sensitise the same HCT116wild type p53 and HCT116p53-/- cells as used in our 
experiments (Petersen et al., 2010). They demonstrated that the HCT116p53-/- 
cells were relatively resistant to IR, but sensitised by 300 nM UCN-01 (3 day 
continuous exposure following IR), the LD90 fell from 4.6 to 3.8 Gy in the 
presence of UCN-01. There was no sensitisation in the HCT116wild type p53 cells, 
the LD90 was 3.9 and 3.8 Gy in treated and untreated groups respectively. 
This is in contrast to our data which showed no significant difference in the 
radiosensitivity of the HCT116wild type p53 and HCT116p53-/- cells without a CHK1 
inhibitor and similar sensitisation with both 50 and 150 nM V158411. 
Radiosensitisation by V158411 was not investigated by ourselves due to time 
constraints in the U2OS wild type and mutant p53 cells. However, in published 
work both 100 nM UCN-01 24 hours following IR and 500 nM CEP-3891 for 24 
hours following IR caused significant radiosensitisation in both the p53 DN and 
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p53 wild type variants (Petersen et al., 2010). The LD90 was 5.2 Gy (no 
treatment), 4.0 Gy (UCN-01) and 3.5 Gy (CEP-3891) in the wild type cells and 
5.1 Gy, 3.8 Gy and 3.4 Gy respectively in the U2OS-VP16 (p53 DN) cancer 
cells.  
Guzi et al suggest a hypothesis in their discussion of the mechanism of action 
of SCH 900776 that when a CHK1 inhibitor is administered with gemcitabine the 
drug combination targets replication fork collapse and potentiates cytotoxicity 
independent of p53 status (Guzi et al., 2011). However, when a CHK1 inhibitor 
is administered after a delay there is potentiation of chemotherapy that in the 
presence of a p53 mutation, and an aberrant G1 checkpoint, allows cells to 
accumulate in G2-M with a resultant increase in cytotoxicity. 
The data presented in this chapter suggests that p53 status is not an important 
determinant of sensitivity to single agent V158411 in either HCT116 or U2OS 
cells and that, as in previous chapter (with MCF7, MDA-MB-231 and HCT116 
cancer cell lines), there was no chemosensitisation in either wild type or p53 
mutated cell lines in combination with gemcitabine and cisplatin. This was 
despite the significantly greater effect of V158411 on cisplatin-induced G2 arrest 
in the HCT116p53-/- cells compared to the HCT116wild type p53 cells. 
There was, similar radiosensitisation in both HCT116wild type p53 and HCT116p53-/- 
cells despite the abrogation of IR mediated G2 cell cycle arrest being greater in 
the mutated cell line.  
The data presented in this chapter does not support the hypothesis that CHK1 
inhibitors will potentiate DNA damaging agents to a greater extent in p53 
dysfunctional cells. Nor does it agree with published literature that suggest p53 
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status is a factor. The data in this chapter suggests that other factors must play 
a role in determining the sensitivity of cancer cell lines to V158411 cytotoxicity. 
The data presented in Chapter 3 showed that a panel of cancer cell lines had a 
wide range of total CHK1 protein expression. The relationship between CHK1 
protein expression, sensitivity to V158411 and other potential factors will be 
explored in Chapter 6. 
 
 
206 
Chapter 6 Dysregulation of DNA damage signalling and repair 
as a determinant of sensitivity to CHK1 inhibition 
As has been explored in the previous chapter there is mixed evidence in both 
the literature and in our own data as to whether p53 plays a significant role in 
determining the sensitivity to CHK1 inhibitors. We wished to examine whether 
there were other important determinants of sensitivity to CHK1 inhibitors. It was 
postulated that there maybe other differences in tumour biology that could be 
exploited to stratify tumours for treatment with a CHK1 inhibitor either as a 
single agent or in combination with other small molecular inhibitors of DNA 
damage signalling and repair pathways. 
 
6.1 DNA damage signalling and repair as a determinant of sensitivity to 
CHK1 inhibition 
As described in section 1.12 both 50 nM UCN-01 and 25 nM AZD7762 were 
synergistically cytotoxic with the PARP inhibitor 3 µM PJ34 in a panel of breast 
cancer cell lines; MCF7, 4T1, SKBR3 and BT474 (Mitchell et al., 2010a). 
Similarly, in pancreatic cell lines (MiaPaCa-2 and MPanc-96) radiosensitisation 
by 100 nM AZD7762 and the PARP inhibitor (1 µM AZD2281) together was 
greater than either alone (Vance et al., 2011). However, a study of microarray 
data on 1846 breast cancer samples casts some doubt on to whether this effect 
is mediated by Chk1 (Daemen et al., 2012). Daeman et al initially examined the 
effect of AZD2281 in 22 breast cancer cell lines and identified 5 genes whose 
transcript levels were associated with resistance to AZD2281 and 2 genes 
which were associated with sensitivity. They validated these genes in with the 
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data from Affymetrix microarrays in the 1846 breast cancer patients. One of the 
genes identified as marker of sensitivity to a PARP inhibitor was CHEK2. 
AZD7762 is a dual CHK1 and CHK2 inhibitor so the synergy seen with a PARP 
inhibitor may be mediated by CHK2 rather than CHK1. 
Mutations in the Ras-MEK-ERK pathway may affect the sensitivity of tumours to 
CHK1 inhibitors. Dai et al looked at the combination of a CHK1 inhibitor (150 
nM UCN-01) and a MEK1/2 inhibitor (10 µM PD184352) in myeloma (8226, 
H929 and U266) cancer cell lines and showed a marked increase in cell death 
in combination compared to single agent UCN-01 (Dai et al., 2008). The authors 
measured using flow cytometry apoptotic cells by Annexin V staining and 
showed an increase in U266 cells from 11% with UCN-01 alone to 82% in 
combination with PD184352; in 8226 cells the increase was from 7% to 85% 
respectively. The combination also induced apoptosis in doxorubicin, melphalan 
and dexamethasone-resistant variants of the 8226 cells (8226/Dox40 8226/LR5 
and MM.1R respectively). 
In normal thyroid cells (quiescent WRT cells) the acute expression of activated 
Ras increased CHK1serine345 phosphorylation more than 5-fold (Abulaiti et al., 
2006). Ras activation is common in thyroid malignancies suggesting that single 
agent CHK1 inhibitors may be of utility in thyroid tumours associated with Ras 
activation. Such a therapeutic strategy was taken forward by Gilad et al who 
demonstrated that ATR inhibition (by shRNA) was synthetically lethal in cell 
lines with oncogenic Ras expression (murine embryonic fibroblasts transformed 
with the introduction of oncogenic Ras by shRNA) (Gilad et al., 2010). The 
authors confirmed activation of the ATR pathway by oncogenic Ras as 
evidenced by increased CHK1serine345 phosphorylation. However, the authors do 
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sound a note of caution as they demonstrated that with only limited reduction in 
ATR activity (ATR haploinsufficiency) there was in fact tumour promotion in 
stark contrast to the synthetic lethality seen with more significant ATR inhibition. 
There is evidence that CHK1 inhibitors may be of use as single agents in 
tumours with amplified Myc. CHK1 is up-regulated in myc-amplified (c-Myc) 
murine and human lymphomas (Hoglund et al., 2011a). A mouse model of the 
ATR-Seckel syndrome was noted to block the induction of c-Myc-induced 
lymphomas and pancreatic tumours (Murga et al., 2011). The authors went on 
to show that 5 mg/kg UCN-01 (i.p.) daily led to significant regression of murine 
myc-induced lymphomas and human Burkitt’s lymphoma cell lines. The 
response to UCN-01 was proportional to the expression of the c-myc protein.  
Both AZD7762 and PF00477736 have been shown to be cytotoxic in in vitro 
assays as single agents in c-Myc-amplified lymphomas (Hoglund et al., 2011b, 
Ferrao et al., 2011). However, this may potentially be due to CHK2 rather than 
CHK1. AZD7762 is a dual inhibitor of CHK1 and CHK2; Hoglund et al showed 
that CHK2 may be regulated by c-Myc though the mechanism is not fully 
understood (Hoglund et al., 2011b). 
Similarly, CCT244747 had anticancer activity against N-myc-amplified 
neuroblastomas in transgenic mice (Walton et al., 2012). In TH-MYCN mice 7 
days of continuous oral administration of 100 mg/kg CCT244747 showed a 79% 
reduction by volume in the growth of tumours compared to mice treated with 
vehicle alone (p < 0.001).  The potential utility of CHK1 inhibitors in the 
treatment of neuroblastoma is supported by an alternative approach by Cole et 
al (Cole et al., 2011). They performed a loss-of-function screen of the protein 
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kinome in neuroblastoma and showed that out of 30 kinases that showed 
significant cytotoxicity that the loss of CHK1 function gave the greatest 
cytotoxicity (greater than 50% growth inhibition in all 4 neuroblastoma cell lines 
tested compared to no growth inhibition in immortalised neuronal cells (hTERT-
RPE-1) even with more than 98% mRNA and protein depletion). They went on 
to show that compared to control cell lines neuroblastoma cells were sensitive 
to two novel CHK1 inhibitors SB21807 and TCS2312 (IC50 of 564 nM and 548 
nM) respectively. The sensitivity of neuroblastoma cell lines to CHK1 inhibition 
correlated with MYC(N) protein levels and that CHK1 inhibition in 
neuroblastoma cells was associated with apoptosis in S phase. 
In a search for alternative regulators of DNA damage response it has been 
noted that CHK2 is phosphorylated at threonine68 by DNA-PKcs and that CHK2 
co-immunoprecipitates with Ku70 and Ku80 (Li and Stern, 2005). Using siRNA 
targeting DNA-PKcs Khanna and colleagues were able to demonstrate that 
DNA-PKcs is a direct activator of CHK1 via phosphorylation at serine345 
(Khanna et al., 2013). There is also a link between CHK1 and Myc, and this too 
has been explored by Khanna and colleagues and reveals DNA-PKcs to be key 
here too (Khanna et al., 2013). The authors demonstrated that inhibiting CHK1 
(using the small molecular inhibitors SB218078 or GO6796 or with siRNA) in 
cancer cell lines induced the tumour suppressor protein phosphatase protein 
phosphatase 2A (PP2A). PP2A dephosphorylates MYC at serine62 which 
downregulates MYC activity and leads the cancer cell down a pro-apoptotic 
route. CHK1 appears to regulate PP2A by decreasing the transcription of 
cancerous inhibitor of PP2A (CIP2A). A graphic of the proposed mechanism is 
shown in figure 6.1. 
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Inhibition of Claspin by siRNA also inhibited CIP2A expression (see Figure 3-1). 
The authors also showed that PF00477736 decreased the growth of 
neuroblastoma tumours and that this was associated with a 45% decrease in 
the expression of CIP2A. The authors showed that constitutive CHK1serine345 
phosphorylation and CHK1-mediated transcriptional regulation of CIP2A was 
independent of the ATR/ATM pathway. 
 
Figure 6-1 CHK1-CIP2A-PP2A-MYC pathway. 
The relationship between CHK1 and MYC via CIP2A and PP2A. Pathway 
proposed by Khanna et al., 2013   
 
DNA-PKcs (DNA-dependent protein kinase catalytic subunit) has an extensive 
role in DSB repair by NHEJ (Shrivastav et al., 2008, Serrano et al., 2013, 
Takata et al., 1998). DNA-PKcs deficient cells are hypersensitive to agents that 
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cause DNA DSBs including IR (Shao et al., 1999, Allalunis-Turner et al., 1995, 
Durocher and Jackson, 2001). 
DNA-PKcs also appears to play a role in replication protein A (RPA) 
phosphorylation. RPA is a single strand binding protein that is involved in DNA 
repair and replication. It is critical to the recruitment and activation of ATR to 
single stranded DNA. There are a series of complex priming events that occur 
with phosphorylation of multiple sites on RPA, leading to activation of the 
downstream ATR-CHK1 pathway in response to replication stress (Serrano et 
al., 2013). Mutation or inhibition of DNA-PKcs (with 40 µM NU7026 for 2 hours) 
or mutation in RPA phosphorylation sites in UM-SCC-32 (human squamous cell 
carcinoma) cells led to a failure to arrest in G2 and accumulation in mitosis 
following replication stress (stimulated by 100 µM etoposide for 2 hours) (Liu et 
al., 2012).  
DNA-PKcs is also an important regulator of the DNA damage response to 
reactive oxygen species. DNA-PKcs has been implicated in the response to 
reactive oxygen species by regulating DNA repair via p53, HIF-1α and via AKT 
both NF-κB and HIF-1α (Chen et al., 2012). There is also cross-talk with ATM 
as described in Figure 6-2. 
With this additional evidence for the key role of DNA-PK, we can adapt the 
pathway diagram (Fig 1-11) originally proposed in the introduction to include 
DNA-PKcs signalling to CHK1, CHK2, ATM and RPA (see Figure 6.2). 
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Figure 6-2 ATR/ATM-CHK1 pathway including the role of DNA-PKcs. 
The role of DNA-PKcs and its postulated relationship with DNA damage, 
ATR, ATM, CHK1 and CHK2. Arrows denote activation and ball-ended-bars 
denote inhibition 
There are a number of different approaches that could be deployed to identify 
determinants of sensitivity to CHK1 inhibitors as single agents. V158411 could 
be used in combination with small molecular inhibitors of potential pathways, 
V158411 could be evaluated in an siRNA synthetic lethality screen or V158411 
could be used as a single agent in panels of cell lines with specific defects in 
DNA damage response pathways. We adopted the latter strategy and looked at 
V158411 in Chinese hamster ovary cells and Chinese lung fibroblasts and 
human cancer cell lines with known defects in DNA damage response 
pathways. 
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The aims of this chapter are: 
a) To explore the sensitivity of a panel of Chinese hamster cells with known 
DDR defects to single agent V158411. 
b) To explore the sensitivity of paired DNA-PKcs proficient and defective 
glioblastoma (M059J) cell lines to single agent V158411. 
c) To explore differences in CHK1 and DNA-PKcs mRNA in publically 
available libraries of paired normal and tumour tissue samples. 
d) To determine the sensitivity of a panel of liver cell cancers to V158411 
+/- the DNA-PKcs inhibitor NU7441 
e) To explore the expression of CHK1 and DNA-PKcs in a panel of liver 
cancer cells and the possible correlation with cytotoxicity to V158411. 
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6.2 Exploration of potential determinants of sensitivity in Chinese 
hamster ovary cells (CHO) and Chinese hamster lung fibroblasts (CHLF) 
As a means of determining the potential for elements of the DNA damage 
response pathway to predict sensitivity to single agent V158411; its cytotoxicity 
in CHO cells and lung fibroblasts (CHLF) was examined. The parental CHO cell 
line are AA8 cells, V3 cells are deficient in NHEJ due to inactivation of DNA-
PKcs, EM9 cells deficient in BER due to loss of XRCC1, and XRS-6 cells also 
lack NHEJ function due to Ku80 deficiency. VC8 CHLF cell line is defective in 
HRR due to a mutation in BRCA2 and the VC8-B2 cell line is proficient in HRR 
due to repair of this defect. 
 
Figure 6-3 Clonogenic cytotoxicity assay in CHO cells. 
V158411 in panel of CHO (p53 mutated) cells (AA8 (black), V3 (green), EM9 
(red) and XRS-6 (blue)). Data are mean +/- SEM of 3 independent 
experiments. Within each experiment there were at least 2 replicates. 
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Figure 6-4 Clonogenic cytotoxicity assay CHLF cells. 
V158411 in panel of Chinese lung fibroblast (p53 wild type) cells (VC8 
(black) and VC8-B2 (green)). Data are mean +/- SEM of 3 independent 
experiments. Within each experiment there were at least 2 replicates. 
 
Figure 6-3 shows the clonogenic survival of CHO cells exposed for 24 hours to 
single agent V158411 and Figure 6-4 the clonogenic survival in CHLF. In 
comparison to the human cell lines the Chinese hamster cells were resistant to 
V158411 with survival at 1 µM in the range 50.5% to 85.1%, compared to <10% 
in the human cancer cells (see figure 4-1 and table 4-1). BER-defective EM9 
cells with an LC50 of 500 nM were significantly more sensitive than the parental 
AA8 cells (p < 0.0001, 2-way ANOVA). Surprisingly, although NHEJ defective, 
Ku80 mutant XRS-6 cells were more sensitive than the AA8 cells, this was not 
statistically significant (2-way ANOVA). The NHEJ defective, DNA-PKcs mutant 
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V3 cells were significantly resistant to V158411 (p = 0.0027, 2-way ANOVA). 
The only cell line with an LC50 of < 5 µM was the EM9 cell line, deficient in 
XRCC1, with an LC50 of 508 nM (Table 6-1). There was no statistically 
significant difference in the sensitivity of the HRR defective and HRR proficient 
CHLF cell lines VC8 and VC8-B2 to V158411. 
 
Cell Line V158411 LC50 Survival at 1 µM V158411 
   
AA8 >5 µM 73.5% 
V3 >5 µM 85.1% 
EM9 508 nM 50.5% 
XRS-6 >5 µM 60.3% 
   
VC8 >5 µM 87.8% 
VC8-B2 >5 µM 78.8% 
   
Table 6-1 LC50 values and estimated survival with 1 µM V158411 in CHO 
and CHLF cell lines. 
LC50 not met within dose range of 50-5000 nM V158411 in 5 cell lines so 
stated as >5 µM. 
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6.3 V158411 in M059J glioblastoma cell line 
In view of the curious resistance of the DNA-PKcs defective V3 cells, the 
cytotoxicity of V158411 was evaluated in another pair of DNA-PKcs proficient 
and deficient human cancer cells. The M059J cell line is a glioblastoma-derived 
cell line with a known defect in DNA-PKcs. The M059J-Fus1 cell line has had a 
functional DNA-PKcs restored by transfer of chromosome 8. This has been 
confirmed by western blotting for total DNA-PKcs and activated pDNAPKser2096 
following 10 Gy ionising radiation (Figure 6-5). In a clonogenic survival assay 
M059J cells with a LC50 of 823 nM were significantly more resistant to single-
agent V158411 than M059J-Fus1 cells (LC50 = 89.5 nM; p = 0.03 (paired t-
test)), (Figure 6-6). (Table 6-2).  It should be noted that c-Myc is also on 
chromosome 8 and increased expression of cMyc could have contributed to the 
sensitivity, so these experiments were repeated using co-incubation with a 
DNA-PKcs inhibitor. 
 
Figure 6-5 Western blot in M059J and M059J-Fus1 cell line +/- 10 Gy 
ionising radiation. 
M059J (p53 mutated, DNA-PKcs deficient) and M059J-Fus-1 (p53 mutated, 
DNA-PKcs corrected). 
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Figure 6-6 Clonogenic cytotoxicity assay in M059J cells. 
V158411 in M059J (black) and M059J-Fus1 (green) cell line. M059J (p53 
mutated, DNA-PKcs deficient) and M059J-Fus-1 (p53 mutated, DNA-PKcs 
corrected).Data are mean +/- SEM of 3 independent experiments. Within 
each experiment there were at least 2 replicates. 
 
6.3.1 V158411 with the DNA-PKcs inhibitor NU7441 
To further explore the role of DNA-PKcs in determining the sensitivity of M059J 
cells to V158411. V158411 was used in combination with the DNA-PK inhibitor 
NU7441 (1 µM) in clonogenic assays. Figure 6-7 summarises the results of 
these experiments. NU7441 had no effect on the sensitivity of M059J cells 
lacking DNA-PKcs to V158411. However, in the M059J-Fus1 cells with 
functional DNA-PKcs NU7441 significantly increased resistance to V158411 (p 
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= 0.0002 2 way ANOVA) and caused an approximate 2-fold increase in the LC50 
and LC90 of V158411 (Table 6-2).  
 
Figure 6-7 Clonogenic cytotoxicity assay with V158411 +/- NU7441. 
V158411 +/- NU7441 1 mM in M059J (black) and M059J-Fus1 (green) cell 
line. M059J (p53 mutated, DNA-PKcs deficient) and M059J-Fus-1 (p53 
mutated, DNA-PKcs corrected). Data are mean +/- SEM of 3 independent 
experiments. Within each experiment there were at least 2 replicates. 
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Drug M059J LC50 M059J LC90 M059J-Fus1 
LC50 
M059J-Fus1 
LC90 
     
V158411 823.0 nM 1498 nM 89.5 nM 417.5 nM 
     
V158411 + 
NU7441 
455.0 nM >5000 nM 196.5 nM 817.1 nM 
     
Table 6-2 LC50 and LC90 values of V158411 +/- 1 µM NU7441 in M059J and 
M059J-Fus1 glioblastoma cancer cell lines 
M059J (p53 mutated, DNA-PKcs deficient) and M059J-Fus-1 (p53 mutated, 
DNA-PKcs corrected). 
 
6.3.2 A comparison of V158411, PF00477736 and AZD7762 in M059J cells 
To determine whether the effect seen in the M059J and M059J-Fus1 cells 
was unique to V158411 or a class effect of CHK1 inhibitors, the 
clonogenic survival of the cells V158411 was compared to two 
commercially available CHK1 inhibitors, the selective CHK1 inhibitor 
PF00477736 and the CHK1/CHK2 inhibitor, AZD7762 (Figure 6-8 and  
Table 6-3). 
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Figure 6-8 Clonogenic cytotoxicity assay with panel of CHK1 inhibitors. 
V158411 in M059J (black) and M059J-Fus1 (green) cell line. PF477736 in 
M059J and M059J-Fus1 cell line. AZD7762 in M059J and M059J-Fus1 cell 
line. M059J (p53 mutated, DNA-PKcs deficient) and M059J-Fus-1 (p53 
mutated, DNA-PKcs corrected). Data are mean +/- SEM of 3 independent 
experiments. Within each experiment there were at least 2 replicates. 
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Drug M059J LC50 M059J LC90 M059J-Fus1 
LC50 
M059J-Fus1 
LC90 
     
V158411 396.9 nM 1498 nM 96.37 nM 417.5 nM 
     
PF00477736 471.5 nM 4684 nM 155.9 nM 1153 nM 
     
AZD7762 99.18 nM 497.5 nM 85.45 nM 441.3 nM 
     
 
Table 6-3 LC50 and LC90 values with panel of CHK1 inhibitors. 
V158411, PF00477736 and AZD7762 in M059J and M059J-Fus1 
glioblastoma cancer cell lines. M059J (p53 mutated, DNA-PKcs deficient) 
and M059J-Fus-1 (p53 mutated, DNA-PKcs corrected). 
 
 
There was a similar difference in cytotoxicity seen between the M059J and 
M059J-Fus1 cell lines with both selective CHK1 inhibitors, V158411 and 
PF00477736, but no significant difference with the dual CHK1/CHK2 inhibitor 
AZD7762. AZD7762 was 4-fold more potent in the M059J cell line than 
V158411 but had a similar LC50 in the M059J-Fus1 cell line. 
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6.4 mRNA expression data from archival libraries of paired normal and 
tumour tissue 
Publically available microarray data can be analysed to examine which DNA 
damage response genes are up-regulated in tumour tissue compared to normal 
tissue. Of particular interest to the current project is the mRNA expression of 
CHK1 and DNA-PKcs in paired datasets of normal and tumour tissues. 
Datasets from studies in breast cancer, pancreatic cancer, NSCLC, 
hepatocellular carcinoma and CLL have been analysed. 
 
6.4.1 Breast cancer 
GEO dataset GSE29431 is derived from a study of breast cancers by Lopez et 
al (Lopez et al., 2012). It contains 54 samples from breast carcinomas and 12 
unmatched normal breast tissue samples. Figure 6-9 (A) shows that CHK1 
mRNA expression is significantly elevated in the breast cancer tissue samples 
compared to the normal breast tissue (p = 0.0044 (unpaired t-test)). Figure 6-9 
(B) demonstrates that DNA-PKcs mRNA expression is significantly 
downregulated is breast cancer tissue samples compared to unmatched breast 
tissue controls (p = 0.0027 (unpaired t-test)). There is no correlation between 
CHK1 and DNA-PKcs mRNA expression in this breast cancer dataset. 
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Figure 6-9 Analysis of mRNA data in breast cancer. 
Analysis of array GSE29431 of paired normal and tumour tissue from 
patients with breast cancer. (A) CHK1 (black) mRNA expression 
normalised to HPRT in normal (open circles) and tumour tissue (filled 
circles). (B) DNA-PKcs (red) mRNA expression normalised to HPRT in 
normal (open circles) and tumour (filled circles) tissue 
 
 
6.4.2 Pancreatic cancer 
GEO data series GSE15471 is an array of 36 paired normal and tumour tissue 
samples from patients with pancreatic cancer from a study by Badea et al 
(Badea et al., 2008).  Figure 6-10 shows the expression of 30 DNA damage 
response genes in tumour tissue compared to paired normal tissue. Figure 6-10 
shows that CHK1 mRNA expression in tumour tissue compared to normal 
tissue had the second highest expression in the panel and that DNA-PKcs 
mRNA is also over-expressed. Figure 6-11 (A) demonstrates that CHK1 mRNA 
expression was significantly up-regulated in tumour tissue compared to paired 
normal tissue samples (p = 0.0003 (paired t-test)). Its upstream activator ATR 
was also up-regulated. DNA-PKcs mRNA expression (Figure 6-11 (B)) was also 
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significantly up-regulated in tumour tissue compared to paired normal tissue 
samples (p < 0.0001 (paired t-test)). Other genes involved in NHEJ, XRCC4 
and ligase 4, were also among those very highly expressed. However, there 
was poor correlation between the up-regulation of these two parameters with r2 
= 0.19 (data not shown). 
  
Figure 6-10 Analysis of mRNA data in pancreatic cancer 
Analysis of array GSE15471 of paired normal and tumour tissue from 
patients with pancreatic cancer. All mRNA expression normalised to 
HPRT expression. DNA-PKcs highlighted in red and CHK1 in black. 
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Figure 6-11 Analysis of mRNA data in pancreatic cancer 
Analysis of array GSE15471 of paired normal and tumour tissue from 
patients with pancreatic cancer. (A) CHK1 (black) mRNA expression 
normalised to HPRT in normal (open circles) and tumour tissue (filled 
circles). (B) DNA-PKcs (red) mRNA expression normalised to HPRT in 
normal (open circles) and tumour (filled circles) tissue 
 
6.4.3 Non-small cell lung cancer (NSCLC) 
GEO data series GSE18842, from a study originally performed by Sanchez-
Palencia et al (Sanchez-Palencia et al., 2011), contains samples from 46 
NSCLC tumours with 42 paired and 3 un-paired controls. Figure 6-12 (A) shows 
that CHK1 mRNA expression was significantly increased in NSCLC tumour 
samples compared to matched controls (p < 0.0001 (paired t-test)) in this data 
set. Figure 6-12 (B) shows that, like CHK1 expression, DNA-PKcs mRNA 
expression was also significantly up-regulated in tumour tissue (p < 0.0001 
(paired t-test)). There was moderate correlation between CHK1 mRNA and 
DNA-PKcs mRNA expression in matched samples; Figure 6-13 shows this 
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correlation which has an r2 value of 0.729 (linear regression analysis; 95% 
confidence interval 0.6233 – 0.8111, p < 0.0001). 
 
 
 
Figure 6-12 Analysis of mRNA data in NSCLC cancer 
Analysis of array GSE18842 of paired normal and tumour tissue from 
patients with NSCLC. (A) CHK1 (black) mRNA expression normalised to 
HPRT in normal (open circles) and tumour tissue (filled circles). (B) DNA-
PKcs (red) mRNA expression normalised to HPRT in normal (open circles) 
and tumour (filled circles) tissue 
 
Normal Tissue Tumour
0
1
2
3
N
or
m
al
is
ed
 C
he
k1
 m
R
N
A
 e
xp
re
ss
io
n
Normal Tissue Tumour
0
1
2
3
4
N
or
m
al
is
ed
 D
N
A
PK
 m
R
N
A
 e
xp
re
ss
io
n
A B
 
 
228 
 
Figure 6-13 Analysis of mRNA data in NSCLC cancer: DNA-PKcs versus 
CHK1. 
Analysis of array GSE18842 of NSCLC. DNA-PKcs and CHK1 mRNA 
expression normalised to HPRT expression plotted against each other. 
 
6.4.4 Hepatocellular carcinoma (HCC) 
GSE6764 is a GEO data series from Wurmbach et al (Wurmbach et al., 2007) 
that contains unpaired samples from patients with a spectrum of liver disease. It 
contains samples of normal liver tissue through the spectrum of cirrhotic liver 
disease to dysplastic liver disease into HCC (very early, early, advanced and 
very advanced HCC). There were samples from 75 patients in total. The tumour 
samples came from patients with HCC associated with hepatitis C virus 
infection (HCV). Figure 6-14 and Fig 6-15 show that both CHK1 and DNA-PKcs 
mRNA expression became increasingly dysregulated with advancing HCC; 
Figure 6-15. Figure 6-16 shows the relatively weak correlation between DNA-
PKcs and CHK1 mRNA expression; the r2 value for this correlation is 0.344 
(linear regression analysis, p < 0.0001) 
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Figure 6-14 Analysis of mRNA data in HCC. 
Analysis of array GSE6764 of spectrum of liver disease, normal tissue 
(open circle) and abnormal tissue (filled circle). CHK1 (black) mRNA 
expression normalised to HPRT expression. 
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Figure 6-15 Analysis of mRNA data in HCC. 
Analysis of array GSE6764 of spectrum of liver disease, normal tissue 
(open circle) and abnormal tissue (filled circle). DNA-PKcs (red) mRNA 
expression normalised to HPRT expression 
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Figure 6-16 Analysis of mRNA data in HCC: DNA-PKcs versus CHK1. 
Analysis of array GSE6764 of hepatocellular carcinoma. DNA-PKcs and 
CHK1 mRNA expression normalised to HPRT expression plotted against 
each other. 
 
6.4.5 Chronic lymphocytic leukaemia (CLL) 
A CLL GEO data series GSE22529 contains samples from 41 patients with CLL 
and 11 age-matched controls (Gutierrez et al., 2010). Figure 6-17 (A) shows the 
comparison of CHK1 mRNA expression between normal B cell controls and B 
cell samples from patients with CLL. There was a small increase in CHK1 
mRNA expression in the samples from patients with CLL, but this was not 
significant. Figure 6-17 (B) shows the DNA-PKcs mRNA expression in the same 
populations. There was no difference between the two groups. 
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Figure 6-17 Analysis of mRNA data in CLL. 
Analysis of array GSE22529 of CLL. (A) CHK1 (black) mRNA expression 
normalised to HPRT in normal (open circles) and CLL (filled circles). (B) 
DNA-PKcs (red) mRNA expression normalised to HPRT in normal (open 
circles) and CLL (filled circles) tissue 
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6.5 Cytotoxicity of V158411 in a panel of HCC cancer cell lines. 
Following the results seen in the M059J/M059J-Fus1 DNA-PKcs proficient and 
deficient paired glioblastoma cells and the correlation of CHK1 and DNA-PKcs 
expression in the archived HCC datasets, the sensitivity of a panel of liver 
cancer cell lines was assessed. These cell lines were already known to have 
differences in their DNA-PKcs expression. The sensitivity of these cell lines to 
V158411 with and without 1 µM NU7411 was assessed in clonogenic assays. 
Figure 6-18 and Figure 6-19 show the results of these experiments and Table 
6-4 the LC50 and LC90 values these experiments. There was a wide range of 
sensitivity to single agent V158411 with LC50 values ranging from 153 nM in 
SNU.182 cell line to 4613 nM in the resistant PLC/PRF/5 cell line. 
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Figure 6-18 Cytotoxicity of V158411 in liver cell line panel. 
Clonogenic cytotoxicity assay in liver cancer cell lines. Individual cell 
lines (PLC/PRF/5 (p53 mutated), HepG2 (p53 wild type), Hep3B (p53 null), 
Huh7 (p53 mutated), SNU.182 (no p53 mutation detected) and SNU.475 
(p53 mutated)) with V158411 (black) +/- 1 µM NU7441 (green). Data are 
mean +/- SEM of 3 independent experiments. Within each experiment 
there were at least 2 replicates. 
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Figure 6-19 Cytotoxicity of V158411 in liver cell line panel. 
Clonogenic cytotoxicity assay. Summary of panel of HCC cell lines 
(PLC/PRF/5 (black, p53 mutated), HepG2 (blue, p53 wild type), Hep3B 
(green, p53 null), Huh7 (rust, p53 mutated), SNU.182 (yellow, no p53 
mutation detected) and SNU.475 (red, p53 mutated)) with V158411 or 
V158411 + 1 µM NU7441. Data are mean +/- SEM of 3 independent 
experiments. Within each experiment there were at least 2 replicates. 
 
 
 LC50 LC90  
Cell Line V158411 V158411 + 
NU7441 
V158411 V158411 + 
NU7441 
     
PLC/PRF/5 4613 nM >5000 nM >5000 nM >5000 nM 
     
Hep3B 3692 nM >5000 nM >5000 nM >5000 nM 
     
HepG2 748.5 nM 1081 nM 4309 nM 4795 nM 
     
Huh7 937.4 nM 4682 nM >5000 nM >5000 nM 
     
SNU.182 153.2 nM 509 nM 1430 nM 2404 nM 
     
SNU.475 634.1 nM 911 nM 4914 nM >5000 nM 
     
Table 6-4 LC50 and LC90 values of V158411 +/- 1 µM NU7441 in liver cancer 
cell lines. 
Data are mean of at least 3 independent experiments. 
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The impact of the DNA-PKcs inhibitor NU7441 on the cytotoxicity of V158411 
was assessed in all cell lines by ANOVA analysis. The only cell line in which 1 
µM NU7441 caused a statistically significantly protection from V158411 was in 
Huh7 cells (p = 0.02 (ANOVA)), in the remaining 5 liver cancer cell lines the 
protection afforded by NU7441 was not significant. Nevertheless a consistent 
pattern was seen in that less sensitivity to V158411 was observed in the 
presence of NU7441 and in every cell line the LC90 and/or LC50 of V158411 was 
higher in the presence of NU7441  
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6.6 DNA-PKcs status as a determinant of sensitivity to CHK1 inhibitors 
in a panel of cell lines 
To extend the investigation of the potential correlation identified between CHK1 
and DNA-PKcs mRNA expression, and the cytotoxicity data in V3 compared to 
AA8 cells and the M059J/M059J-Fus1 glioblastoma cell line pair further 
experiments were planned to look for a correlation between the expression of 
CHK1 and DNA-PKcs protein in the panel of cell lines used in the current study. 
Furthermore, it was wished to explore whether the expression of either CHK1 or 
DNA-PKcs protein correlated with the sensitivity to V158411 seen in clonogenic 
assays.  
 
6.6.1 DNA-PKcs expression main cell line panel 
DNA-PKcs expression and autophosphorylation, as an indication of activity, was 
measured in untreated cells and in cells one hour after 10 Gy ionising radiation 
in all the cell lines previously used (K562, MCF7, MDA-MB-231, HCT116 (wild 
type and p53 -/-), M059J/M059J-Fus1 and U2OS (wild type and dominant 
negative p53). Figure 6-20 shows representative western blots from these 
experiments. 
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Figure 6-20 Example western blots in cell line panel. 
Representative western blots of DNA-PKcs, pDNA-PKcsserine2096 and actin 
in cell lines treated with 10 Gy ionising radiation. 
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Figure 6-21 Expression of DNA-PKcs in cell line panel. 
Expression of DNA-PKcs normalised to actin in a cell line panel. Data are 
mean +/- SEM of at least 3 independent experiments. 
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The mean expression of total DNA-PKcs normalised to actin is shown in Figure 
6-21. There is a wide variation in total DNA-PKcs expression with the highest 
expression in K562 cell line. The mean level of pDNA-PKcsserine2096 (the 
autophosphorylation form) normalised to actin both in untreated cell lines and 
samples treated with 10 Gy IR is shown in  
 
Figure 6-22. There was considerable interassay variability in these results 
suggesting that the results should be interpreted with caution. The ratio 
between untreated and treated samples is shown in Figure 6-23. 10 Gy IR 
induces the expression of pDNA-PKcsserine2096 in the majority of cell lines. Some 
cell lines (MCF7, MDA-MB-231) with a low baseline expression of pDNA-
PKcsserine2096 did not have any detectable increase in expression following 
treatment with 10 Gy IR. 
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Figure 6-22 Expression of pDNA-PKcsserine2096 in cell line panel. 
Expression of pDNA-PKcsserine2096 normalised to actin in controls and 
paired samples 1 hour after 10 Gy ionising radiation. Note significant 
interassay variability. Data from 2 independent experiments. 
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Figure 6-23 Relative expression of pDNA-PKcsserine2096 in cell line panel. 
Relative expression of pDNA-PKcsserine2096 in cell lines treated with 10 Gy 
ionising radiation compared to untreated controls. Note significant 
interassay variability. Data from 2 independent experiments. 
 
6.6.2 DNA-PKcs expression in HCC cell lines 
DNA-PKcs expression, total DNA-PKcs and pDNA-PKcsserine2096, had previously 
been determined in the panel of liver cancer cell lines (PLC/PRF/5, Huh7, 
Hep3B, HepG2, SNU.182 and SNU.475) by Liam Cornell. DNA-PKcs 
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expression data is shown in Figure 6-24; pDNAPKcsserine2095 expression in 
untreated controls and cells treated with 10 Gy IR one hour before harvesting in 
Figure 6-25, and the ratio of pDNA-PKcsserine2096 expression between treated 
and untreated samples in Figure 6-26. There was significant inter-assay 
variation such that it was not possible to determine if there were differences in 
the expression of DNA-PKcs between cell lines (Figure 6-24). 10 Gy IR 
consistently increased DNA-PKcs autophosphorylation (pDNA-PKcsserine2096) in 
all cell lines (Figure 6-25). There is wide variation in the extent of this 
upregulation between cell lines with the most significant increase being seen in 
the Hep3B cell line (Figure 6-26). 
 
Figure 6-24 Expression of DNA-PKcs in liver cell line panel. 
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Expression normalised to actin in a panel of liver cancer cell lines. Data 
from at least 2 independent experiments. Note significant interassay 
variability. Data courtesy of Liam Cornell. 
  
Figure 6-25 Expression of pDNA-PKcsserine2096 in liver cell line panel 
Expression normalised to actin in controls and paired samples 1 hour 
after 10 Gy ionising radiation. Data from 2 independent experiments. Data 
courtesy of Liam Cornell 
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Figure 6-26 Relative expression of pDNA-PKcsserine2096 in liver cell line 
panel 
Relative expression of pDNA-PKcsserine2096 in cell lines treated with 10 Gy 
ionising radiation compared to untreated controls. Data are mean 2 
independent experiments. Data courtesy of Liam Cornell. 
 
6.6.3 CHK1 expression in HCC cell lines 
CHK1 expression in the liver cancer cell line panel was also examined by 
western blotting. A representative blot from these experiments is shown in 
Figure 6-27.  
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Figure 6-27 Representative western blot of CHK1 expression in liver cell 
line panel. 
Expression of CHK1, pCHK1serine296 and actin in cell lines treated with 1 µM 
gemcitabine. 
 
Total CHK1 expression normalised to actin expression is shown in Figure 6-28. 
There was only modest variation in CHK1 expression, it being highest, when 
normalised to actin expression, in HepG2 and Hep3B cell lines. 
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Figure 6-28 CHK1 expression in liver cell line panel. 
Expression of CHK1 normalised to actin in a panel of liver cancer cell 
lines. Data are mean +/- SEM of 3 independent experiments. 
 
The expression of pCHK1serine296 after a one hour exposure to 1 µM gemcitabine 
was also examined in the liver cancer cell line panel. A summary of this data is 
shown in Figure 6-29. Figure 6-30 shows that gemcitabine reliably increases the 
expression of the activated pCHK1serine296 across most of the cell line panel 
apart from SNU.475 cells where both the basal and induced pCHK1serine296 
expression was very low. The greatest induction of pCHK1serine296 expression 
was seen in the Hep3B cell line.  
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Figure 6-29 Expression of pCHK1serine296 in liver cell line panel. 
Expression of pCHK1serine296 normalised to actin in controls and paired 
samples 1 hour after 1 µM gemcitabine. Data are mean +/- SEM of 3 
independent experiments. 
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Figure 6-30 Relative expression of pChk1serine296 in liver cell line panel. 
Relative expression of pChk1serine296 in cell lines treated with 1 µM 
gemcitabine compared to untreated controls. Data are mean +/- SEM of 3 
independent experiments. 
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analysed as shown in Figure 6-31. There was no correlation between total 
CHK1 and total DNA-PKcs expression (r2 = 0.203, p = 0.09, linear regression 
analysis) or between induced pCHK1serine296 and pDNA-PKcsserine2096 expression 
(r2 = 0.475, p = 0.130, linear regression analysis) in this cell line panel. 
  
Figure 6-31 CHK1 and DNA-PKcs expression in all cell lines. 
Correlation between (a) total CHK1 expression and total DNA-PKcs 
expression and (b) pCHK1serine296 and pDNA-PKcsserine2096 expression in a 
panel of cell lines including the liver cancer cell lines. Individual points 
constitute the mean expression levels from a summary of at least 3 
experiments. 
 
Further to this, the cytotoxicity of V158411 in clonogenic assays as summarised 
by their LC50 value in both the main cell line panel and the liver cancer cell line 
panel was correlated to the expression of total CHK1, total DNA-PKcs and the 
induced expression of pCHK1serine296 and pDNA-PKcsserine2096. The results of 
this analysis are shown in Figure 6-32.  
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Figure 6-32 LC50 values and protein expression in all cell lines. 
Correlation between V158411 LC50 values from a cell line panel including 
the liver cancer cell line panel and (a) total CHK1 expression, (b) 
pCHK1serine296 expression 1 hour after 1 µM gemcitabine, (c) total DNA-
PKcs expression and (d) pDNA-PKcsserine2096 expression 1 hour after 2 Gy 
IR. Individual points constitute the mean expression levels from a 
summary of at least 3 experiments. 
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Using linear regression analysis, there was no correlation between V158411 
LC50 and total CHK1 expression (r2 = 0.08, p = 0.31), pCHK1serine296 expression 
1 hour after 1 µM gemcitabine (r2 = 0.0004, p = 0.94), and total DNA-PKcs 
expression (r2 = 0.018, p = 0.63). However, there was a correlation between 
V158411 LC50 and the expression of pDNA-PK-csserine2096 1 hour after 10 Gy IR 
(r2 = 0.63, p = 0.0007).  
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6.7 Discussion 
 
The aim of this chapter was to explore the determinants of sensitivity to 
V158411 and in particular to identify factors that might make tumours and 
patients suitable for treatment with a CHK1 inhibitor as a single agent or in 
combination with another small molecular inhibitor of the DNA damage 
response system. 
The starting point for this work was to examine the cytotoxicity of V158411 as a 
single agent in cells with specific DNA repair defects. For these studies we used 
the well characterised Chinese hamster ovary (CHO) and Chinese hamster lung 
fibroblast (CHLF) cells. There was no significant difference in sensitivity to 
single agent V158411 between the BRCA2 deficient VC8 and the BRCA2 
corrected VC8-B2 CHLF cell lines indicating that HRR defects are not 
associated with CHK1 sensitivity. In contrast, CHO cell lines lacking XRCC1 
(EM9) were more sensitive to V158411 than the parental AA8 cell line. XRCC1 
is a scaffold protein in BER that is recruited to DNA SSB by PARP-1. Other 
authors have shown synergy between CHK1 inhibitors and PARP inhibitors 
(Mitchell et al., 2010a, Vance et al., 2011). Our data in CHLF cells suggests that 
the synergy between CHK1 and PARP inhibitors may be due to a BRCA2 
independent mechanism. This suggests that BER defects may be synthetically 
lethal with CHK1 inhibitors. 
Curiously the Ku-80- defective cells (XRS-6) were more sensitive but the V3 cell 
line that lacks DNA-PKcs was more resistant to V158411 than the parental AA8 
cells.  Since DNA-PKcs is recruited to DNA DSB by Ku80 and Ku70 to promote 
repair by NHEJ these observations may indicate that either (i) Ku80 has some 
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function, other than its role in NHEJ that protects cells from CHK1 inhibition or 
(ii) the role of DNA-PKcs in conferring sensitivity to V158411 would not appear 
to be linked to its role in NHEJ. There is growing evidence that DNA-PKcs acts 
as a regulator of the ATR-CHK1 pathway both through regulation of RPA/ATR 
and through direct activation of CHK1 at serine 345 (Serrano et al., 2013) 
(Khanna et al., 2013). 
This led us to explore the cytotoxicity of V158411 in a glioblastoma cell line 
M059J which has a well characterised defect in DNA-PKcs and its paired cell 
line M059J-Fus1 in which functional DNA-PKcs has been restored by transfer of 
chromosome 8. The DNA-PKcs expressing cells were approximately 10-fold 
more sensitive to a 24 hour continuous exposure to single-agent V158411. To 
determine whether this interesting difference in sensitivity of the M059J cell line 
pair was unique to V158411 or a class-effect with other CHK1 inhibitors, the 
cytotoxicity of two other commercially available CHK1 inhibitors, AZD7762 and 
PF00477736, was compared in the M059J and M059J-Fus1. PF00477736 was 
similarly more cytotoxic to the M059J-Fus1 cell with a 3-fold lower LC50 than the 
M059J cells. There was, however, no difference in sensitivity between the cells 
with AZD7762. This might be explained by the observation that unlike the 
selective CHK1 inhibitors V158411 and PF00477736, AZD7762 is dual 
CHK1/CHK2 inhibitor. 
A possible alternative explanation for the sensitivity complicating factor in the 
interpretation of these data is that the M059J-Fus1 cells were created by the 
transfer of chromosome 8 (the gene for DNA-PKcs is located on 8q11) these 
cells also express cMyc (located on 8q24). CHK1 inhibitors have previously 
been shown to be active as single agents in myc-amplified neuroblastomas and 
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lymphomas (Hoglund et al., 2011a, Hoglund et al., 2011b, Murga et al., 2011, 
Ferrao et al., 2011, Walton et al., 2012). So the increased sensitivity of the 
M059J-Fus1 cell line may be due to increased expression of myc leading to 
increased sensitivity to V158411. However, since the V3 cells, lacking DNA-
PKcs, were also resistant to V158411, and they do not differ from parental AA8 
cells in their Myc status, it is likely that DNA-PKcs itself is contributing to the 
sensitivity. 
To explore this further the effects of the DNA-PKcs inhibitor NU7441 on the 
sensitivity of the paired glioblastoma cells to V158411 were investigated. As 
expected NU7441 had no effect in the M059J cells; however, it did confer 
resistance to V158411 in the M059J-Fus1 cells implicating the kinase activity of 
DNA-PKcs in the sensitivity to CHK1 inhibition. What exactly this role is remains 
to be identified. The data regarding the differential sensitivity of Ku80 and DNA-
PKcs defective CHO cells would suggest that it is not related to its NHEJ 
function. DNA-PKcs has been implicated in the stabilization of c-Myc and, as 
described above, amplified Myc is associated with sensitivity to CHK1 inhibition 
(An et al., 2008). 
To investigate the relationship between CHK1 and DNA-PKcs further the 
expression of the genes was examined in publically available archived mRNA 
microarrays. Analysis of data from mRNA expression arrays comparing normal 
tissue and tumour tissue from different tumour sites showed that in one dataset 
(CLL) there was no significant difference between CHK1 or DNA-PKcs 
expression in normal and tumour tissue. In another dataset (breast cancer) 
there was a discordant relationship with CHK1 being over-expressed in tumour 
tissue and DNA-PKcs being under-expressed. However, in three datasets from 
 
 
256 
patients with pancreatic cancer, NSCLC and HCC increased CHK1 and DNA-
PKcs mRNA levels were seen in tumour tissue compared to normal tissue. Of 
greatest interest in the dataset from with liver disease and HCC, there was 
increasing dysregulation of both DNA-PKcs and CHK1 with the advancing stage 
of disease from normal liver tissue through to very advanced HCC. There was 
concordance between the mRNA expression levels, with samples with 
increased CHK1 levels also having increased DNA-PK levels. 
The interesting relationship between CHK1 and DNA-PKcs in the HCC dataset 
led us to examine the sensitivity of a panel of 6 liver cancer cell lines to 
V158411 with or without the DNA-PKcs inhibitor 1 µM NU7441 24 hour co-
treatment in clonogenic assays. The cells displayed a spectrum of sensitivity to 
V158411 and in all cases there was a modicum of protection by NU7441, which 
was significant in the case of the Huh7 cells. 
To further explore if there is a relationship between V158411 cytotoxicity and 
DNA-PKcs; the baseline expression of DNA-PKcs, IR-induced activation of 
DNA-PKcs autophosphorylation at serine2096 and the baseline expression of 
CHK1 along with gemcitabine-induced autophosphorylation at serine296 was 
explored in the main cell line panel and the panel of 6 liver cancer cell lines. 
There was no correlation between baseline CHK1 and DNA-PKcs expression or 
between the induced phosphorylation of CHK1serine296 and induced DNA-
PKcsserine2096 phosphorylation. Furthermore, there was no correlation between 
the LC50 for V158411 in individual cell lines and the basal expression of either 
CHK1, DNA-PKcs or the induced phosphorylation of CHK1serine296 in the cell 
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lines. However, there was a correlation between the LC50 for V158411 and the 
induced phosphorylation of DNA-PKcsserine2096 1 hour after 10 Gy IR. 
This does not fit with our hypothesis, based on the work from CHO cells and 
M059J cells that cells that the lack of functional DNA-PKcs confers resistance to 
CHK1 inhibitors. It would seem more likely that DNA-PKcs acts as an important 
regulator of the ATR-CHK1 pathway, and that is not simply its presence or 
absence that confers sensitivity to CHK1 inhibitors, but its time-sensitive 
inducible function that plays a critical role in the efficacy of CHK1 inhibitors. 
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Chapter 7 Conclusion 
The first priority of the work presented here was to develop a means to measure 
the extent of CHK1 inhibition so that suitable concentrations of V158411 could 
be selected for subsequent experiments and to identify a potential biomarker 
that could be used to measure the pharmacodynamic effect of CHK1 inhibitors 
in clinical trials. 
Total CHK1 expression, CHK1serine296 phosphorylation and CHK1serine345 
phosphorylation was investigated in western blots using lysates from cancer cell 
lines and a number of assays validated. The choice of a biomarker for use with 
single agent V158411 is more difficult; CHK1serine296 autophosphorylation was 
reduced by a 1 hour exposure to V158411, but as the baseline level of 
CHK1serine296 phosphorylation is very low the sensitivity of such a test is reduced 
and is not practical for clinical trial biomarker use.  
The selection of a potential biomarker for use in combination with cytotoxic 
therapy or in an ex vivo stimulation assay is more straight forward. CHK1serine296 
autophosphorylation was reliably induced by a short (1 hour) exposure to 
cytotoxic (1 µM gemcitabine). This increase was abrogated in a concentration-
dependent fashion by 50, 150 and 500 nM V158411 respectively. A 1 hour 
treatment with gemcitabine or V158411 increased CHK1serine345 
phosphorylation; combination of the agents was additive, but not synergistic. 
Hence, CHK1serine345 phosphorylation is probably less helpful as a biomarker in 
combination studies. 
CHK1serine345 phosphorylation was reliably increased in the presence of 
V158411. As this is not a downstream event of CHK1 inhibition, it cannot be 
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used a proof-of-mechanism biomarker, but could be used as a measure of 
CHK1 inhibition, if other factors such as the phosphorylation of serine345 (e.g. 
ATR after DNA damage) could be controlled. Other downstream targets of 
CHK1 were explored in preliminary studies that are not presented in this thesis. 
Cdc25A expression was not found to change in a reliable or specific fashion 
following short 1 hour exposures to cytotoxic agents (1 µM gemcitabine or 10 
mM hydroxyurea) or with 50, 150 or 500 nM V158411. An ELISA assay for 
Wee1 phosphorylation as a downstream assay of CHK1 function was also 
explored during this project. Unfortunately the assay was not sensitive during 
early work, but with further development could be an alternative downstream 
biomarker of CHK1 inhibition. 
The mechanism of cytotoxicity for single agent V158411 was only partly 
determined by this work. It appears to be potentially related to CHK1 inhibition, 
as siRNA knockdown of CHK1 in MCF7 cells was cytotoxic in clonogenic 
assays. V158411 as a single agent reliably reduced the fraction of cells in G2 of 
the cell cycle. However, whether the cytotoxicity of V158411 is related to the 
role of CHK1 in cell cycle regulation at the S and G2 cell cycle checkpoints, or 
via an alternative mechanism is unclear. Further mechanistic exploration of this 
is required. The effect of V158411 at the S phase checkpoint could be more 
reliably determined by using a staining technique such as BrdU-labelling to 
accurately quantify the proportion of cells in S phase. 
The work to determine the specificity of V158411 was hampered by the non-
viability of the CHK1 siRNA knockdown. Alternative strategies to explore the 
specificity of V158411 would be the development of an inducible kinase-dead 
CHK1 cell line, or a cell line with a mutation at the serine296 phosphorylation site 
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or a cell line mimicking a constitutively phosphorylated (and therefore activated) 
CHK1serine296. 
This work shows that V158411 has significant single agent activity. The LC50 of 
V158411 in MCF7 breast cancer cells was 113 nM despite there only being 
45% inhibition of Chk1serine296 phosphorylation with 150 nM V158411. In K562 
CML cells the LC50 was 152 nM with approximately 50% inhibition of 
Chk1serine296 phosphorylation with 150 nM. This suggests that only partial CHK1 
inhibition results in significant cytotoxicity or that cytotoxicity is not entirely 
dependent on CHK1 inhibition. Germline CHK1 +/- mice do not have tumours 
that lose the second allele (Liu et al., 2000). This suggests that CHK1 is a 
haploinsufficient tumour suppressor gene. However, Lam et al demonstrated 
that haploinsufficiency in CHK1 heterozygotes leads to cells accumulate DNA 
damage following inappropriate S phase entry and a failure to restrain entry into 
mitosis (Lam et al., 2004). This raises the concern that the use of a CHK1 
inhibitor may cause problems in normal tissue, and may lead to significant 
toxicity limiting the therapeutic window. 
A potential hypothesis for the mechanism of single agent cytotoxicity of 
V158411 can be based on data by Drew (Drew et al., 2011). They showed that 
inhibition of DNA repair for 24 hours (with the PARP inhibitor AG014699 10 µM 
in HCC1937 cells) led to an equivalent level of DNA damage (as quantified by 
γH2AX foci) as to the exposure of cells to 2 Gy of ionising radiation. This 
suggests that the level of spontaneous DNA damage is high in all cells. In 
cancer cells, with an absent G1 checkpoint, the exposure to V158411 for 24 
hours leads to cells continuing through the G2 checkpoint without stopping to 
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facilitate DNA repair. This results in the acquisition of significant levels of DNA 
damage accounting for the single agent cytotoxicity of V158411. 
There is relatively sparse pre-clinical data in the literature on the cytotoxicity of 
other CHK1 inhibitors used as single agents. Some activity has been seen in 
cancer cell lines with 300 nM XL9844 for 24 hours, 100 nM AZD7762 for 25 
hours, and 500 nM SCH 900776 for 24 hours, though with all compounds more 
cell lines showed minimal cytotoxicity than were sensitive (Matthews et al., 
2007, Mitchell et al., 2010b, Montano et al., 2012). However, in light of the 
single agent activity seen in this work (12 cell lines with an LC50 between 100 
nM and 1000 nM) and in work performed by Vernalis in triple–negative breast, 
ovarian, lymphoma and leukaemia cell lines (Bryant et al., 2014a, Bryant et al., 
2014b), further work to assess the efficacy of single agent V158411 in animal 
models and then potentially in early phase clinical trials should be considered. 
The work outlined in this thesis did not show synergistic cytotoxicity when 
V158411 was combined with gemcitabine or cisplatin. This is despite there 
being significant inhibition of CHK1 activity (as determined by CHK1serine296 
phosphorylation) and abrogation of cisplatin-mediated cell cycle arrest (in 
HCT116 cells). This is in contrast to work with many other CHK1 inhibitors, 
where there is enhancement of cytotoxicity due to CHK1 inhibition in 
combination with a range of cytotoxic agents. There is pre-clinical and early 
phase clinical trial data demonstrating potential synergism between AZD7762 
and gemcitabine (Zabludoff et al., 2008, McNeely et al., 2010, Seto et al., 2013, 
Sausville et al., 2014), and SCH 900776 and gemcitabine (Montano et al., 2012, 
Guzi et al., 2011, Daud et al., 2010). 
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Cisplatin has been used in other pre-clinical studies in combination with CHK1 
inhibitors with mixed results. Bunch and Eastman showed chemosensitisation of 
cisplatin in CHO and breast cancer cell lines with UCN-01 and ICP-1 (Bunch 
and Eastman, 1996, Eastman et al., 2002). However, Wagner and Karnitz failed 
to demonstrate any chemosensitisation with UCN-01 and AZD7762 in HeLa 
cells (Wagner and Karnitz, 2009). 
One potential explanation for the lack of chemopotentiation is that the 
concentrations of both V158411 and gemcitabine were cytotoxic as single 
agents, additivity was seen, but not synergism. Other studies have not always 
used clonogenic assays to assess cytotoxicity and it is sometimes unclear 
whether the data has been normalised to ensure that potentiation rather than 
additivity is being seen. 
This is not to say that V158411 may not show synergism with other 
conventional cytotoxics. This would require additional in vivo and in vitro 
studies. It may be that V158411 needs to be present for longer than 24 hours 
following exposure to a conventional cytotoxic, though the work described in 
Section 4.3 with single agent V158411 suggested that a shorter duration 
exposure to a higher concentration of V158411 was more cytotoxic than a 
longer exposure to a lower concentration of V158411. Following the work of 
Calvo, using LY2603618 in combination with pemetrexed +/- cisplatin showing 
significant chemopotentiation; it would be interesting to explore in in vitro 
studies whether V158411 showed any chemopotentiation with this combination 
(Calvo et al., 2014). 
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The data that V158411 may act as a radiosensitiser are encouraging  (see 
Section 4.7). V158411 was shown to significantly abrogate IR-mediated G2 cell 
cycle arrest and significantly potentiated the cytotoxicity of IR in (MCF7 and 
HCT116 wild type and p53-/- cells). However, there are significant challenges 
using agents as radiosensitisers in in vivo studies and in clinical studies. In 
clinical practice, palliative radiotherapy is sometimes given as a single fraction 
(8 Gy for instance in cases of isolated bone metastases) or when a patient is 
too frail to attend on consecutive days for radiotherapy. However, most radiation 
regimens, both curative and palliative, involve multiple fractions (normally doses 
of 0.5-2 Gy per fraction) of radiotherapy given on consecutive days. An 
additional problem with using single palliative fractions of radiotherapy in 
combination trials with novel agents, is that the aim of such treatment is 
normally to palliate symptoms in patients nearing the end of their life and that 
output measures to evaluate efficacy are rare. 
In an early phase drug-only trial, it is normal to wait for 3-6 weeks to observe 
toxicity; however, when combining a novel agent with radiotherapy the potential 
that the novel therapy has potentiated the side effects of radiotherapy means 
that the delay has to be considerably longer (Zaidi et al., 2009). Radiation 
experts recommend waiting at least 6 weeks between cohorts to detect 
problems like acute lung toxicity from radiation. The implications of this are that 
radiosensitisation trials are generally slow to recruit and complete. It is very 
difficult to detect true late side effects from novel cytotoxics in combination with 
radiation in an early phase clinical trial, as cardiac side effects such as 
accelerated coronary artery disease are only seen after a number of years and 
the prognosis for most patients in early phase clinical trials is around 12 weeks.  
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V158411 is an intravenous compound, some other CHK1 inhibitors are 
bioavailable as oral compounds, XL9844, GNE-900, and CCT244747, GDC-
0425 and GDC-0575 (Matthews et al., 2007, Blackwood et al., 2013, Walton et 
al., 2012). Oral CHK1 inhibitors would be more suitable to use in combination 
with radiotherapy. Common radical or high-dose palliative radiotherapy 
regimens normal involve daily fractions of radiotherapy for 4 to 6 weeks. 
Administering a daily intravenous infusion would not be practical over a 4 to 6 
week period, but a once or twice a day oral inhibitor would be accepted by 
patients and doctors alike. 
The data presented in Chapter 5 suggested that there was no relationship 
between single agent V158411 cytotoxicity, chemo-sensitisation or radio-
sensitisation and p53 status. This may be because loss of G1 cell cycle 
checkpoint control is very common in cancer; p53 is only one of a number of 
elements of the G1 cell cycle checkpoint control pathway that may lost or non-
functional leading to a dependence in cancer cells on the S and G2 checkpoints 
(Massague, 2004). A further implication of this is that p53 status is not likely to 
be a suitable biomarker for patient stratification. Nevertheless it may be useful 
to investigate the relationship between the clinical outcome and p53 status of 
the diagnostic biopsy. This approach has been employed by the investigators in 
the Phase 1 clinical trial of SCH 900776 in combination with gemcitabine, 
though no correlation between p53 status and outcome has been presented in 
the data that has been released thus far (Daud et al., 2010). 
Data published by Dai suggested that inhibition of the Ras/MEK/ERK pathway 
with a small molecular inhibitor (AZD6244 – a MEK 1/2 inhibitor) conferred 
sensitivity to the CHK1 inhibitor UCN-01 (Dai et al., 2002). Myc amplification 
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was shown to confer sensitivity to CHK1 inhibition in lymphomas (Hoglund et 
al., 2011a) and in neuroblastomas (Walton et al., 2012). Further pre-clinical 
work exploring whether the relative sensitivity and resistance of the cell lines to 
V158411 might be correlated with myc, Ras, MEK, and ERK expression would 
be useful. Exploratory examination of Ras, MEK, ERK and myc mRNA and 
protein expression levels in tumour samples from patients in early phase clinical 
trials may also be informative if this could be correlated with clinical outcome 
data. 
The data presented in Chapter 6 shows that other elements of the DNA damage 
response may also play a role in determining the sensitivity to V158411. Of 
great interest from is that CHO cells lacking functional DNA-PKcs were 
relatively resistant to single agent V158411. In the glioblastoma cell line pair 
M059J cells lacking functional DNA-PKcs were more resistant to V158411 than 
M059J-Fus1 cells. Co-treatment with a DNA-PKcs inhibitor (NU7741) made the 
M059J-Fus1 cells more resistant to V158411. This phenomenon was seen with 
AZD7762 and PF00477736 suggesting that this is not an effect limited to 
V158411, but a class effect with CHK1 inhibitors. This suggests that in the 
absence of functional DNA-PKcs cells are resistant to CHK1-mediated 
cytotoxicity. Analysis of archived mRNA data from normal tissue and tumours 
suggested that both CHK1 and DNA-PKcs mRNA levels were commonly both 
up-regulated/dysregulated in tumour samples compared to normal tissues.  
The data suggests that the LC50 of V158411 on its own in cancer cell lines may 
correlate to the inducible (2 Gy IR) phosphorylation of DNA-PKcsserine2096. Cell 
lines with a low level of inducible DNA-PKcsserine2096 phosphorylation were more 
sensitive to V158411 in clonogenic assays. Conversely, high levels of inducible 
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DNA-PKcsserine2096 phosphorylation were associated with relative resistance to 
V158411.  This is in contrast to the data suggesting that loss of DNA-PKcs or 
the presence of a DNA-PKcs inhibitor correlates with resistance to CHK1-
mediated cytotoxicity. DNA-PKcs a role in regulation and control of the CHK1-
ATR pathway (as proposed in Figure 6-2), but this relationship is likely to be 
complex. 
This data suggests that it may be useful to attempt to correlate the PK and 
efficacy data from early phase clinical trials with the potential data from an ex 
vivo assessment of the inducible phosphorylation of DNA-PKcsserine2096 on 
patient material. Exploratory examination of other components of the NHEJ 
pathway including such as Ku70, Ku80, as well as total CHK1 and DNA-PKcs 
mRNA levels and protein expression levels in tumour samples from patients in 
early phase clinical trials may also be informative. 
The only single agent CHK1 inhibitor early phase clinical trial to date has been 
with the oral CHK1 inhibitor LY2606368. No pre-clinical data with this 
compound has been published. The first-in-human Phase I clinical trial of 
V158411 was due to have a single-agent run in phase, with V158411 delivered 
on Day 1 and Day 8 of a cycle 0, prior to the delivery of V158411 in combination 
with conventional cytotoxics. A single agent V158411 alone arm should be 
considered either as a stand-alone Phase 1 clinical trial or as an additional arm 
on the existing combination trial as it is currently proposed. This would give the 
recommended Phase II dose (RP2D) of V158411 alone for use in future trials.  
A protocol for the first-in-human Phase I clinical trial of V158411 in combination 
with single agent carboplatin or gemcitabine or the combination of gemcitabine 
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and carboplatin has been prepared and Vernalis are actively looking to partner 
the project. 
There will obviously be concern about potential cardiac toxicity with any first-in-
man CHK1 inhibitor trials, including V158411. Cardiac toxicity seen with 
AZD7762, which led to the clinical development of the compound being 
abandoned (Sausville et al., 2014, Seto et al., 2013). Cardiac toxicity had been 
seen in the pre-clinical animal toxicity work. 
As other early phase clinical trials have not reported any cardiac toxicity it is 
likely that the cardiac toxicity seen with AZD7762 is not a class effect and 
specific to the compound. AZD7762 is not a selective CHK1 inhibitor and has 
activity against a number of other kinase targets. The inhibition of receptor 
tyrosine kinases (RTKs) is known to be associated with cardiac toxicity (Force 
and Kolaja, 2011). 
However, it would be prudent to have strict inclusion criteria for entrants into 
clinical trials excluding any patients with potentially increased cardiac risk. 
Increased cardiac monitoring for patients in early phase clinical trials including 
baseline ECHO/MUGA, serial ECGs and cardiac troponin monitoring should 
also be considered. 
Following on from the work presented here on the choice of a suitable 
biomarker, there is also the issue of the type of biomarker material for animal 
studies and early phase clinical trials. There has to be balance between the 
technical difficulty in obtaining biomarker material, whether obtaining material is 
burdensome to the patient and the suitability of the material for biomarker work. 
The sampling of blood is technically easy, tolerable to the patient, but presents 
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a problem for developing a biomarker for a cell cycle checkpoint inhibitor, as 
most PBMCs are not actively cycling, but in G0. Hair follicles have been used 
(Fong et al., 2009), plucking and obtaining good quality hair follicles can be time 
consuming and the preparation of material is fiddly, time-consuming whilst 
yielding only small volumes of material. 
With respect to solid biopsy material, biopsies of normal skin tissue to use as a 
surrogate tissue are technically relatively easy to collect and process. Using 
normal skin as a surrogate tissue has been used as a biomarker in radiotherapy 
trials (Qvarnstrom et al., 2004). Repeated biopsies of skin may be unacceptable 
to some patients. Often the ‘gold-standard’ tissue to collect is a sample of the 
patient’s tumour. This may carry a morbidity and even a mortality risk and 
depending on the location tumour be technically challenging. An additional 
problem is tumour heterogeneity; the sample biopsied may not be 
representative of the whole tumour (Chan and Bristow, 2010). For these 
reasons, repeated biopsies of patient’s tumours are not normally acceptable to 
the patient or physician. 
However, the antibodies used in this work were only validated in western 
blotting. Western blotting could be performed in PBMCs and material from hair 
follicles, but is not suitable for other material. New antibodies for CHK1serine296 
are now available; and it would be interesting to explore whether these could be 
used in other applications. If the antibodies were shown to be suitable for 
immunohistochemistry (IHC) then it may be possible to look for CHK1serine296 
phosphorylation following cytotoxic therapy, with and without a CHK1 inhibitor, 
in either tumour or normal skin biopsy tissue in mice or patients receiving early 
phase clinical trials. 
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If the newer antibodies worked in flow cytometry, it opens up the possibility that 
in future studies, changes in CHK1serine296 phosphorylation in circulating tumour 
cells (CTCs), could be explored using imaging flow cytometry (eg: Imagestream 
platform). The potential pitfalls of such an approach are that CTCs are not 
present in all cancer patients and in those patients who do have CTCs they can 
vary widely in number (Nole et al., 2008). There is also concern as to whether 
CTCs truly represent the biology of the primary tumour. 
In conclusion V158411 is a novel CHK1 inhibitor that shows potential as both a 
single agent drug and in combination with radiotherapy. A phase I trial should 
seek to determine the single agent MTD of V158411 and the MTD in 
combination with ionising radiation. There is no evidence to select patients for 
clinical trials based on the p53 status of their tumour, but it would be useful to 
correlate this information and data on other elements of the DNA repair pathway 
against efficacy in early phase clinical trials. Further development of 
CHK1serine296 phosphorylation as a biomarker for use in clinical trials is also 
warranted. 
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